<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>377</serviceExecutionTime><Trial id="105916"><TitleDisplay>A multicenter, efficacy study of interferon alfa-2b in French patients with chronic hepatitis C</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Other">CMS-2583</Identifier></Identifiers><Indications><Indication id="153">Hepatitis C virus infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>interferon alfa-2b</Name><Drug id="45998">interferon alfa-2b</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="45998">interferon alfa-2b</Drug><IndicationsPioneer/><Companies><Company><Company id="29570">Institut Necker</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="45998" type="Drug"><TargetEntity id="165805" type="siDrug">Interferon alfa-2b</TargetEntity></SourceEntity><SourceEntity id="29570" type="Company"><TargetEntity id="5035530296" type="organizationId">Institut Necker</TargetEntity></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"/><TargetEntity id="D019698" type="MeSH"/><TargetEntity id="-776640207" type="omicsDisease"/><TargetEntity id="430" type="siCondition"/></SourceEntity><SourceEntity id="917" type="Action"><TargetEntity id="1953" type="Mechanism">Interferon alpha Receptor (IFNAR) Ligands</TargetEntity><TargetEntity id="2945" type="Mechanism">IFN-alpha Modulators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="29570">Institut Necker</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="917">Interferon alpha ligand modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15190">Systemic dermatological antiviral product</Class><Class id="1545">Anticancer</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="740">Infusion</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>95</PatientCountEnrollment><PatientCountEvaluable>95</PatientCountEvaluable><DateStart>1997-05-24T00:00:00Z</DateStart><DateChangeLast>2013-01-28T04:20:24Z</DateChangeLast><DateAdded>2013-01-28T04:20:24Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Anti-HCV- and RNA-positive patients with chronic hepatitis&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this  multicenter study was to evaluate the efficacy of &lt;ulink linkType="Drug" linkID="45998"&gt;interferon alfa-2b&lt;/ulink&gt; in French patients with chronic hepatitis C [&lt;ulink linkType="Reference" linkID="1359501"&gt;1359501&lt;/ulink&gt;]. &lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in May 1997.  &lt;ulink linkType="Drug" linkID="45998"&gt;Interferon alfa-2b&lt;/ulink&gt; was effective in patients with genotype 1 chronic hepatitis C (anti HCV and serum HCV RNA-positive). The age &amp;lt; 40 years, viremia &amp;lt; 3.5·10E5 Eq/ml, SSCP bands &amp;lt; 3, genotype non 1 and absence of cirrhosis were associated with better response [&lt;ulink linkType="Reference" linkID="1359501"&gt;1359501&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients received either &lt;ulink linkType="Drug" linkID="45998"&gt;interferon alfa-2b&lt;/ulink&gt;, 3  MU tiw for  6 months (n = 57) or   6 MU tiw for  6 months  followed by 3 MU tiw for  6 months (n = 38)  [&lt;ulink linkType="Reference" linkID="1359501"&gt;1359501&lt;/ulink&gt;]. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-01-28T04:20:24Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="111376"><TitleDisplay>An Open Study To Evaluate The Efficacy Of Photodynamic Therapy Of Vulvar And Vaginal Condyloma And Intraepithelial Neoplasia Using Topically Applied 5-aminolevulinic Acid</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="3105">Vulvar intraepithelial neoplasia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>aminolevulinic acid hydrochloride</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="25121" type="Company"><TargetEntity id="4298324201" type="organizationId">UniversitaetsSpital Zuerich</TargetEntity></SourceEntity><SourceEntity id="3105" type="ciIndication"><TargetEntity id="137583" type="ORPHANET"/><TargetEntity id="2415" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="25121">University Hospital Zurich</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>38</PatientCountEnrollment><PatientCountEvaluable>38</PatientCountEvaluable><DateStart>2002-12-31T00:00:00Z</DateStart><DateChangeLast>2013-02-21T09:50:02Z</DateChangeLast><DateAdded>2013-02-21T09:50:02Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with vulvar and vaginal intraepithelial neoplasia [n = 22] or condyloma [n = 16]&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this open study was to evaluate the efficacy of photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid [&lt;ulink linkType="Reference" linkID="1372585"&gt;1372585&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 2002, results showed that photodynamic therapy with 5-aminolevulinic acid gel was effective without scarring and associated with rapid healing [&lt;ulink linkType="Reference" linkID="1372585"&gt;1372585&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received  aminolevulinic acid 10% gel followed by photodynamic therapy, 80 to 125 J/cm2 laser light at 635 nm wavelength [&lt;ulink linkType="Reference" linkID="1372585"&gt;1372585&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-02-21T09:50:02Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="114074"><TitleDisplay>A Randomized, Double-Blind, Placebo-Controlled Study To Assess Efficacy Of Metoclopramide In Contraception</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="226">Nausea</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>metoclopramide</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="20597" type="Company"><TargetEntity id="4298443528" type="organizationId">University of Kansas</TargetEntity></SourceEntity><SourceEntity id="226" type="ciIndication"><TargetEntity id="R11.0" type="ICD10"/><TargetEntity id="10028813" type="MEDDRA"/><TargetEntity id="D009325" type="MeSH"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="20597">University of Kansas</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>141</PatientCountEnrollment><PatientCountEvaluable>141</PatientCountEvaluable><DateStart>2003-02-28T00:00:00Z</DateStart><DateChangeLast>2015-07-16T14:13:41Z</DateChangeLast><DateAdded>2013-03-06T07:50:37Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients requiring emergency contraception with high dose estrogen/progestin&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this randomized, double-blind, placebo-controlled study was to assess efficacy of metoclopramide in contraception [&lt;ulink linkType="Reference" linkID="1376670"&gt;1376670&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In February 2003, results were published. Pretreatment with metoclopramide reduced the nausea and cramping associated with the high-dose combination of estrogen and progestins given for emergency contraception [&lt;ulink linkType="Reference" linkID="1376670"&gt;1376670&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received metoclopramide, 10 mg (n = 47); Placebo (n = 59) [&lt;ulink linkType="Reference" linkID="1376670"&gt;1376670&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-03-06T07:50:37Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="116676"><TitleDisplay>A Randomized, Phase II Study of Repeated Rhenium-188 HEDP Combined with Docetaxel Versus Docetaxel Alone in Castration Resistant Prostate Cancer (Crpc) Metastatic to Bone</TitleDisplay><TitleOfficial>A Randomized, Phase II Study of Repeated Rhenium-188 HEDP Combined With Docetaxel Versus Docetaxel Alone In Castration Resistant Prostate Cancer (CRPC) Metastatic to Bone</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">EudraCT 2009-018044-18</Identifier><Identifier type="Secondary Organisational">TaxiumII</Identifier></Identifiers><Indications><Indication id="1829">Bone metastases</Indication><Indication id="3246">Hormone refractory prostate cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="38" role="Therapeutic effect marker" type="Genomic;Proteomic">Prostate-specific antigen</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>docetaxel</Name><Drug id="2953">docetaxel</Drug></Intervention><Intervention type="InterventionPrimary"><Name>docetaxel + prednisone</Name></Intervention><Intervention type="InterventionPrimary"><Name>docetaxel + prednisone + rhenium-188-HEDP</Name></Intervention><Intervention type="InterventionPrimary"><Name>prednisone</Name></Intervention><Intervention type="InterventionPrimary"><Name>rhenium-188-HEDP</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2953">docetaxel</Drug><IndicationsPioneer/><Companies><Company><Company id="1056882">Meander Medical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2953" type="Drug"><TargetEntity id="140605" type="siDrug">Docetaxel</TargetEntity></SourceEntity><SourceEntity id="1056882" type="Company"><TargetEntity id="5035551033" type="organizationId">Meander Medical Center</TargetEntity></SourceEntity><SourceEntity id="1829" type="ciIndication"><TargetEntity id="10027452" type="MEDDRA"/></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1056882">Meander Medical Center</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="1545">Anticancer</Class><Class id="2575">Microtubule inhibitor</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1647">Natural product</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>88</PatientCountEnrollment><PatientCountEvaluable>86</PatientCountEvaluable><DateStart>2012-06-22T00:00:00Z</DateStart><DateChangeLast>2017-12-12T11:40:23Z</DateChangeLast><DateAdded>2013-03-22T05:58:39Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>VU medical center</Affiliation><Email>j.vandodewaard@vumc.nl</Email><Name>JM van Dodewaard-de Jong</Name><Phone>+31204444336</Phone></Contact><Contact type="Public contact"><Affiliation>VU medical center;  De Boelelaan 1117 1081 HV Amsterdam Netherlands</Affiliation><Email>j.vandodewaard@vumc.nl</Email><Name>Jm Jong</Name><Phone>31204444336</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Prostate carcinoma&lt;/li&gt;&lt;li&gt;Bone metastases&lt;/li&gt;&lt;li&gt;Hormone therapy resistent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Previous exposure to rhenium or&lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Bone marrow insufficiency&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To compare time to progression (clinical ie, change of treatment required, or biochemical ie, PSA) in men with progressive CRPC involving bone between standard care of 3-weekly docetaxel 75 mg/m2 (to maximum ten cycles) versus 3-weekly docetaxel 75 mg/m2 + two infusions of rhenium-188 HEDP</Description><Timeframe>9, 12, 18, 24 months after treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>PSA response</Description><Timeframe>9, 12, 18, 24 months after treatment</Timeframe></Measure><Measure><Description>Overall survival</Description><Timeframe>9, 12, 18, 24 months after treatment</Timeframe></Measure><Measure><Description>Maximum percent decrease of PSA from baseline between treatments</Description><Timeframe>9, 12, 18, 24 months after treatment</Timeframe></Measure><Measure><Description>Pain response</Description><Timeframe>9, 12, 18, 24 months after treatment</Timeframe></Measure><Measure><Description>Toxicity</Description><Timeframe>9, 12, 18, 24 months after treatment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results were published in August 2017. Experimental group reported more frequent thrombocytopenia (25% versus 0%)  [&lt;ulink linkType="Reference" linkID="1985218"&gt;1985218&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The main objective of this randomized, phase II study was to compare the time to progression  in men with progressive castration resistant prostate cancer (CRPC) involving bone between standard care of 3-weekly &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; 75 mg/m2 (to maximum ten cycles) versus 3-weekly &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; 75 mg/m2 + two infusions of rhenium-188 HEDP.&lt;/para&gt;&lt;para&gt;The secondary objectives were:&lt;br/&gt;Safety.&lt;br/&gt;To compare PSA response rates.&lt;br/&gt;To compare overall survival.&lt;br/&gt;To determine the effects of these two treatment regimens on pain response, in patients with pain and quality of life [&lt;ulink linkType="Reference" linkID="1394015"&gt;1394015&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in August 2017. No differences were found in PFS and survival in the intention to treat analysis and PSA was found to become apparent between the two groups. Median overall survival was observed to be significantly longer in the experimental group (33.8 months) than in the control group (21 months; p = 0.012), as evaluated by an exploratory per-protocol analysis. Patients who received combination treatment with a baseline phosphatase &amp;gt; 220 U/l reported a significantly better median PFS (9 versus 6.2 months; p = 0.005) [&lt;ulink linkType="Reference" linkID="1985218"&gt;1985218&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive rhenium-188 (37 	MBq/kg, iv) HEDP in combination with &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; (40 mg/ml, iv) or &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; (40 mg/ml, iv) alone 			 [&lt;ulink linkType="Reference" linkID="1394015"&gt;1394015&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized to receive first-line docetaxel 75 mg/m2 3-weekly plus prednisone with (experimental group) or without (control group) two injections of rhenium-188 HEDP after the third (40 MBq/kg) and sixth (20 MBq/kg) cycle of docetaxel [&lt;ulink linkType="Reference" linkID="1985218"&gt;1985218&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>docetaxel + prednisone + rhenium-188-HEDP</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="324">Thrombocytopenia</Indication><CountPatientsAffectedPercentage>25.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="279181">docetaxel</Intervention><Treatments><Treatment><Dose>40 mg/ml</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="278896">docetaxel + prednisone</Intervention><Treatments><Treatment><Dose>75 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Netherlands"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3564">Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3565">Subjects with Stage IV Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3583">Subjects with Castrate Resistant Prostate Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">EudraCT 2009-018044-18</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate tumor" id="7088"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7089">Assessment of time to disease progression (TTP)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Prostate tumor" id="7045"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7076"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7129"><Endpoint>Assessment of Prostate Specific Antigen(PSA) Dependent Variables</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7130">Assessment of PSA response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7189"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate tumor" id="3695"><Criterion>Subjects with Stage IV Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3755"><Criterion>Subjects with Castrate Resistant Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="7091"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate tumor" id="4918"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4921">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4965"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4967">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-03-22T05:58:39Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2017-12-13T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="Added"><Date>2017-12-13T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change></ChangeHistory></Trial><Trial id="117000"><TitleDisplay>A Parallel, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of SagaPro on Nocturia in Men</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">EudraCT 2010-019668-35</Identifier><Identifier type="Secondary Organisational">Saga-001</Identifier></Identifiers><Indications><Indication id="2545">Nocturia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>SagaPro</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1080671" type="Company"><TargetEntity id="5038916362" type="organizationId">SagaMedica Heilsujurtir ehf</TargetEntity></SourceEntity><SourceEntity id="2545" type="ciIndication"><TargetEntity id="R35.1" type="ICD10"/><TargetEntity id="10029446" type="MEDDRA"/><TargetEntity id="D053158" type="MeSH"/><TargetEntity id="-133194658" type="omicsDisease"/><TargetEntity id="3539" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1080671">SagaMedica</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>70</PatientCountEnrollment><PatientCountEvaluable>69</PatientCountEvaluable><DateStart>2010-05-11T00:00:00Z</DateStart><DateEnd type="actual">2011-02-11T00:00:00Z</DateEnd><DateChangeLast>2018-01-10T22:03:36Z</DateChangeLast><DateAdded>2013-03-25T13:57:41Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male volunteers with bothersome LUTS, &gt; 45  years of age&lt;/li&gt;&lt;li&gt;Willing and able to complete the micturition diary and questionnaires correctly&lt;/li&gt;&lt;li&gt;An average of &gt;/= 3 nocturnal voids per night as determined by the participant diary (average over nights of the screening period)&lt;/li&gt;&lt;li&gt;I-PSS total score of &gt;/= 8 and the I-PSS QoL score of &gt;/= 3&lt;/li&gt;&lt;li&gt;Written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Residual urine&amp;gt; 250 ml measured by ultrasound&lt;/li&gt;&lt;li&gt;Total urine output over 24 h exceeding 3000 ml as determined by the participant diary&lt;/li&gt;&lt;li&gt;Abnormal urinary findings suggestive of urinary tract infection, significant hematuria or glucosuria requiring further evaluation&lt;/li&gt;&lt;li&gt;Surgical treatment for bladder outlet obstruction/BPH performed within the past 6 months&lt;/li&gt;&lt;li&gt;History of urologic malignancy (eg, bladder cancer, prostate cancer, etc)&lt;/li&gt;&lt;li&gt;Medical history or active conditions which, in the opinion of the principal investigator (PI) would prohibit participation in the study. This includes, but is not limited to: cancer, renal failure, cirrhosis or chronic liver disease, pancreatic diseases, recent (&amp;lt; 6 months) myocardial infarction or unstable coronary artery disease&lt;/li&gt;&lt;li&gt;Use of medications affecting urination (eg, loop diuretics (furosemide), alpha blockers (including doxazosin), antimuscarinic agents, finasteride or dutasteride), or natural products used for BPH, such as saw palmetto (Sabal serrulata or Serenoa repens)&lt;/li&gt;&lt;li&gt;Use of SagaPro or other products containing A. archangelica within the previous 2 months prior to randomization&lt;/li&gt;&lt;li&gt;Known allergy to A  archangelica or any other ingredients of SagaPro&lt;/li&gt;&lt;li&gt;Receipt of an investigational product within 30 days prior to enrollment or expected receipt during this study&lt;/li&gt;&lt;li&gt;Work or lifestyle potentially interfering with regular nighttime sleep, eg, shift workers&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The primary endpoint is the change in the number of nocturnal voids</Description><Timeframe>From baseline until after 8 weeks on SagaPro/placebo treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In February 2013,  results demonstrated  that SagaPro was safe. There were no severe adverse events   reported, and the number of reports was similar in both treatment groups, 24 in the placebo group and 21 in the SagaPro group. The most frequent adverse events were  common cold (n = 4 in the placebo group and n = 3 in the SagaPro group), diarrhea (n = 3 in each group), vomiting (n = 2 in each group) and sore throat (n = 2 in the SagaPro group and n = 1 in the placebo group). No other adverse events were reported by more than one patient.   In the SagaPro group, one patient discontinued treatment because of two   adverse events, bloating and weight gain, which were later revealed to have been most probably due to gallstones. The remaining adverse events found to be possibly related to the treatment were constipation (SagaPro) and diarrhea (placebo) [&lt;ulink linkType="Reference" linkID="1416202"&gt;1416202&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, double-blind, parallel-group, placebo-controlled study was to evaluate the safety and efficacy of SagaPro on nocturia in men. The primary objective of the study was to assess the effect of SagaPro compared with placebo, given once-daily in the evening, in reducing bothersome LUTS, especially nocturia, often associated in men with BPH. The secondary objective of the study was  investigating the effect of SagaPro on sleep time and prostatic symptoms and QoL according to the International prostate symptom score (I-PSS) [&lt;ulink linkType="Reference" linkID="1394821"&gt;1394821&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In February 2013,  results were published. There was a reduction in actual number of nocturnal voids (ANV), nocturnal polyuria index (NPi) and nocturnal bladder capacity index (NBC index)  in the test population, but there was no significant difference between the treatment groups. Subsequent subgroup analysis showed that SagaPro significantly reduced the NBC index and nocturnal voids per sleeping hour in comparison to the placebo in participants with baseline NBC index &amp;gt; 1.3.  ANV was also significantly reduced for the SagaPro group in comparison to the placebo group, when participants with sleep disorders were excluded from this group [&lt;ulink linkType="Reference" linkID="1416202"&gt;1416202&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive SagaPro or placebo orally [&lt;ulink linkType="Reference" linkID="1394821"&gt;1394821&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients (n = 69)  were randomized to receive SagaPro or placebo, for 8 weeks [&lt;ulink linkType="Reference" linkID="1416202"&gt;1416202&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iceland"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate hyperplasia</Disease><PatientSegments><PatientSegment><PatientSegment id="11507">Subjets with Benign Prostatic Hypertrophy/Hyperplasia(BPH)</PatientSegment><SubSegments><SubSegment id="11514">Subjects with lower urinary tract symptoms(LUTS)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="15518">Subjects with Symptomatic Disease</PatientSegment><SubSegments><SubSegment id="11505">Subjets with Moderately Symptomatic BPH</SubSegment><SubSegment id="11506">Subjets with Severely Symptomatic BPH</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">EudraCT 2010-019668-35</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate hyperplasia" id="22610"><Endpoint>Subjective Assessment of BPH Symptoms</Endpoint><SubEndpoints><SubEndpoint disease="Prostate hyperplasia" id="22611">Assessment of voiding symptoms</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Prostate hyperplasia" id="22647"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Prostate hyperplasia" id="22649">Assessment of treatment efficacy(unspecified)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate hyperplasia" id="20360"><Criterion>Subjets with Benign Prostatic Hypertrophy/Hyperplasia(BPH)</Criterion><SubCriteria><SubCriterion disease="Prostate hyperplasia" id="20362">Subjets with moderately symptomatic BPH</SubCriterion><SubCriterion disease="Prostate hyperplasia" id="20363">Subjets with severely symptomatic BPH</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate hyperplasia" id="20371"><Criterion>Subjects with lower urinary tract symptoms(LUTS)</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate hyperplasia" id="17864"><Criterion>Subjects with Lower Urinary Tract Symptoms</Criterion><SubCriteria><SubCriterion disease="Prostate hyperplasia" id="17867">Subjects with hematuria</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate hyperplasia" id="17869"><Criterion>Subjects with Urinary Tract Infection</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17872"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17876"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17879"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17880"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17886"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17889"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Prostate hyperplasia" id="17914">Subjects with history of/scheduled for BPH procedures</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate hyperplasia" id="17919"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Prostate hyperplasia" id="17927"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-03-25T13:57:41Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="121509"><TitleDisplay>Pharmacokinetics And Clinical Outcomes of Bortezomib in Patients With Newly Diagnosed Myeloma</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000006257</Identifier></Identifiers><Indications><Indication id="1828">Multiple myeloma</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>bortezomib</Name><Drug id="15954">bortezomib</Drug></Intervention><Intervention type="InterventionPrimary"><Name>dexamethasone</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="15954">bortezomib</Drug><IndicationsPioneer/><Companies><Company><Company id="24183">Keio University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="15954" type="Drug"><TargetEntity id="260757" type="siDrug">Bortezomib</TargetEntity></SourceEntity><SourceEntity id="24183" type="Company"><TargetEntity id="4296566429" type="organizationId">Keio University</TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"/><TargetEntity id="10028228" type="MEDDRA"/><TargetEntity id="D009101" type="MeSH"/><TargetEntity id="29073" type="ORPHANET"/><TargetEntity id="-18870694" type="omicsDisease"/><TargetEntity id="710" type="siCondition"/></SourceEntity><SourceEntity id="4917" type="Action"><TargetEntity id="1125" type="Mechanism">Proteasome Inhibitors</TargetEntity><TargetEntity id="3073" type="Mechanism">Immunoproteasome Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="24183">Keio University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4917">Proteasome inhibitor</Action><Action id="76469">26S proteasome complex inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class></Class><Technologies><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2011-09-01T00:00:00Z</DateStart><DateChangeLast>2013-10-10T06:04:40Z</DateChangeLast><DateAdded>2013-04-18T09:58:38Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Keio University, School of Meidicine, Division of Hematology, Department of Medicine; 35 Shinano-machi Shinjuku-ku Tokyo 160-8582, Japan</Affiliation><Name>Shinichiro Okamoto</Name><Phone>81-3-3353-1211</Phone></Contact><Contact type="Public contact"><Affiliation>Keio University, School of Meidicine, Division of Hematology, Department of Medicine; 35 Shinano-machi Shinjuku-ku Tokyo 160-8582, Japan</Affiliation><Email>keyokoya@sc.itc.keio.ac.jp</Email><Name>Kenji Yokoyama</Name><Phone>81-3-3353-1211</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with multiple myeloma currently visiting or admitting in Keio University Hospital and plan to receive weekly&lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; + dexamethasone therapy. Those who do not receive prior chemotherapy except for dexamethasone or zoledronic acid are included&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients without consent&lt;/li&gt;&lt;li&gt;Patients with PS 3 or worse&lt;/li&gt;&lt;li&gt;ANC&amp;lt; 1000/cmm&lt;/li&gt;&lt;li&gt;AST&amp;gt;/= 3 x upper limit, ALT &amp;gt;/= 3 x upper limit, TB &amp;gt;/= 2 x upper limit&lt;/li&gt;&lt;li&gt;Interstitial pneumonia diagnosed by imaging, pulmonary function test, or blood examination. Patients with increased level of KL-6 without any other findings suspicious of interstitial pneumonia are included&lt;/li&gt;&lt;li&gt;Peripheral neuropathy grade 3 or higher&lt;/li&gt;&lt;li&gt;Drug allergy against&lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; or dexamethasone&lt;/li&gt;&lt;li&gt;Primary physician thinks it is inappropriate to enroll the patient&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Response rate (VGPR + CR + sCR) to bortezomib + dexamethasone</Description><Timeframe>At the end of second and fourth course of treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>PFS (progression free survival), OS (overall survival) and incidence of adverse events (adverse events are evaluated according to NCI CTCAE version 4)</Description><Timeframe>At the end of second and fourth course of treatment</Timeframe></Measure><Measure><Description>Peripheral neuropathy is also evaluated based on the modified FACT/GOG-NTx scale</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim was to analyze the effect of plasma concentration of &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; on efficacy or adverse events [&lt;ulink linkType="Reference" linkID="1404988"&gt;1404988&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with multiple myeloma currently visiting or admitting in Keio University Hospital would receive weekly &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; + dexamethasone therapy [&lt;ulink linkType="Reference" linkID="1404988"&gt;1404988&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000006257</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Multiple myeloma" id="7391"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Multiple myeloma" id="7393">Assessment of tumor response rate (Duration of response)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Multiple myeloma" id="7354"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Multiple myeloma" id="7360"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Multiple myeloma" id="7432"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Multiple myeloma" id="26392">Assessment by Common Terminology Criteria for Adverse Events (CTCAE)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Multiple myeloma" id="7488"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Multiple myeloma" id="7416">Assessment of peripheral neuropathy</SubEndpoint><SubEndpoint disease="Multiple myeloma" id="7489">Assessment of other adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Multiple myeloma" id="4711"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="4715">Patient with history of targeted therapy</SubCriterion><SubCriterion disease="Multiple myeloma" id="4718">Patient with history of steroid therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Multiple myeloma" id="22383"><Criterion>Treatment Naive Subjects</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Multiple myeloma" id="6065"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="6091">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Multiple myeloma" id="6086"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="6093">Subjects with abnormal hematological tests</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Multiple myeloma" id="6104"><Criterion>Subjects with Protocol Specified Performance Status </Criterion></Exclusion><Exclusion disease="Multiple myeloma" id="6107"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="6108">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Multiple myeloma" id="27059"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Multiple myeloma" id="6090">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-18T09:58:38Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="122284"><TitleDisplay>Double-Blind, Randomized, Placebo-Controlled Trial to Examine the Efficacy and the Safety of Rikkunshito for PPI Resistant Functional Dyspepsia</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000006881</Identifier></Identifiers><Indications><Indication id="432">Dyspepsia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rikkunshito</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1041701" type="Company"><TargetEntity id="5000044890" type="organizationId">Japan, Ministry Of Health Labour And Welfare(Government)</TargetEntity></SourceEntity><SourceEntity id="432" type="ciIndication"><TargetEntity id="R12" type="ICD10"/><TargetEntity id="10013946" type="MEDDRA"/><TargetEntity id="D004415" type="MeSH"/><TargetEntity id="382" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1041701">Japanese Ministry of Health, Labor and Welfare</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>120</PatientCountEnrollment><DateStart>2012-03-01T00:00:00Z</DateStart><DateEnd type="actual">2012-09-30T00:00:00Z</DateEnd><DateChangeLast>2019-03-07T16:24:12Z</DateChangeLast><DateAdded>2013-04-26T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan Japan</Affiliation><Email>mami142143@gmail.com</Email><Name>Mami Okada</Name></Contact><Contact type="Public contact"><Affiliation>Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine; 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan</Affiliation><Name>Hidekazu Suzuki</Name><Phone>+81-3-5363-3288</Phone></Contact><Contact type="Public contact"><Affiliation>Keio University School of Medicine, Center for Clinical Research; 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan</Affiliation><Name>Naoki Tomotsugu</Name><Phone>03-5363-3288</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with functional dyspepsia diagnosed according to the Rome three classification&lt;/li&gt;&lt;li&gt;Patients with dyspeptic symptom by symptomatic scale 3 points or more, for over 4 days, for 2 weeks before registration&lt;/li&gt;&lt;li&gt;Patients aged &gt;/= 20 years&lt;/li&gt;&lt;li&gt;Regardless of sex&lt;/li&gt;&lt;li&gt;Regardless of admission to hospital&lt;/li&gt;&lt;li&gt;Patients whose written informed consent has been obtained&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patient with Organic disease such as reflux esophagitis (&amp;gt; grade A) and erosive gastritis&lt;/li&gt;&lt;li&gt;Patients with past history of upper gastrointestinal surgery&lt;/li&gt;&lt;li&gt;Patients with past history of gastrectomy&lt;/li&gt;&lt;li&gt;Patients with an obvious cause of symptom&lt;/li&gt;&lt;li&gt;NSAIDs or low-dose aspirin-related dyspepsia&lt;/li&gt;&lt;li&gt;Patients with organic disease in the brain or with psychological disorders&lt;/li&gt;&lt;li&gt;Patients with alcoholics or with drug dependence&lt;/li&gt;&lt;li&gt;Severe endocrine disease including hyperthyroidism&lt;/li&gt;&lt;li&gt;Severe diseases in heart, liver and kidney. Severe infections or hemotological diseases&lt;/li&gt;&lt;li&gt;Drug allegy for rikkunshito&lt;/li&gt;&lt;li&gt;Expectant mother, mother with breast-feeding, or females who wish to become pregnant&lt;/li&gt;&lt;li&gt;Patient with H pylori eradication within 6 months&lt;/li&gt;&lt;li&gt;Patients who take gastric secretion inhibitor, prokinetic agent, gastric antacid, anticholineric drug, cholinergic agent, tranquilizer, anxiolytic agent drug, antidepressive drug within 1 week&lt;/li&gt;&lt;li&gt;Patients with suspected IBS&lt;/li&gt;&lt;li&gt;Other not applicable person recognized by a doctor&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Improvement rate of Global Patient Assessment (GPA)</Description><Timeframe>At 8 weeks after initial treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Rate of Gastrointestinal Symptom Rating Scale(GSRS) after treatment</Description></Measure><Measure><Description>Improvement rate of dyspeptic symptoms by symptomatic scale</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this double-blind, randomized, placebo-controlled trial was to examine the efficacy and safety of rikkunshito in proton pump inhibitor (PPI)  resistant functional dyspepsia    [&lt;ulink linkType="Reference" linkID="1406392"&gt;1406392&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be randomized to receive either  rikkunshito or placebo [&lt;ulink linkType="Reference" linkID="1406392"&gt;1406392&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Dyspepsia</Disease><PatientSegments><PatientSegment><PatientSegment id="10817">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000006881</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Dyspepsia" id="16088"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Dyspepsia" id="27856">Global Patient Assessment (GPA)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Dyspepsia" id="16051"><Endpoint>Assessment of Functional Dyspepsia Symptoms Using Protocol Specified Scales/Scores</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Dyspepsia" id="16064"><Endpoint>Assessment of Co-morbidity</Endpoint><SubEndpoints><SubEndpoint disease="Dyspepsia" id="16065">Assessment of symptoms of gastroesophageal reflux disease (GERD)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Dyspepsia" id="14301"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion><SubCriteria><SubCriterion disease="Dyspepsia" id="14303">Subjects fulfilling Rome III diagnostic criteria for functional dyspepsia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Dyspepsia" id="14304"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Dyspepsia" id="14338"><Criterion>Subjects with Treatment Resistant Disease</Criterion><SubCriteria><SubCriterion disease="Dyspepsia" id="14339">Subjects resistant/refractory to proton pump inhibitors</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Dyspepsia" id="11700"><Criterion>Subjects by disease severity</Criterion></Exclusion><Exclusion disease="Dyspepsia" id="11712"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Dyspepsia" id="11715">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion><SubCriterion disease="Dyspepsia" id="11717">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Dyspepsia" id="11718">Subjects with endocrine diseases/disorders</SubCriterion><SubCriterion disease="Dyspepsia" id="11722">Subjects with infectious diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Dyspepsia" id="11713"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Dyspepsia" id="11716"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Dyspepsia" id="11736"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Dyspepsia" id="11742">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Dyspepsia" id="11745"><Criterion>Subjects with History of Functional Dyspepsia Therapy</Criterion><SubCriteria><SubCriterion disease="Dyspepsia" id="11746">Subjects with history of proton pump inhibitors</SubCriterion><SubCriterion disease="Dyspepsia" id="11750">Subjects with history of Helicobacter pylori eradication therapy</SubCriterion><SubCriterion disease="Dyspepsia" id="11753">Subjects with history of antacids</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Dyspepsia" id="11752"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Dyspepsia" id="11761">Subjects with history of major surgery for other indication</SubCriterion><SubCriterion disease="Dyspepsia" id="11762">Subjects with history of non-steroidal anti-inflammatory drugs for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Dyspepsia" id="11897"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Dyspepsia" id="11754">Subjects with history of/scheduled to receive prokinetics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Dyspepsia" id="28372"><Criterion>Subjects with history of gastrointestinal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Dyspepsia" id="11705">Subjects with history of gastroesophageal reflux disease (GERD)</SubCriterion><SubCriterion disease="Dyspepsia" id="11706">Subjects with history of Irritable Bowel Syndrome</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-01-24T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="122738"><TitleDisplay>An Open label Prospective Non Comparative Phase III Study for Efficacy and Safety of FDC of Ispaghula Husk IP 3.5 g and Lactitol Monohydrate BP 10 g Granules, in the treatment of Acute Idiopathic Constipation</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">CTRI/2010/091/001106</Identifier><Identifier type="Secondary Organisational">NEX/AKUM/CTIII-101/05/10</Identifier></Identifiers><Indications><Indication id="404">Constipation</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ispaghula husk + lactitol monohydrate</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1051573" type="Company"><TargetEntity id="4298174701" type="organizationId">Akums Drugs &amp; Pharmaceuticals Ltd</TargetEntity></SourceEntity><SourceEntity id="404" type="ciIndication"><TargetEntity id="K59.0" type="ICD10"/><TargetEntity id="10010774" type="MEDDRA"/><TargetEntity id="D003248" type="MeSH"/><TargetEntity id="-729250398" type="omicsDisease"/><TargetEntity id="378" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>6</NumberOfSites><CompaniesSponsor><Company id="1051573">Akums Drugs &amp; Pharmaceuticals Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2010-06-30T00:00:00Z</DateStart><DateChangeLast>2018-01-11T22:04:59Z</DateChangeLast><DateAdded>2013-04-26T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Narendra Prakash Health Care Center,, Da-3/a, Main Shakar Pur,laxminagar, New Delhi, Delhi, 110 092, India</Affiliation><Email>drdeepakbhambe@gmail.com</Email><Name>Deepak Bhambe</Name><Phone>9654807946</Phone></Contact><Contact type="Public contact"><Affiliation>Anuj, Plot No. 45, Ist Floor,, Mumbai-pune Highway, Near D. Y. Patil Stadium, Sector-13, Nerul (e), Mumbai, Maharashtra, 400 706, India</Affiliation><Email>dramit.bhatt@gmail.com</Email><Name>Amit Bhatt</Name><Phone>+91-22-27714204</Phone></Contact><Contact type="Public contact"><Affiliation>S-524,school Block, Laxmi Nagar110 092; New Delhi; Delhi</Affiliation><Email>kumar6511@gmail.com</Email><Name>Satish Gupta</Name><Phone>9811212494</Phone></Contact><Contact type="Public contact"><Affiliation>No.8 City Point, ,kodiabail-575003; Bangalore; Karnataka</Affiliation><Email>mohanpai@rediff.com</Email><Name>Mohan Pai</Name><Phone>9845083135</Phone></Contact><Contact type="Public contact"><Affiliation>General Manager, Akums Drugs And Pharmaceuticals Ltd , 304, Mohan Place, Lsc, Block  C, Saraswati Vihar, New Delhi, Delhi, 110 034, India</Affiliation><Email>prasad@akums.net</Email><Name>R. Prasad</Name><Phone>091 11 47511000</Phone></Contact><Contact type="Public contact"><Affiliation>B-1, 56/57/58, Subhash Nagar,teen Dongri, M.g.road, Goregaon (w)-400 062; Mumbai; Maharashtra</Affiliation><Email>p_p_rege@yahoo.co.in</Email><Name>Prakash Rege</Name><Phone>9223477294</Phone></Contact><Contact type="Public contact"><Affiliation>C-2/96,,new Kondli-110 096; New Delhi; Delhi</Affiliation><Email>docsaurabh76@rediffmail.com</Email><Name>Saurabh Singh</Name><Phone>9711112080</Phone></Contact><Contact type="Public contact"><Affiliation>Chippi Tank250 001; Meerut; Uttar Pradesh</Affiliation><Email>trsirohi@yahoo.com</Email><Name>Tanuraj Sirohi</Name><Phone>9917000583</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects of both sexes , aged between 18 to 50 years&lt;/li&gt;&lt;li&gt;Subjects with acute idiopathic constipation (defined as presence of less than three stools per week and/or straining at stool for at least 3 months) who have one or more of the following symptoms associated with at least 25% of bowel movements (BMs) for at least 3 months prior to the baseline visit: very hard (little balls) and/or hard stools, a sensation of incomplete evacuation, or straining at defecatio.&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Documented mechanical obstruction, megacolon/megarectum or a diagnosis of pseudoobstruction&lt;/li&gt;&lt;li&gt;Hypersensitivity to lactitol, Ispaghula Husk or any other constituents of the investigational product&lt;/li&gt;&lt;li&gt;Known or suspected organic disorders of the large or small intestine&lt;/li&gt;&lt;li&gt;Secondary causes of constipation&lt;/li&gt;&lt;li&gt;Hospitalization for any gastrointestinal or abdominal surgical procedure during the 3 months before the start of the study&lt;/li&gt;&lt;li&gt;Prior bowel resection&lt;/li&gt;&lt;li&gt;Clinically significant cardiovascular, liver, lung, or other systemic disease; neurological or psychiatric disorders&lt;/li&gt;&lt;li&gt;Cancer within the past five years&lt;/li&gt;&lt;li&gt;Women of childbearing potential who cannot use oral or implanted contraceptives or to have used a double-barrier method during the trial&lt;/li&gt;&lt;li&gt;Breastfeeding women&lt;/li&gt;&lt;li&gt;Any other illness which could seriously effect the safety of subjects and/or the integrity of the study&lt;/li&gt;&lt;li&gt;Subjects who, within the past 30 days have participated in an investigational clinical study&lt;/li&gt;&lt;li&gt;Subjects currently taking, or planning to take any of the following medications that are known to effect bowel habits:&lt;ul&gt;&lt;li&gt;Antidiarrheals&lt;/li&gt;&lt;li&gt;Antacids containing magnesium or aluminum salts&lt;/li&gt;&lt;li&gt;Anticholinergics&lt;/li&gt;&lt;li&gt;Antispasmodic agents&lt;/li&gt;&lt;li&gt;Erythromycin and other macrolides&lt;/li&gt;&lt;li&gt;Opiods/narcotic analgesics&lt;/li&gt;&lt;li&gt;Prokinetics&lt;/li&gt;&lt;li&gt;Serotonin re-uptake inhibitors or tricyclic antidepressants&lt;/li&gt;&lt;li&gt;Calcium antagonists&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Full response to treatment as a patient who has achieved type 3 to 4 category according to Bristol scale for stool passage</Description></Measure><Measure><Description>Proportion of subjects with full response to treatment at the end of 7 days of treatment which is defined as: full response to treatment is defined as a patient who has a SBM frequency of =3 for a given week, Spontaneous Bowel Movements (SBMs) are defined as any Bowel Movement (BM) that occurs without using rescue medication; 24 h after the use of rescue medication used to relieve constipation</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Proportion of subjects with full response to treatment at the end of follow up phase</Description></Measure><Measure><Description>The frequency of SBMs during 1st week of treatment</Description></Measure><Measure><Description>Time-to-first SBM proportion of subjects with a SBM within 24 and 48 h of first study drug administration</Description></Measure><Measure><Description>To evaluate the safety of fixed dose combination of Ispaghula Husk IP 3.5 g and Lactitol Monohydrate BP 10 g Granules in the treatment of Acute Idiopathic Constipation</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this open-label, prospective, non-comparative,  phase III study was to evaluate the efficacy and safety of fixed dose combination of  (FDC) of ispaghula husk and lactitol monohydrate granules, in the treatment of acute idiopathic constipation [&lt;ulink linkType="Reference" linkID="1408553"&gt;1408553&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive FDC of ispaghula husk IP 3.5 g and lactitol monohydrate BP 10 g granules [&lt;ulink linkType="Reference" linkID="1408553"&gt;1408553&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>Managalore heart Centre</Name><Address1>Bangalore</Address1><Address3> 575003</Address3><Contacts/></Site><Site><Name>NARENDRA PRAKASH HEALTH CARE CENTER</Name><Address1>New Delhi</Address1><Address3> 110092</Address3><Contacts/></Site><Site><Name>RAMAKRISNA MOTHER AND CHILD CLINIC</Name><Address1>New Delhi</Address1><Address3> 110096</Address3><Contacts/></Site><Site><Name>Rege Clinic</Name><Address1>Mumbai</Address1><Address3> 400062</Address3><Contacts/></Site><Site><Name>SIROHI CLINIC</Name><Address1>Meerut</Address1><Address3> 250001</Address3><Contacts/></Site><Site><Name>Somdatt Poly Clinic</Name><Address1>New Delhi</Address1><Address3> 110092</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Constipation</Disease><PatientSegments><PatientSegment><PatientSegment id="10699">Subjects with Idiopathic Constipation</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier type="Secondary Organisational">CTRI/2010/091/001106</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Constipation" id="15106"><Endpoint>Assessment of Bowel Movements</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Constipation" id="15107"><Endpoint>Assessment of Stool Consistency</Endpoint><SubEndpoints><SubEndpoint disease="Constipation" id="15108">Assessment by Bristol Stool Form Scale</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Constipation" id="15130"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Constipation" id="15131">Assessment of efficacy</SubEndpoint><SubEndpoint disease="Constipation" id="15132">Assessment of treatment response</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Constipation" id="15106"><Endpoint>Assessment of Bowel Movements</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Constipation" id="15130"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Constipation" id="15132">Assessment of treatment response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Constipation" id="15150"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Constipation" id="13844"><Criterion>Subjects with Idiopathic Constipation</Criterion></Inclusion><Inclusion disease="Constipation" id="13853"><Criterion>Subjects with Symptomatic Disease</Criterion><SubCriteria><SubCriterion disease="Constipation" id="13854">Subjects with protocol specified bowel movements</SubCriterion><SubCriterion disease="Constipation" id="13855">Subjects with straining during defecations</SubCriterion><SubCriterion disease="Constipation" id="13856">Subjects with lumpy or hard stools</SubCriterion><SubCriterion disease="Constipation" id="13857">Subjects with sensation of incomplete evacuation</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Constipation" id="11170"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Constipation" id="11172">Subjects with neurologic/psychiatric disorders</SubCriterion><SubCriterion disease="Constipation" id="11180">Subjects with cancer</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Constipation" id="11174"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Constipation" id="11181"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Constipation" id="11189"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Constipation" id="11190">Subjects with history of/scheduled for surgery for other indication</SubCriterion><SubCriterion disease="Constipation" id="11191">Subjects with history of opioids</SubCriterion><SubCriterion disease="Constipation" id="11192">Subjects with history of/scheduled to receive anti-depressants for other indication</SubCriterion><SubCriterion disease="Constipation" id="11194">Subjects with history of antacids for other indication</SubCriterion><SubCriterion disease="Constipation" id="11195">Subjects with history of antidiarrheals for other indication</SubCriterion><SubCriterion disease="Constipation" id="11196">Subjects with history of anticholinergics</SubCriterion><SubCriterion disease="Constipation" id="11197">Subjects with history of antispasmodics for other indication</SubCriterion><SubCriterion disease="Constipation" id="11198">Subjects with history of/scheduled to receive prokinetics for other indication</SubCriterion><SubCriterion disease="Constipation" id="11199">Subjects with history of calcium channel blockers</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Constipation" id="11200"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Constipation" id="11201">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Constipation" id="26075"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Constipation" id="11178">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Constipation" id="26934"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Constipation" id="11167">Subjects with Organic/Secondary Cause for constipation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Constipation" id="27104"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Constipation" id="11175">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="127804"><TitleDisplay>A Phase I/II Study of P-113 Mouthrinse for Clinical and Microbial Evaluation in HIV Seropositive Individuals with Oral Candidiasis</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers/><Indications><Indication id="1308">Candida infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>PAC-113</Name><Drug id="56262">PAC-113</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="56262">PAC-113</Drug><IndicationsPioneer><Indication id="1308">Candida infection</Indication></IndicationsPioneer><Companies/></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="56262" type="Drug"><TargetEntity id="307415" type="siDrug">Histatin P-113L</TargetEntity></SourceEntity><SourceEntity id="1308" type="ciIndication"><TargetEntity id="B37" type="ICD10"/><TargetEntity id="112" type="ICD9"/><TargetEntity id="10007152" type="MEDDRA"/><TargetEntity id="D002177" type="MeSH"/><TargetEntity id="-1584183089" type="omicsDisease"/><TargetEntity id="820" type="siCondition"/><TargetEntity id="822" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor/><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="1748">Fungicide</Class><Class id="59620">Unspecified drug target</Class><Class id="955">Antimicrobial permeability enhancer</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="1647">Natural product</Technology><Technology id="585">Oral formulation</Technology><Technology id="80">Peptide</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateStart>2006-07-01T00:00:00Z</DateStart><DateEnd type="actual">2007-07-31T00:00:00Z</DateEnd><DateChangeLast>2014-03-12T11:28:07Z</DateChangeLast><DateAdded>2013-05-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Name>Marlie Haefele</Name><Phone>+27 12 671 2259</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects must be documented HIV positive&lt;/li&gt;&lt;li&gt;Subjects must have pseudomembranous and/or erythematous oral candidiasis as confirmed by KOH preparation of mucosal scraping&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects who have received systemic antifungal therapy within 14 days of starting study&lt;/li&gt;&lt;li&gt;Subjects who have received prior topical therapy for oral candidiasis within 7 days of starting study&lt;/li&gt;&lt;li&gt;Subjects with concomitant fungal infections requiring systemic therapy&lt;/li&gt;&lt;li&gt;Subjects currently receiving immunosuppressive therapy (eg, corticosteroids), or cancer chemotherapy&lt;/li&gt;&lt;li&gt;Female subjects who are pregnant (as determined by a positive serum or urine pregnancy test) or lactating, or female subjects who are of childbearing potential and who are not using hormonal or barrier methods of birth control (eg, oral or parenteral contraceptives, diaphragm plus spermicide, condoms) or who have not characterized themselves as abstinent&lt;/li&gt;&lt;li&gt;Subjects who use hormonal contraceptives must have started the method at least 30 days prior to the screening examination&lt;/li&gt;&lt;li&gt;Subjects requiring treatment with broad-spectrum antibiotics (prophylactic therapy for PCP or MAC is allowed)&lt;/li&gt;&lt;li&gt;Subjects with active substance&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>To evaluate P-113 mouthrinse for clinical and microbial evaluation in HIV seropositive individuals with oral candidiasis</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial was to study the &lt;ulink linkType="Drug" linkID="56262"&gt;P-113&lt;/ulink&gt; (PAC-113) mouthrinse for clinical and microbial evaluation in HIV seropositive individuals with oral candidiasis [&lt;ulink linkType="Reference" linkID="1416204"&gt;1416204&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive &lt;ulink linkType="Drug" linkID="56262"&gt;P-113&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1416204"&gt;1416204&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="South Africa"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>HIV infection</Disease><PatientSegments><PatientSegment><PatientSegment id="7085">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="7382">Subjects with opportunistic/other infections</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="19022">Subjects with HIV Infection</PatientSegment><SubSegments><SubSegment id="7126">Subjects with HIV-1 Infection</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Candida infection</Disease><PatientSegments><PatientSegment><PatientSegment id="8617">Subjects with Oropharyngeal Candidiasis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8629">Immunocompromised Subjects</PatientSegment><SubSegments><SubSegment id="8630">Subjects immuno-compromised with HIV infection</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries/><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Candida infection" id="13745"><Endpoint>Assessment of Clinical Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Candida infection" id="13746"><Endpoint>Assessment of Microbiological Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Candida infection" id="13747"><Endpoint>Assessment by Global Assessment Scales</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="HIV infection" id="5278"><Criterion>Subjects with HIV Infection</Criterion></Inclusion><Inclusion disease="HIV infection" id="5297"><Criterion>Subjects with Opportunistic/Other Infections</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5298">Subjects with candidiasis </SubCriterion></SubCriteria></Inclusion><Inclusion disease="Candida infection" id="7403"><Criterion>Subjects with Oropharyngeal Candidiasis</Criterion><SubCriteria><SubCriterion disease="Candida infection" id="7404">Subjects with pseudomembranous candidiasis(thrush)</SubCriterion><SubCriterion disease="Candida infection" id="7405">Subjects with erythematous candidiasis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Candida infection" id="7417"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Candida infection" id="7418">Subjects immunocompromised with HIV infection</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="HIV infection" id="6859"><Criterion>Pregnant or Breast Feeding Subjects</Criterion></Exclusion><Exclusion disease="HIV infection" id="6892"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6893">Subjects on antibacterial drugs</SubCriterion><SubCriterion disease="HIV infection" id="6894">Subjects with history of/scheduled to receive antifungals for other indication</SubCriterion><SubCriterion disease="HIV infection" id="6940">Subjects on treatment for malignancy</SubCriterion><SubCriterion disease="HIV infection" id="6963">Subjects with history/scheduled to receive immunomodulators for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bipolar disorder" id="7403"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="7404">Subjects with family history of bipolar disorder</SubCriterion><SubCriterion disease="Bipolar disorder" id="7405">Parent/Parents with bipolar disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bipolar disorder" id="7413"><Criterion>Subjects with Protocol Specified Clinical Manifestations</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="7418">Subjects with anxiety</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Candida infection" id="10835"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Candida infection" id="10845"><Criterion>Subjects on anti-fungal therapy</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><ChangeHistory><Change type="added"><Date>2013-05-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="143431"><TitleDisplay>Bioequivalence Study of Lamotrigine Extended-Release Tablets 50 mg Under Fasting Condition</TitleDisplay><TitleOfficial>An Open-label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Conditions</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01888731</Identifier><Identifier type="Organisational Study">717/09</Identifier></Identifiers><Indications/><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lamotrigine ER</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>lamotrigine (extended release), GlaxoSmithKline</Name><Drug id="48478">lamotrigine (extended release), GlaxoSmithKline</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="29387" type="Company"><TargetEntity id="4295872868" type="organizationId">Dr.Reddy's Laboratories Ltd</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="29387">Dr Reddy's Laboratories Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies><Technology id="590">Enteric coated formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="660">Oral sustained release formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioequivalence</Term><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>62</PatientCountEnrollment><DateStart>2010-08-31T00:00:00Z</DateStart><DateEnd type="actual">2010-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-09-05T08:24:48Z</DateChangeLast><DateAdded>2013-07-03T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Bioserve Clinical Research Private Limited,</Affiliation><Name>Srinivas Yadav K, Dr.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Provide written informed consent&lt;/li&gt;&lt;li&gt;Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive) weighing at least 50 kg&lt;/li&gt;&lt;li&gt;Having a body mass index between 18.5 and 24.9 (both inclusive), calculated as kg/m2&lt;/li&gt;&lt;li&gt;Must be of normal health as determined by medical history, physical examination and laboratory investigation performed within 28 days prior to the commencement of the study (laboratory values must be within normal limits or considered by the physician/investigator to be of no clinical significance)&lt;/li&gt;&lt;li&gt;Female subjects of child-bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence&lt;/li&gt;&lt;li&gt;Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects were excluded based on the following criteria screening and during the study:&lt;ul&gt;&lt;li&gt;Incapable of understanding the informed consent&lt;/li&gt;&lt;li&gt;Systolic blood pressure&amp;lt; 90 or &gt; 140 mmHg&lt;/li&gt;&lt;li&gt;Diastolic blood pressure&amp;lt; 60 or &gt; 90 mmHg&lt;/li&gt;&lt;li&gt;Oral temperature is&amp;lt; 95.0  or &gt; 98.6degF&lt;/li&gt;&lt;li&gt;Pulse rate&amp;lt; 50 or &gt; 100/min&lt;/li&gt;&lt;li&gt;History of hypersensitivity or idiosyncratic reaction to investigational drug product or any other related drugs or its ingredients&lt;/li&gt;&lt;li&gt;Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function&lt;/li&gt;&lt;li&gt;Consumption of grapefruit for the past 10 days prior to the check-in, in each period&lt;/li&gt;&lt;li&gt;Regular smoker who has a habit of smoking &gt; 9 cigarettes/day and has difficulty in abstaining from smoking during sample collection period&lt;/li&gt;&lt;li&gt;Habit of tobacco chewing&lt;/li&gt;&lt;li&gt;Habit of alcoholism and difficulty in abstaining from alcohol during the sample collection period&lt;/li&gt;&lt;li&gt;Difficulty in abstaining from xanthine containing food or beverages (like tea, coffee, chocolates and cola drinks) during the sample collection period&lt;/li&gt;&lt;li&gt;Intake of over the counter (OTC) or prescribed medications and enzyme modifying medication or systemic medication for the last 30 days before dosing&lt;/li&gt;&lt;li&gt;Clinically significant abnormalities and/or with significant diseases&lt;/li&gt;&lt;li&gt;Confirmed positive in alcohol screening&lt;/li&gt;&lt;li&gt;Confirmed positive in urine cotinine test&lt;/li&gt;&lt;li&gt;Confirmed positive in selected drug of abuse&lt;/li&gt;&lt;li&gt;Participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study&lt;/li&gt;&lt;li&gt;Confirmed positive in urine pregnancy test&lt;/li&gt;&lt;li&gt;Female detected to be pregnant, breast feeding or who is likely to become pregnant during the study&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Area under curve (AUC)</Description><Timeframe>Predose (0.00) and 2.00, 4.00, 6.00, 8.00, 9.00, 10.00, 12.00, 14.00, 15.50, 17.00, 18.50, 20.00, 21.50, 23.00, 24.50, 26.00, 27.50, 29.00, 36.00, 48.00, 72.00, 96.00, 120.00, 144.00 and 168.00 h post dose in each period</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was an open-label, randomized, balanced, two-treatment, two-period, two-sequence, single-dose, crossover, oral bioequivalence study lamotrigine extended-release tablets 50 mg under fasting condition.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would be randomized to receive lamotrigine ER tablets (25 or 50 or 100 or 200 or 300 mg) of &lt;ulink linkType="Company" linkID="29387"&gt;Dr Reddy's Laboratories Limited&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="48478"&gt;Lamictal XR&lt;/ulink&gt; tablets (50 mg) of &lt;ulink linkType="Company" linkID="28355"&gt;GlaxoSmithKline&lt;/ulink&gt; Research Triangle Park, NC under fasting condition.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>Bioserve Clinical Research Private Limited</Name><Address1>Balanagar</Address1><Address2>Hyderabad</Address2><Address3>500 037</Address3><CountrySubDivision>Hyderabad</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01888731</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2010-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2013-06-26T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-07-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="144898"><TitleDisplay>A Cross-Sectional Study to Evaluate the Association of Low Dose Cabergoline With Clinically Significant Valvular Heart Disease in Hyperprolactinemia</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="255">Parkinsons disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cabergoline</Name><Drug id="2705">cabergoline</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2705">cabergoline</Drug><IndicationsPioneer/><Companies><Company><Company id="1086008">Michael White Diabetes Centre</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2705" type="Drug"><TargetEntity id="115048" type="siDrug">Cabergoline</TargetEntity></SourceEntity><SourceEntity id="255" type="ciIndication"><TargetEntity id="G20" type="ICD10"/><TargetEntity id="10061536" type="MEDDRA"/><TargetEntity id="D010300" type="MeSH"/><TargetEntity id="-342157116" type="omicsDisease"/><TargetEntity id="127" type="siCondition"/></SourceEntity><SourceEntity id="149" type="Action"><TargetEntity id="131" type="Mechanism">Dopamine D2 Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1086008">Michael White Diabetes Centre</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="149">Dopamine D2 receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2947">Antiparkinsonian</Class><Class id="3301">Prolactin release inhibitor</Class><Class id="74">Antioxidant agent</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Cross-sectional</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>610</PatientCountEnrollment><PatientCountEvaluable>610</PatientCountEvaluable><DateChangeLast>2014-02-04T11:47:06Z</DateChangeLast><DateAdded>2013-07-09T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients treated with&lt;ulink linkType="Drug" linkID="2705"&gt;cabergoline&lt;/ulink&gt; for hyperprolactinaemia underwent transthoracic echocardiography&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to study if &lt;ulink linkType="Drug" linkID="2705"&gt;cabergoline&lt;/ulink&gt; in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease [&lt;ulink linkType="Reference" linkID="1449622"&gt;1449622&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In October 2008, results were published. The mean cumulative dose of &lt;ulink linkType="Drug" linkID="2705"&gt;cabergoline&lt;/ulink&gt; in the cases was observed to be 311 mg. No significant, severe or moderate, right- or left-sided valvular regurgitation was seen in either group. In the mitral and aortic valves of the left heart, the rate of mild and trivial valvular regurgitation was not different between the two groups. In the right heart of the &lt;ulink linkType="Drug" linkID="2705"&gt;cabergoline&lt;/ulink&gt; group mild tricuspid and pulmonary regurgitation on color Doppler alone was increased significantly, odds ratios of 3.1 and 7.8 respectively (p = 0.04 and p &amp;lt; 0.0001 respectively) [&lt;ulink linkType="Reference" linkID="1449622"&gt;1449622&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients treated with &lt;ulink linkType="Drug" linkID="2705"&gt;cabergoline&lt;/ulink&gt; were included in this study [&lt;ulink linkType="Reference" linkID="1449622"&gt;1449622&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms><PatientSegmentByDisease><Disease>Parkinsons disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7373">Subjects with comorbid conditions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries/><OutcomeMeasureTerms><OtherEndpoints><OtherEndpoint disease="Parkinsons disease" id="10203"><Endpoint>Assessment of Cardiac Function</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Parkinsons disease" id="6089"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Parkinsons disease" id="6090"><Criterion>Subjects co-morbid with cardiovascular disease/disorder</Criterion></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><ChangeHistory><Change type="added"><Date>2013-07-09T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="149693"><TitleDisplay>Phase II Study of Docetaxel and TS-1 Combination Therapy for Outpatients With Relapsed or Refractory Non-small Cell Lung cancer</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000000501</Identifier></Identifiers><Indications><Indication id="1262">Non-small-cell lung cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="2527" role="Therapeutic effect marker" type="Genomic;Proteomic">Aspartate aminotransferase</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>docetaxel</Name><Drug id="2953">docetaxel</Drug></Intervention><Intervention type="InterventionPrimary"><Name>tegafur + gimeracil + oteracil potassium</Name><Drug id="10084">tegafur + gimeracil + oteracil potassium</Drug></Intervention><Intervention type="InterventionPrimary"><Name>tegafur + gimeracil + oteracil potassium + docetaxel</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="10084">tegafur + gimeracil + oteracil potassium</Drug><IndicationsPioneer/><Companies><Company><Company id="1080991">Kyoto University Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2953">docetaxel</Drug><IndicationsPioneer/><Companies><Company><Company id="1080991">Kyoto University Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2953" type="Drug"><TargetEntity id="140605" type="siDrug">Docetaxel</TargetEntity></SourceEntity><SourceEntity id="10084" type="Drug"><TargetEntity id="203364" type="siDrug">Tegafur/gimeracil/oteracil</TargetEntity><TargetEntity id="217985" type="siDrug">TS1</TargetEntity></SourceEntity><SourceEntity id="1080991" type="Company"><TargetEntity id="5039148121" type="organizationId">Kyoto University Hospital</TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"/><TargetEntity id="D002289" type="MeSH"/><TargetEntity id="-1730468577" type="omicsDisease"/><TargetEntity id="612" type="siCondition"/></SourceEntity><SourceEntity id="782" type="Action"><TargetEntity id="512" type="Mechanism">Uracil Dehydrogenase Inhibitors</TargetEntity><TargetEntity id="2868" type="Mechanism">Dihydropyrimidine Dehydrogenase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1080991">Kyoto University Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="6661">Orotate phosphoribosyltransferase inhibitor</Action><Action id="782">Dihydropyrimidine dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="2575">Microtubule inhibitor</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="175">Drug combination</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1647">Natural product</Technology><Technology id="102">Nucleotide and derivatives</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>35</PatientCountEnrollment><PatientCountEvaluable>35</PatientCountEvaluable><DateStart>2006-04-30T00:00:00Z</DateStart><DateEnd type="actual">2008-12-01T00:00:00Z</DateEnd><DateChangeLast>2014-03-26T05:06:13Z</DateChangeLast><DateAdded>2013-08-12T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Kyoto University Hospital, Outpatient Oncology Unit,54 Shogoinkawahara-choSakyo-ku, Kyoto, Japan 606-8507</Affiliation><Name>Kazuhiro Yanagihara</Name><Phone>+81-75-366-7500</Phone></Contact><Contact type="Public contact"><Email>kazuhiro@kuhp.kyoto-u.ac.jp</Email><Name>Kazuhiro Ynagihara</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histologically or cytologically confirmed stage IIIB, IV, or recurrent NSCLC&lt;/li&gt;&lt;li&gt;Measurable lesions (RECIST)&lt;/li&gt;&lt;li&gt;Relapsed or refractory to prior chemotherapy or chemoradiotherapy (&amp;lt; 3 regimes, exclusive of postoperative Tegafur-Uracil)&lt;/li&gt;&lt;li&gt;Complete recovery from hematological adverse effct of prior therapy&lt;/li&gt;&lt;li&gt;No intrathoracic irradiation within 12 weeks or recovery from toxicity due to irradiation within 12 weeks&lt;/li&gt;&lt;li&gt;PS (ECOG) 0 to 1&lt;/li&gt;&lt;li&gt;Age ranging from 20 to 74 years&lt;/li&gt;&lt;li&gt;Sufficient organ functions within 2 weeks. Defined as:&lt;ul&gt;&lt;li&gt;White blood cell count&amp;lt;/= 12,000/mm3&lt;/li&gt;&lt;li&gt;Neutrophil count&amp;gt;/= 2000/mm3&lt;/li&gt;&lt;li&gt;Platelet&amp;gt;/= 100,000/mm3&lt;/li&gt;&lt;li&gt;Hemoglobin&amp;gt;/= 9.0 g/dl&lt;/li&gt;&lt;li&gt;AST and ALT within 2 x the upper limit of normal for the institution&lt;/li&gt;&lt;li&gt;Serum bilirubin level&amp;lt;/=1.5 mg/dl&lt;/li&gt;&lt;li&gt;Serum creatinine level&amp;lt;/= 1.5 mg/dl&lt;/li&gt;&lt;li&gt;Normal ECG&lt;/li&gt;&lt;li&gt;SaO2&amp;gt;/= 94% (room air)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Expected survival over 3 months&lt;/li&gt;&lt;li&gt;Possible to oral intake&lt;/li&gt;&lt;li&gt;Provided written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Active ineterstitial pneumonitis&lt;/li&gt;&lt;li&gt;History of using&lt;ulink linkType="Drug" linkID="10084"&gt;TS-1&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Active infectious disease&lt;/li&gt;&lt;li&gt;Active hepatitis or hepatocirrhosis&lt;/li&gt;&lt;li&gt;Active concomitant malignancy&lt;/li&gt;&lt;li&gt;Uncontrollable diabetes&lt;/li&gt;&lt;li&gt;Serious cardiac disease&lt;/li&gt;&lt;li&gt;Psycological illness&lt;/li&gt;&lt;li&gt;Other severe complications&lt;/li&gt;&lt;li&gt;Pleural or pericardial effusion, or ascites requiring treatment&lt;/li&gt;&lt;li&gt;Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy&lt;/li&gt;&lt;li&gt;Regular use of warfarin&lt;/li&gt;&lt;li&gt;Regular use of fenitoin or frucitocin&lt;/li&gt;&lt;li&gt;High fever&lt;/li&gt;&lt;li&gt;Clinical symptom of brain metastases&lt;/li&gt;&lt;li&gt;Serious nephropathy and/or edema&lt;/li&gt;&lt;li&gt;Regular use of steroid&lt;/li&gt;&lt;li&gt;Medical history of serious allergy reactions to any drug&lt;/li&gt;&lt;li&gt;Inappropriate patients for this study judged by the physicians&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Overall response rate (ORR)</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Overall survival</Description></Measure><Measure><Description>Progression-free survival</Description></Measure><Measure><Description>Adverse events</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In 2009, results were presented. Neutropenia (31%) and anemia (11%) were the hematological grade 3/4 toxicity observeed. No febrile neutropenia was observed. Diarrhea (17%), infection (8.6%), anorexia (5.7%), rash (5.7%), elevation of serum aspartate aminotransferase (AST) (5.7%) were the non-hematological  grade 3 toxicities reported. No grade 4 non-hematologic toxicity was observed.  Possible treatment-related death (n = 1) due to pneumonitis and infection after the first chemotherapy cycle was observed  [&lt;ulink linkType="Reference" linkID="1463982"&gt;1463982&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this trial was to determine safety and efficacy in combination with &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="10084"&gt;S-1&lt;/ulink&gt; for relapsed or refractory non-small cell lung cancer [&lt;ulink linkType="Reference" linkID="1463972"&gt;1463972&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1463982"&gt;1463982&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In 2009, results were presented. Median number of treatment cycles were  3 (1 to 7). The objective responses were observed to be  CR 0; PR 9; SD 14; PD 10; and NE 2, resulting in an ORR of 26%. The overall disease control rate and  median PFS were  66% and 4.1 months, respetively  [&lt;ulink linkType="Reference" linkID="1463982"&gt;1463982&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive iv &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; 40 mg/m2 on day1 and &lt;ulink linkType="Drug" linkID="10084"&gt;S-1&lt;/ulink&gt; po, 80 mg/m2/day from day1 to 14 every 3weeks [&lt;ulink linkType="Reference" linkID="1463972"&gt;1463972&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="10084"&gt;S-1&lt;/ulink&gt; (80 mg/m2) on days 1 to 14 and &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; (25 mg/m2) on days 1 and 15 of each 28-day cycle [&lt;ulink linkType="Reference" linkID="1463982"&gt;1463982&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>tegafur + gimeracil + oteracil potassium + docetaxel</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>17.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="17">Anemia</Indication><CountPatientsAffectedPercentage>11.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1991">Neutropenia</Indication><CountPatientsAffectedPercentage>31.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3020">Skin rash</Indication><CountPatientsAffectedPercentage>5.7</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3038">Appetite loss</Indication><CountPatientsAffectedPercentage>5.7</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="746">Infectious disease</Indication><CountPatientsAffectedPercentage>8.6</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="341181">docetaxel</Intervention><Treatments><Treatment><Dose>25 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="341182">tegafur + gimeracil + oteracil potassium</Intervention><Treatments><Treatment><Dose>80 milligram/m2</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lung tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3617">Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3623">Subjects with Advanced Stage Lung Cancer</PatientSegment><SubSegments><SubSegment id="3634">Subjects with metastatic/stage IV lung cancer</SubSegment><SubSegment id="10295">Subjects with locally advanced/stage III lung cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3650">Subjects with Recurrent/Relapsed Lung Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000000501</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lung tumor" id="8504"><Endpoint>Assessment of Objective Response</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8505">Assessment of objective response rate(ORR)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Lung tumor" id="8508"><Endpoint>Assessment of Overall Response</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lung tumor" id="8481"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lung tumor" id="8555"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8556">Assessment of all cause mortality</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lung tumor" id="8639"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8640">Adverse events as graded by CTCAE/CTC</SubEndpoint><SubEndpoint disease="Lung tumor" id="8642">Assessment of gastrointestinal toxicities (Upper and Lower)</SubEndpoint><SubEndpoint disease="Lung tumor" id="8643">Assessment of pulmonary toxicities</SubEndpoint><SubEndpoint disease="Lung tumor" id="8645">Assessment of hematological toxicities</SubEndpoint><SubEndpoint disease="Lung tumor" id="8648">Assessment of hepatotoxicity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lung tumor" id="8677"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="9419">Assessment of Other Treatment Related Outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Lung tumor" id="8489"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></OtherEndpoint><OtherEndpoint disease="Lung tumor" id="44828"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8517">Assessment of clinical response rate</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lung tumor" id="3900"><Criterion>Subjects with Non Small Cell Lung Cancer (NSCLC)</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3913"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3914">Subjects with measurable disease as per RECIST criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3925"><Criterion>Subjects with Protocol Specified Stages of Lung Cancer(TNM staging)</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3933">Subjects with stage III lung cancer</SubCriterion><SubCriterion disease="Lung tumor" id="3935">Subjects with stage IIIB lung cancer</SubCriterion><SubCriterion disease="Lung tumor" id="3936">Subjects with stage IV lung cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3940"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3968"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3971">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3975"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3976">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Lung tumor" id="3977">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3988"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3994">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="4000"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4002">Subjects with relapsed/recurrent disease after radiation therapy</SubCriterion><SubCriterion disease="Lung tumor" id="4003">Subjects with relapsed/recurrent disease after chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="4049"><Criterion>Subjects with Normal/Acceptable Pulmonary Function Tests</Criterion></Inclusion><Inclusion disease="Lung tumor" id="4056"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Lung tumor" id="4073"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4098">Subjects recovered from all prior therapies and/or their toxic/adverse effects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="22380"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion></Inclusion><Inclusion disease="Lung tumor" id="33317"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4024">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34001"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4032">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34925"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4074">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lung tumor" id="5121"><Criterion>Subjects with Evidence of Metastasis</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5122">Subjects with symptomatic/uncontrolled metastases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="5132"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5149"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5168"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5185"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5193"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5236"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5269"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5270">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="5291"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5344"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5365">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="20281"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5128">Subjects with central nervous system diseases/disorders</SubCriterion><SubCriterion disease="Lung tumor" id="5163">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="20282"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="27073"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5139">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="27883"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5349">Subjects unable/unwilling to comply with protocol requirements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="28316"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5366">Sexually active male or female unwilling to use adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-08-12T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="153417"><TitleDisplay>Australasian Collaborative Trial Of Vitamin C And Vitamin E Supplementation For The Prevention Of Pre-Eclampsia</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN00416244</Identifier></Identifiers><Indications><Indication id="1259">Pre-eclampsia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>vitamin C</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>vitamin E</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="20522" type="Company"><TargetEntity id="4298146726" type="organizationId">University of Adelaide</TargetEntity></SourceEntity><SourceEntity id="1259" type="ciIndication"><TargetEntity id="O14" type="ICD10"/><TargetEntity id="642.7" type="ICD9"/><TargetEntity id="10036485" type="MEDDRA"/><TargetEntity id="D011225" type="MeSH"/><TargetEntity id="275555" type="ORPHANET"/><TargetEntity id="-1562278984" type="omicsDisease"/><TargetEntity id="568" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20522">University of Adelaide</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Prevention</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>1877</PatientCountEnrollment><PatientCountEvaluable>1877</PatientCountEvaluable><DateStart>2001-12-01T00:00:00Z</DateStart><DateEnd type="estimated">2005-01-31T00:00:00Z</DateEnd><DateChangeLast>2014-01-16T08:00:05Z</DateChangeLast><DateAdded>2013-09-05T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>University of Adelaide, Womens and Childrens Hospital, 72 King William Road, North Adelaide, 5006, Australia</Affiliation><Email>caroline.crowther@adelaide.edu.au</Email><Name>Caroline Crowther</Name><Phone>+61 (0)8 8161 7647</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;All nulliparous women presenting to the antenatal clinic at the collaborating centre with a singleton pregnancy, between 14 to 22 weeks gestation, a normal blood pressure, and expected to give birth at the collaborating center. Informed, written consent is necessary and there must be no contraindication to vitamin C or E therapy&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Women with any of the following: multiple pregnancy, life threatening fetal anomaly on ultrasound, known thrombophilia, chronic renal failure, hemochromatosis, women on heparin, warfarin or antihypertensive therapy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Incidence of small for gestational age infants</Description></Measure><Measure><Description>Clinical pre-eclampsia</Description></Measure><Measure><Description>Death or serious adverse pregnancy outcome for the infant</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Severe adverse outcomes for the woman</Description><Timeframe>Up to 6 weeks postpartum</Timeframe></Measure><Measure><Description>Delivering an infant whose birth weight was below the tenth percentile for gestational age</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results were published in April 2006. The differences between the vitamin and placebo groups in death or serious outcomes in the infant (9.5 and 12.1%; relative risk, 0.79)   were not significant [&lt;ulink linkType="Reference" linkID="1473222"&gt;1473222&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results were published in July 2008. Compared with women with a normal OGCT, a higher overall risk of adverse maternal outcome was observed in women with BGDM (12.9 versus 8.1%, RR 1.59, p = 0.05). Compared to women with normal glucose tolerance, pregnancy induced hypertension was more likely to occur in women with BGDM (17.9 versus 11.8%, RR 1.51, p = 0.03) and they were more likely to have a cesarean for fetal distress (17.1 versus 10.5%, RR 1.63, p = 0.01), and require a longer postnatal hospital stay (mean difference 0.4 day, p = 0.01). Infants born to BGDM mothers were more likely to be born preterm (10.7 versus 6.4%, RR 1.68, p = 0.05). It was observed that they were more likely to have macrosomia (birth weight &gt;/= 4.5 kg) (4.3 versus 1.7%, RR 2.53, p = 0.04), be admitted to the neonatal intensive care unit (NICU) (6.5 versus 3.0%, RR 2.18, p = 0.03) or the neonatal nursery (40.3 versus 28.4%, RR 1.42, p = 0.002), and have a longer hospital stay (p = 0.001). Sarnat stage 2 or 3 neonatal encephalopathy was seen in most of the infants in the BGDM group (12.9 versus 7.8%, RR 1.65, p = 0.03) [&lt;ulink linkType="Reference" linkID="1473217"&gt;1473217&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The hypothesis of the study was  that vitamin C and E supplementation from 14 weeks gestation in nulliparous women:&lt;br/&gt;Reduces the incidence of small for gestational age infants.&lt;br/&gt;Reduces the incidence of clinical pre-eclampsia.&lt;br/&gt;Reduces the risk of death or serious adverse outcome for the infant.&lt;br/&gt;Reduces the risks of adverse outcomes for the woman up to 6 weeks postpartum.   [&lt;ulink linkType="Reference" linkID="1473245"&gt;1473245&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1473222"&gt;1473222&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The purpose of this study was to assess maternal and infant health outcomes in women with borderline gestational diabetes mellitus (BGDM) and compared these to women who had a normal oral glucose challenge test (OGCT)  screen for gestational diabetes. This study would assess the prevalence and impact of mothers being overweight and obese in early to mid-pregnancy on maternal, peripartum and neonatal outcomes  [&lt;ulink linkType="Reference" linkID="1473217"&gt;1473217&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1473221"&gt;1473221&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in April 2006. The differences between the vitamin and placebo groups in the risk of preeclampsia (6.0 and 5.0%, respectively; relative risk, 1.20),  having an infant with a birth weight below the tenth percentile for gestational age (8.7 and 9.9%; relative risk, 0.87) were not significant    [&lt;ulink linkType="Reference" linkID="1473222"&gt;1473222&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results were published in July 2008. Compared to the women who screened negative on oral glucose tolerance test (OGTT), women who had BGDM were older (p = 0.01) and more likely to be obese (27.1 versus 14.1%, relative risk [RR] 1.92, p &amp;lt; 0.0001) [&lt;ulink linkType="Reference" linkID="1473217"&gt;1473217&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results were published in September 2010. Compared with women with a normal BMI, the risk of pre-eclampsia was higher in obese women (RR 2.99, p &amp;lt; 0.0001) and gestational diabetes (RR 2.10, p = 0.01). Compared with women of normal BMI, the need for induction of labor and requirement of cesarean section was more likely to occur in obese and overweight women (induction - RR 1.33, p = 0.001 and 1.78, p &amp;lt; 0.0001, cesarean section - RR 1.42, p = 0.0002 and 1.63, p &amp;lt; 0.0001). When compared with babies of women with a normal BMI, the babies of women who were obese were more likely to be large for gestational age (LFGA) (RR 2.08, p &amp;lt; 0.0001) and macrosomic (RR 4.54, p = 0.0003)  [&lt;ulink linkType="Reference" linkID="1473221"&gt;1473221&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Women would receive vitamin C (1000 mg) and vitamin E (400 IU) daily  [&lt;ulink linkType="Reference" linkID="1473245"&gt;1473245&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Women were randomized to receive vitamin C (1000 mg) and   vitamin E (400 IU) or placebo (microcrystalline cellulose) until delivery   [&lt;ulink linkType="Reference" linkID="1473222"&gt;1473222&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1473217"&gt;1473217&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1473221"&gt;1473221&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Women were divided into three groups according to their body mass index (BMI):&lt;br/&gt;Group 1: normal (BMI 18.5 to 24.9 kg/m2).&lt;br/&gt;Group 2: overweight (BMI 25 to 29.9 kg/m2).&lt;br/&gt;Group 3: obese (BMI 30 to 34.9 kg/m2) [&lt;ulink linkType="Reference" linkID="1473221"&gt;1473221&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="348519">vitamin C</Intervention><Treatments><Treatment><Dose>1000 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pregnancy Induced Hypertension</Disease><PatientSegments><PatientSegment><PatientSegment id="11145">Subjects with Risk for Preeclampsia Development</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN00416244</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pregnancy Induced Hypertension" id="24324"><Endpoint>Assessment of Preeclampsia/Related Outcomes</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pregnancy Induced Hypertension" id="24331"><Endpoint>Assessment of Fetal/Neonatal Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pregnancy Induced Hypertension" id="24337">Assessments of small for gestational age (SGA)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pregnancy Induced Hypertension" id="24412"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Pregnancy Induced Hypertension" id="24416">Assessment of neonatal and infant mortality</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pregnancy Induced Hypertension" id="24447"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pregnancy Induced Hypertension" id="24447"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pregnancy Induced Hypertension" id="21155"><Criterion>Subjects with Hypersensitivity/Intolerance to Therapy</Criterion></Inclusion><Inclusion disease="Pregnancy Induced Hypertension" id="21159"><Criterion>Pregnancy Related Other Inclusions</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="21168">Nulliparous women</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="21174">Protocol specified gestational age</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="21175">Subjects with singleton pregnancy</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pregnancy Induced Hypertension" id="18753"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18755">Subjects with planned/history of anticoagulant therapy</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="18758">Subjects with planned/history of antihypertensive</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pregnancy Induced Hypertension" id="18828"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18835">Subjects with thrombophilia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pregnancy Induced Hypertension" id="18836"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18839">Subjects with renal failure/renal insufficiency</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pregnancy Induced Hypertension" id="18849"><Criterion>Exclusion based on Pregnancy</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18861">Subjects with multifetal gestation/pregnancy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-09-05T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="156111"><TitleDisplay>The pilot project for infertility treatment using Korean Medicine: The efficacy of Jokyungjongoktang-gagambang(JKJOT-GGB), Sutaehwan-gagambang(STH-GGB), acupuncture and moxibustion treatment.</TitleDisplay><TitleOfficial>The pilot project for infertility treatment using Korean Medicine: The efficacy of Jokyungjongoktang-gagambang(JKJOT-GGB), Sutaehwan-gagambang(STH-GGB), acupuncture and moxibustion treatment.</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">KCT0000854</Identifier><Identifier type="Other">SR-24</Identifier></Identifiers><Indications><Indication id="1080">Female infertility</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Acupuncture</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Jokyungjongoktang-gagambang(JKJOT-GGB)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Moxibustion</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Sutaehwan-gagambang(STH-GGB)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1075575" type="Company"><TargetEntity id="5037957316" type="organizationId">Dongguk University Gyeongju Hospital</TargetEntity></SourceEntity><SourceEntity id="1080" type="ciIndication"><TargetEntity id="N97" type="ICD10"/><TargetEntity id="628" type="ICD9"/><TargetEntity id="10021928" type="MEDDRA"/><TargetEntity id="D007247" type="MeSH"/><TargetEntity id="-932722270" type="omicsDisease"/><TargetEntity id="553" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1075575">Dongguk University Gyeongju Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>34</PatientCountEnrollment><DateStart>2011-09-02T00:00:00Z</DateStart><DateChangeLast>2017-05-10T16:00:08Z</DateChangeLast><DateAdded>2013-09-30T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Dongguk University Ilsan Oriental Hospital</Affiliation><Name>Kim Dongil</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Woman unsuccessful at conceiving over a year even after many tries to become pregnant; diagnosed with unexplained infertility or ovulation related infertility from infertility clinic&lt;/li&gt;&lt;li&gt;Woman who has intercourse with reasonable frequency at least twice or more per week except during menstrual period&lt;/li&gt;&lt;li&gt;Woman who approves of participating in this project and of sharing the results&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Woman who cannot maintain the treatment of acupuncture and herbs for the duration of 6 months&lt;/li&gt;&lt;li&gt;Taking or planning of taking medication for infertility like hormonal drugs&lt;/li&gt;&lt;li&gt;Diagnosed with polycystic ovarian syndrome&lt;/li&gt;&lt;li&gt;Taking psychiatric medications&lt;/li&gt;&lt;li&gt;Experiences allergic reaction to metal or herbs&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pregnancy rate</Description><Timeframe>after 6 menstrual cycle period</Timeframe></Measure><Measure><Description>Live birth rate</Description><Timeframe>after 6 menstrual cycle period</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Body fat mass</Description><Timeframe>after 6 menstrual cycle period</Timeframe></Measure><Measure><Description>Body Mass Index</Description><Timeframe>after 6 menstrual cycle period</Timeframe></Measure><Measure><Description>Endometrial thickness</Description><Timeframe>after 6 menstrual cycle period</Timeframe></Measure><Measure><Description>The changes of hormone levels in luteinizing hormone</Description><Timeframe>after 6 menstrual cycle period</Timeframe></Measure><Measure><Description>The changes of hormone levels in estrogen</Description><Timeframe>after 6 menstrual cycle period</Timeframe></Measure><Measure><Description>The changes of hormone levels in Anti-Mullerian Hormone</Description><Timeframe>after 6 menstrual cycle period</Timeframe></Measure><Measure><Description>The changes of hormone levels in follicle stimulating hormone</Description><Timeframe>after 6 menstrual cycle period</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study would evaluate the efficacy of Jokyungjongoktang-gagambang(JKJOT-GGB), Sutaehwan-gagambang(STH-GGB), acupuncture and moxibustion treatment in infertile women&lt;ulink linkType="Reference" linkID="1482437"&gt;[1482437]&lt;/ulink&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be treated with acupuncture, moxibustion treatment,herbal medicine(Jokyungjongoktang-gagambang, Sutaehwan-gagambang): JKJOT-GGB for 10 days and STH-GGB for 15 days &lt;ulink linkType="Reference" linkID="1482437"&gt;[1482437&lt;/ulink&gt;]&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="South Korea"><Sites><Site><Name>Dongguk university Ilsan oriental hospital</Name><Address1>Goyang</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Infertility</Disease><PatientSegments><PatientSegment><PatientSegment id="11671">Subjects with Histroy of Infertility</PatientSegment><SubSegments><SubSegment id="11672">Women with infertility</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11674">Subjects with Ovulatory Dysfunction</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1010">Korea Clinical Research Information Service (CRiS)</Name><Identifiers><Identifier>KCT0000854</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Infertility" id="23245"><Endpoint>Assessment of Pregnancy</Endpoint><SubEndpoints><SubEndpoint disease="Infertility" id="23246">Assessment of live birth</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Infertility" id="23234"><Endpoint>Assessment of Endometrium</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Infertility" id="23242"><Endpoint>Assessment of Hormone Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Infertility" id="23261"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Infertility" id="23264">Anthropometry/vital signs</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Infertility" id="21052"><Criterion>Subjects with History of Infertility</Criterion><SubCriteria><SubCriterion disease="Infertility" id="21053">Women with a history of infertility</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Infertility" id="21055"><Criterion>Subjects with Ovulatory Dysfunction</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Infertility" id="17968"><Criterion>Subjects co-morbid with genitourinary disorders</Criterion></Exclusion><Exclusion disease="Infertility" id="17979"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Infertility" id="17992"><Criterion>Subjects with history of/scheduled for pharmacological therapy</Criterion></Exclusion><Exclusion disease="Infertility" id="17997"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Infertility" id="18002"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-09-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="159666"><TitleDisplay>Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix</TitleDisplay><TitleOfficial>Phase II, Prospective, Randomized, Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01973101</Identifier><Identifier type="Organisational Study">NP 217/2012</Identifier><Identifier type="Trial Acronym">CIRCE</Identifier></Identifiers><Indications><Indication id="427">Uterine cervix tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="213" role="Toxic effect marker" type="Biochemical">Creatinine</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>CRT alone group (Arm B)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>brachytherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cisplatin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>radiation therapy (45 to 50 Gy)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>NAC group (Arm A)</Name></Intervention><Intervention type="InterventionPrimary"><Name>cisplatin</Name></Intervention><Intervention type="InterventionPrimary"><Name>gemcitabine</Name><Drug id="3199">gemcitabine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3199">gemcitabine</Drug><IndicationsPioneer/><Companies><Company><Company id="1072874">Instituto do Cancer do Estado de São Paulo</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3199" type="Drug"><TargetEntity id="102180" type="siDrug">Gemcitabine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1072874" type="Company"><TargetEntity id="5037843891" type="organizationId">Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira</TargetEntity></SourceEntity><SourceEntity id="427" type="ciIndication"><TargetEntity id="C53" type="ICD10"/><TargetEntity id="10008342" type="MEDDRA"/><TargetEntity id="D002583" type="MeSH"/><TargetEntity id="-837567682" type="omicsDisease"/><TargetEntity id="590" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1072874">Instituto do Cancer do Estado de São Paulo</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>120</PatientCountEnrollment><PatientCountEvaluable>107</PatientCountEvaluable><DateStart>2012-06-30T00:00:00Z</DateStart><DateEnd type="estimated">2017-04-01T00:00:00Z</DateEnd><DateChangeLast>2018-07-20T06:34:00Z</DateChangeLast><DateAdded>2013-11-05T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>pesquisa.clinica@icesp.org.br</Email><Name>Maria Del Pilar Estevez Diz, MD</Name><Phone>55 11 3893-2000</Phone></Contact><Contact type="Scientific contact"><Affiliation>Instituto do Cancer do Estado de São Paulo</Affiliation><Name>Maria Del Pilar Estevez Diz, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Advanced carcinoma of uterine cervix histological confirmed&lt;/li&gt;&lt;li&gt;Indication for definitive chemoradiation treatment&lt;/li&gt;&lt;li&gt;Measurable disease by RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) criteria&lt;/li&gt;&lt;li&gt;Age between 18 and 70 years old&lt;/li&gt;&lt;li&gt;Adequate bone marrow and organ function defined by laboratory values&lt;/li&gt;&lt;li&gt;Non evidence of disease in para-aortic lymph node&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Previous treatment with chemotherapy or radiotherapy&lt;/li&gt;&lt;li&gt;Previous surgery for primary tumor&lt;/li&gt;&lt;li&gt;Distant metastasis&lt;/li&gt;&lt;li&gt;Performance status according to Eastern Cooperative Oncology Group &gt; 2&lt;/li&gt;&lt;li&gt;Peripheric neuropathy greater than grade 2 by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 3.0&lt;/li&gt;&lt;li&gt;Significant Cardiac disease (history of and/or active disease)&lt;/li&gt;&lt;li&gt;Other treatment for cancer, including hormonotherapy&lt;/li&gt;&lt;li&gt;Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Progression-free survival (PFS)</Description><Timeframe>Three years</Timeframe></Measure><Measure><Description>Disease free survival</Description><Timeframe>From the randomization until the end of the treatment - up to 36 month.</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Acute and chronic toxicity in both arms</Description><Timeframe>From the randomization until the end of the treatment.</Timeframe></Measure><Measure><Description>Locoregional disease control rate</Description><Timeframe>36 month after the end of treatment.</Timeframe></Measure><Measure><Description>Overall survival</Description><Timeframe>36 month after the end of the treatment.</Timeframe></Measure><Measure><Description>Response rate</Description><Timeframe>36 month after the end of the treatment.</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results were presented in June 2018. Anemia (85.4 versus 82.3%), neutropenia (67.2 versus 46.1%), thrombocytopenia (45.4 versus 26.9%), creatinine elevation (16.3 versus 5.7%), hypomagnesemia (27.2 versus 7.6%), neuropathy (25.4 versus 1.9%), dysuria (36.3 versus 50%), nausea (92 versus 84.6%) and diarrhea (58.1 versus 57.6%) were the any grade acute adverse events reported in NAC versus CRT groups, respectively  [&lt;ulink linkType="Reference" linkID="2039308"&gt;2039308&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;      The purpose of this phase II study was to determine the survival free disease of patients      diagnosed with invasive locally advanced carcinomas of uterine cervix treated with induction      chemotherapy with cisplatin and gemcitabine followed by chemoradiation and definitive      chemoradiation.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were presented in June 2018. The PFS rates at 3 years were 41.1 and 59.6% in NAC and CRT alone groups, respectively (p = 0.134), while OS rates at 3 years were 74.2 and 81.9%, respectively (p = 0.230). It was observed that CRT alone group reported superior complete response rate (CR) compared to NAC followed by CRT group (54 versus 82%, p = 0.002). Median time to CR was 9.5 and 10 weeks in NAC and CRT groups, respectively [&lt;ulink linkType="Reference" linkID="2039308"&gt;2039308&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive cisplatin 50 mg/m2 on day 1 plus &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; 1000 mg/m2 on day 1 and 8 for three cycles followed by cisplatin 40 mg/m2 on day 1, 8, 15, 22 and 36, radiotherapy 45 Gy and brachytherapy 80 Gy.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized to receive three cycles of neoadjuvant chemotherapy (NAC) including cisplatin 50 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 q21d followed by standard chemoradiation with cisplatin (CRT) 40 mg/m2/wk/6 wk plus pelvic radiotherapy (45 to 50 Gy) followed by brachytherapy (BCT; Arm A) or standard CRT and BCT alone (Arm B) [&lt;ulink linkType="Reference" linkID="2039308"&gt;2039308&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>NAC group (Arm A)</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>58.1</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="17">Anemia</Indication><CountPatientsAffectedPercentage>85.4</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1991">Neutropenia</Indication><CountPatientsAffectedPercentage>67.2</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>92.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2733">Hypomagnesemia</Indication><CountPatientsAffectedPercentage>27.2</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="324">Thrombocytopenia</Indication><CountPatientsAffectedPercentage>45.4</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="433">Dysuria</Indication><CountPatientsAffectedPercentage>36.3</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="678">Neuropathy</Indication><CountPatientsAffectedPercentage>25.4</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>CRT alone group (Arm B)</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>57.6</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="17">Anemia</Indication><CountPatientsAffectedPercentage>82.3</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1991">Neutropenia</Indication><CountPatientsAffectedPercentage>46.1</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>84.6</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2733">Hypomagnesemia</Indication><CountPatientsAffectedPercentage>7.6</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="324">Thrombocytopenia</Indication><CountPatientsAffectedPercentage>26.9</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="433">Dysuria</Indication><CountPatientsAffectedPercentage>50.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="678">Neuropathy</Indication><CountPatientsAffectedPercentage>1.9</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="363450">cisplatin</Intervention><Treatments><Treatment><Dose>40 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>50 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="363451">gemcitabine</Intervention><Treatments><Treatment><Dose>1000 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Brazil"><Sites><Site><Name>ICESP</Name><Address1>São Paulo</Address1><Address2>SP</Address2><CountrySubDivision>SP</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>pesquisa.clinica@icesp.org.br</Email><Name>Maria Del Pilar Estevez Diz, MD</Name><Phone>55 11 3893-2000</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Papillomavirus infection</Disease><PatientSegments><PatientSegment><PatientSegment id="10868">Subjects with Cervical Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Uterine cervix tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8527">Subjects with Invasive Cervical Cancer (ICC)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8541">Subjects with Locally Advanced Cervical Cancer (Stage IIB - IVA)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8547">Subjects with Advanced/Metastatic Cervical Cancer (Stage IVB)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01973101</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Uterine cervix tumor" id="12651"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Papillomavirus infection" id="17916"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Uterine cervix tumor" id="12650"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Uterine cervix tumor" id="12661"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Uterine cervix tumor" id="12735"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Uterine cervix tumor" id="12743">Assessment of dose limiting toxicity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Papillomavirus infection" id="17896"><Endpoint>Assessment of Tumor Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Papillomavirus infection" id="17915"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Papillomavirus infection" id="17921"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Papillomavirus infection" id="17922">Adverse events/reactogenicity</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Papillomavirus infection" id="17892"><Endpoint>Resolution/Progression of HPV Infections/Lesions</Endpoint><SubEndpoints><SubEndpoint disease="Papillomavirus infection" id="17893">Resolution/progression of cervical lesions</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Uterine cervix tumor" id="7658"><Criterion>Subjects with Invasive Cervical Cancer (ICC)</Criterion></Inclusion><Inclusion disease="Uterine cervix tumor" id="7680"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Uterine cervix tumor" id="7681"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Uterine cervix tumor" id="7684"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Uterine cervix tumor" id="7696"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Uterine cervix tumor" id="7697">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Uterine cervix tumor" id="7698">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Uterine cervix tumor" id="7699">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Uterine cervix tumor" id="7715"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion></Inclusion><Inclusion disease="Papillomavirus infection" id="16610"><Criterion>Subjects with Cervical Cancer</Criterion></Inclusion><Inclusion disease="Papillomavirus infection" id="16634"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Uterine cervix tumor" id="9247"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Uterine cervix tumor" id="9275"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Uterine cervix tumor" id="9276">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Uterine cervix tumor" id="9279">Subjects with history of/scheduled to receive hormone therapy</SubCriterion><SubCriterion disease="Uterine cervix tumor" id="9280">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Uterine cervix tumor" id="9281">Subjects with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Uterine cervix tumor" id="9284"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Papillomavirus infection" id="14629"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Papillomavirus infection" id="14631"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Papillomavirus infection" id="14642"><Criterion>Subjects on Prior/Concurrent Anti-neoplastic Therapy</Criterion></Exclusion><Exclusion disease="Uterine cervix tumor" id="26376"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Uterine cervix tumor" id="9242">Subjects with Advanced/Metastatic Cervical Cancer (Stage IVB)</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2017-04-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2013-10-22T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-11-05T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-07-20T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-07-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change></ChangeHistory></Trial><Trial id="167529"><TitleDisplay>Bioequivalence Study of Three New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)</TitleDisplay><TitleOfficial>An Open-Label, Single-Dose, Randomized, Four-Period, Cross-over, Bioequivalence Study of Three New Formulations of Premarin 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg Compared With a Reference Formulation of Premarin/MPA (Prempro) 0.45 mg/1.5 mg in Healthy Postmenopausal Women</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00472927</Identifier><Identifier type="Organisational Study">0713E1-1142</Identifier></Identifiers><Indications/><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sodium estrone sulfate + sodium equilin sulfate + medroxyprogesterone acetate</Name><Drug id="4157">sodium estrone sulfate + sodium equilin sulfate + medroxyprogesterone acetate</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4157">sodium estrone sulfate + sodium equilin sulfate + medroxyprogesterone acetate</Drug><IndicationsPioneer/><Companies><Company><Company id="18767">Pfizer Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4157" type="Drug"><TargetEntity id="224340" type="siDrug">Premarin/medroxyprogesterone acetate</TargetEntity><TargetEntity id="224341" type="siDrug">Conjugated equine estrogens/medroxyprogesterone acetate</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="401" type="Action"><TargetEntity id="1285" type="Mechanism">Estrogen Receptor (ER) Agonists</TargetEntity></SourceEntity><SourceEntity id="624" type="Action"><TargetEntity id="559" type="Mechanism">Progesterone Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="18767">Pfizer Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="401">Estrogen receptor agonist</Action><Action id="624">Progesterone receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology id="723">Drug coating</Technology><Technology id="175">Drug combination</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioequivalence</Term><Term>Pharmacokinetics</Term></TermsEndpoint><DateStart>2007-05-31T00:00:00Z</DateStart><DateEnd type="actual">2007-08-01T00:00:00Z</DateEnd><DateChangeLast>2018-07-07T11:17:13Z</DateChangeLast><DateAdded>2014-01-17T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Wyeth</Affiliation><Name>Medical Monitor</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy, postmenopausal women, aged 35 to 70 years&lt;/li&gt;&lt;li&gt;Spontaneous amenorrhea for at least 12 months (no FSH required) or spontaneous amenorrhea for at least 6 months (FSH level &gt;/= 38 mIU/ml); spontaneous amenorrhea must have begun by the age of 55&lt;/li&gt;&lt;li&gt;BMI in the range of 18 to 35 kg/m2&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History or presence of hypertension (&amp;gt; 139 mmHg systolic or &amp;gt; 89 mmHg diastolic)&lt;/li&gt;&lt;li&gt;History of drug allergy to conjugated estrogens (CE) or selective estrogen receptor modulators (SERMs)&lt;/li&gt;&lt;li&gt;Use of prescription or investigatioanl drugs within 30 days before test article administration&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Plasma concentration data and PK parameters of MPA and premarin (esrone and equilin components)</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate three new investigational tablet formulations of the Food and drug administration      (FDA) approved medication &lt;ulink linkType="Drug" linkID="4157"&gt;Prempro&lt;/ulink&gt;, premarin combined with medroxyprogesterone acetate      (MPA).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive either premarin (0.45 mg) + medroxyprogesterone acetate (MPA) (1.5 mg) or premarin (0.45 mg) + MPA(1.5 mg) (&lt;ulink linkType="Drug" linkID="4157"&gt;Prempro&lt;/ulink&gt;).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33126</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Address1>Miami</Address1><Address2>Florida</Address2><Address3> 33126</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Menopause</Disease><PatientSegments><PatientSegment><PatientSegment id="19017">Subjects with Protocol Specified Menstrual Status</PatientSegment><SubSegments><SubSegment id="11612">Postmenopausal Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00472927</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Menopause" id="20769"><Criterion>Subjects with protocol Specified Hormonal Levels</Criterion><SubCriteria><SubCriterion disease="Menopause" id="20770">Subjects with protocol specified FSH levels</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Menopause" id="20774"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion></Inclusion><Inclusion disease="Menopause" id="33715"><Criterion>Subjects with Protocol Specified Menstrual Status</Criterion><SubCriteria><SubCriterion disease="Menopause" id="20758">Postmenopausal subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Menopause" id="18302"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Menopause" id="18308"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Menopause" id="18310"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Menopause" id="18311">Subjects with history of/scheduled to receive hormone therapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2007-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>1.03 Months</EnrollmentPeriod><DateFirstReceived>2007-05-10T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-01-17T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="168786"><TitleDisplay>A Randomized, Open-label, Cross over Assignment, Comparative Study to Evaluate Pharmacokinetics, Bioequivalence and Safety of Drugs  Tamsulosin 0.4 mg Capsules with a Modified Release Manufactured Sinton Spain SL, Spain and Omnic 0.4 mg Capsules Modified Release (Astellas pharma  Europe BV Netherlands) in Healthy Volunteers</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">DKLS_12_1</Identifier></Identifiers><Indications/><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tamsulosin (Sinton Spain)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>tamsulosin hydrochloride</Name><Drug id="4513">tamsulosin hydrochloride</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1010541" type="Company"><TargetEntity id="5000892031" type="organizationId">Moskhimfarmpreparaty im. N.A. Semashko OAO</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1010541">Skovskoe Proizvodstvennoe Khimiko-Farmatsevticheskoe Ob"Edinenie Im Na Semashko</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="660">Oral sustained release formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioequivalence</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>24</PatientCountEnrollment><DateStart>2012-04-20T00:00:00Z</DateStart><DateChangeLast>2018-07-09T05:07:03Z</DateChangeLast><DateAdded>2014-01-22T00:00:00Z</DateAdded><Contacts/><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Pharmacokinetics</Description></Measure><Measure><Description>Bioequivalence</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study a comparative study of the pharmacokinetics, bioequivalence and safety of drugs  tamsulosin 0.4 mg capsules with a modified release manufactured Sinton Spain SL, Spain and &lt;ulink linkType="Drug" linkID="4513"&gt;Omnic&lt;/ulink&gt; 0.4 mg capsules modified release (&lt;ulink linkType="Company" linkID="21283"&gt;Astellas pharma  Europe BV&lt;/ulink&gt;, Netherlands) in healthy volunteers.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive tamsulosin 0.4 mg or &lt;ulink linkType="Drug" linkID="4513"&gt;Omnic&lt;/ulink&gt; 0.4 mg  modified release capsules.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Russian Federation"><Sites><Site><Name>State Budget Institution of Health Nizhny Novgorod region "City Hospital № 33 Leninsky district of Nizhny Novgorod" (Nizhny Novgorod).</Name><Address1>Nizhny Novgorod</Address1><Address3>603076</Address3><Contacts/></Site><Site><Name>Municipal clinical health care facility "Medical - Care Unit Yaroslavl Diesel Equipment Plant"</Name><Address1>Yaroslavl</Address1><Address3>150007</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1030">Russian State Register of Medicines Clinical Trials Registry</Name><Identifiers><Identifier/></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-01-22T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="191117"><TitleDisplay>Vyndaqel Drug Use Investigation (Regulatory Post-Marketing Commitment Plan)</TitleDisplay><TitleOfficial>Vyndaqel Drug Use Investigation (Regulatory Post-Marketing Commitment Plan)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02146378</Identifier><Identifier type="Organisational Study">B3461042</Identifier></Identifiers><Indications><Indication id="3399">Familial amyloid neuropathy</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tafamidis</Name><Drug id="54273">tafamidis</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="54273">tafamidis</Drug><IndicationsPioneer/><Companies><Company><Company id="18767">Pfizer Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="54273" type="Drug"><TargetEntity id="409139" type="siDrug">Tafamidis meglumine</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="3399" type="ciIndication"><TargetEntity id="D028227" type="MeSH"/><TargetEntity id="85447" type="ORPHANET"/><TargetEntity id="-1689796418" type="omicsDisease"/><TargetEntity id="2878" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="18767">Pfizer Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="11256">Transthyretin modulator</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2014-01-10T00:00:00Z</DateStart><DateEnd type="estimated">2022-04-29T00:00:00Z</DateEnd><DateChangeLast>2018-02-01T02:12:33Z</DateChangeLast><DateAdded>2014-06-02T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Pfizer</Affiliation><Name>Pfizer CT.gov Call Center</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;The patients of this surveillance are all patients who received&lt;ulink linkType="Drug" linkID="54273"&gt;Vyndaqel&lt;/ulink&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who have not receive&lt;ulink linkType="Drug" linkID="54273"&gt;Vyndaqel&lt;/ulink&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The incidence of adverse drug reaction in this study</Description><Timeframe>Three years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change from baseline on the following scale: NIS, QOL-DN, mBMI</Description><Timeframe>Three years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to understand safety (eg, occurrence of adverse drug      reactions [ADRs]) and efficacy data on the long-term use of &lt;ulink linkType="Drug" linkID="54273"&gt;Vyndaqel&lt;/ulink&gt; (tafamidis) capsules in all patients who received this drug under actual use conditions      after its marketing.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Both prospective and retrospective data from the  patients  who received &lt;ulink linkType="Drug" linkID="54273"&gt;Vyndaqel&lt;/ulink&gt; (20 mg/day) will be collected and observed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02146378</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Anticipated">2022-04-29T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2015-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>13.71 Months</EnrollmentPeriod><EnrollmentRate>14.59 Patients/Month</EnrollmentRate><DateFirstReceived>2014-05-21T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-06-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="194612"><TitleDisplay>The Natural History of Traumatic Spinal Cord Injury Using fMRI, MRS and DTI</TitleDisplay><TitleOfficial>Mapping the Natural History of Traumatic Spinal Cord Injury in the Sensorimotor Cortex Using Functional Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00790361</Identifier><Identifier type="Organisational Study">13652</Identifier></Identifiers><Indications><Indication id="1258">Spinal cord injury</Indication></Indications><BiomarkerNames><BiomarkerName id="161" role="Disease marker" type="Biochemical">N-Acetyl-L-aspartic acid</BiomarkerName><BiomarkerName id="6540" role="Disease marker" type="Biochemical">Glutamic acid</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1041110" type="Company"><TargetEntity id="5035543671" type="organizationId">Physicians Services Inc Foundation</TargetEntity></SourceEntity><SourceEntity id="1043527" type="Company"><TargetEntity id="4297906117" type="organizationId">Lawson Health Research Institute</TargetEntity></SourceEntity><SourceEntity id="1258" type="ciIndication"><TargetEntity id="10041552" type="MEDDRA"/><TargetEntity id="D013119" type="MeSH"/><TargetEntity id="90058" type="ORPHANET"/><TargetEntity id="-1980782964" type="omicsDisease"/><TargetEntity id="178" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1043527">Lawson Health Research Institute</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1041110">Physicians' Services Incorporated Foundation</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2009-06-18T00:00:00Z</DateStart><DateEnd type="actual">2010-01-31T00:00:00Z</DateEnd><DateChangeLast>2017-09-28T09:04:27Z</DateChangeLast><DateAdded>2014-06-10T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>London Health Research Institute, London Health Sciences Centre</Affiliation><Name>Neil Duggal, M.D., MSc</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Between 30 and 85 years of age&lt;/li&gt;&lt;li&gt;Right handed&lt;/li&gt;&lt;li&gt;With normal/corrected hearing and vision&lt;/li&gt;&lt;li&gt;Fluent in reading and speaking Canadian or American English&lt;/li&gt;&lt;li&gt;Able to follow simple task instructions&lt;/li&gt;&lt;li&gt;Able to maintain standardized movements&lt;/li&gt;&lt;li&gt;Available to return for the 15 day and 6 month imaging sessions&lt;/li&gt;&lt;li&gt;Competent to give consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Must not have any other neurological disorder or systemic disease that may affect neurologic function&lt;/li&gt;&lt;li&gt;Not have any potential magnetic metal fragments in their body&lt;/li&gt;&lt;li&gt;Suffering from claustrophobia&lt;/li&gt;&lt;li&gt;Having a pacemaker or other electronic implants&lt;/li&gt;&lt;li&gt;Have been or currently is a welder or soldier&lt;/li&gt;&lt;li&gt;Have been injured by a metallic object that has not been removed&lt;/li&gt;&lt;li&gt;Pregnant or trying to conceive&lt;/li&gt;&lt;li&gt;Have cerebral aneurysm clips&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Measure the volume of activation, signal intensity and levels of NAA and glutamate using fMRI, MRS and DTI</Description><Timeframe>Acutely (up to 48 h after injury), subacutely (15 Days after injury), and late (6 Months after injury)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Clinical changes will be measured using validated disease specific scoring instruments including the Japanese Orthopedic Association scale (JOA), ASIA/ISCOS Impairment Scale, and the Neck Disability Index (NDI)</Description><Timeframe>Acutely (up to 48 h after injury), subacutely (15 Days after injury), and late (6 Months after injury)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this  study was to detect differences in brain      metabolism and activation of different parts of the brain during specific movement and in      the nerve fibers in the brain. The investigators hypothesize that there would be decreased levels of N-acetylaspartate (NAA) and decreased levels of glutamate in the motor cortex in subjects with traumatic central cord syndrome (CCS) when compared with controls. Over      time, the investigators hypothesize that the normalization of metabolite levels would correlate with the      extent of neurological recovery. The investigators also hypothesize a reorganization of brain activation      patterns with time such that subjects would show increased volumes of activation in the motor      cortex with recovery and that this would correlate with the extent of neurological outcome.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The long-term goal of this project would be to develop predictors of neurological recovery based on brain metabolism, brain activation patterns, and fibre tracks in patients with traumatic CCS. The objective of this preliminary study would be to evaluate metabolic changes, brain activation pattern reorganization and altered spinal cord fibre tracks in patients suffering from traumatic CCS to gain a better understanding of the natural history of this condition. Magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI), and      diffusion tensor imaging (DTI) would be used to investigate the changes in brain metabolite      concentrations, cerebral cortical activation, and fibre tract anatomy, respectively, in      subjects and controls. The CCS subjects  would have three      scans, one acutely (up to 48 h after injury), one subacutely (15 days after injury), and      one late (6 months after injury). Healthy volunteers would  have two scans 6 months apart to      determine reproducibility. Clinical changes would be measured using validated disease specific scoring instruments      including the Japanese Orthopedic Association scale (JOA), ASIA/ISCOS Impairment Scale, and      the Neck Disability Index (NDI). General quality of life would be measured using the 36-item      Short-Form Health Survey (SF-36).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>London Health Sciences Center, University Campus</Name><Address1>London</Address1><Address2>Ontario</Address2><Address3>N6A-5A5</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00790361</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2010-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2008-11-12T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-06-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-09-28T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="196067"><TitleDisplay>Pharmacodynamic Study on Efficacy of Clopidogrel With St John's Wort</TitleDisplay><TitleOfficial>The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01330589</Identifier><Identifier type="Organisational Study">2010-56-LGH</Identifier><Identifier type="Trial Acronym">INDUCE-it</Identifier></Identifiers><Indications><Indication id="3258">Acute coronary syndrome</Indication></Indications><BiomarkerNames><BiomarkerName id="2272" role="Disease marker" type="Genomic;Proteomic">Cytochrome P450 2C19</BiomarkerName><BiomarkerName id="7838" role="Therapeutic effect marker" type="Physiological">Platelet aggregation</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>St Johns Wort</Name></Intervention><Intervention type="InterventionPrimary"><Name>clopidogrel</Name><Drug id="2836">clopidogrel</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2836">clopidogrel</Drug><IndicationsPioneer/><Companies><Company><Company id="1096760">Lancaster General Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1097253">H. G. Barsumian Memorial Fund</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1097254">Louise von Hess Medical Research Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2836" type="Drug"><TargetEntity id="142672" type="siDrug">Clopidogrel bisulfate</TargetEntity></SourceEntity><SourceEntity id="1096760" type="Company"><TargetEntity id="5000390117" type="organizationId">Lancaster General Hospital</TargetEntity></SourceEntity><SourceEntity id="1097253" type="Company"><TargetEntity id="5042950343" type="organizationId">H G Barsumian Memorial Fund</TargetEntity></SourceEntity><SourceEntity id="1097254" type="Company"><TargetEntity id="5042950339" type="organizationId">Louise von Hess Medical Research Institute</TargetEntity></SourceEntity><SourceEntity id="3258" type="ciIndication"><TargetEntity id="10051592" type="MEDDRA"/><TargetEntity id="D054058" type="MeSH"/><TargetEntity id="-489209930" type="omicsDisease"/><TargetEntity id="3262" type="siCondition"/></SourceEntity><SourceEntity id="4913" type="Action"><TargetEntity id="613" type="Mechanism">P2Y12 (P2T) Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1096760">Lancaster General Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1097253">H. G. Barsumian Memorial Fund</Company><Company id="1097254">Louise von Hess Medical Research Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4913">P2Y12 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="312">Platelet aggregation inhibitor</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><DateStart>2011-04-30T00:00:00Z</DateStart><DateEnd type="actual">2015-03-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-26T04:18:50Z</DateChangeLast><DateAdded>2014-06-13T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Lancaster General Hospital</Affiliation><Name>Jill A Rebuck, PharmD</Name></Contact><Contact type="Scientific contact"><Affiliation>Lancaster General Hospital</Affiliation><Name>Kathy M Makkar, PharmD</Name></Contact><Contact type="Scientific contact"><Affiliation>Lancaster General Research Institute</Affiliation><Name>Michael A Horst, PhD</Name></Contact><Contact type="Scientific contact"><Affiliation>Lancaster General Hospital</Affiliation><Name>Richard D Paoletti, RPh</Name></Contact><Contact type="Scientific contact"><Affiliation>Lancaster General Hospital</Affiliation><Name>Roy S Small, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Lancaster General Hospital</Affiliation><Name>Rupal P Dumasia, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Lancaster General Hospital</Affiliation><Name>Yee M Lee, PharmD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients age &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Patients with a history of ACS and/or who receive PCI with stent placement at Lancaster General Hospital requiring dual antiplatelet therapy with aspirin and&lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with active or any known history of bleeding such as gastrointestinal, intracranial, or any other bleeding diathesis&lt;/li&gt;&lt;li&gt;History of major surgery in the last year (any surgical procedure that involves general anesthesia or respiratory assistance)&lt;/li&gt;&lt;li&gt;Clinical findings associated with an increased risk of bleeding at the judgment of the investigator&lt;/li&gt;&lt;li&gt;Patients actively receiving anticoagulation therapy&lt;/li&gt;&lt;li&gt;Hemoglobin&amp;lt;/= 10 g/dl&lt;/li&gt;&lt;li&gt;Platelets&amp;lt;/= 150,000/mm3&lt;/li&gt;&lt;li&gt;Known hepatic dysfunction&lt;/li&gt;&lt;li&gt;History of intracranial malignancy or stroke&lt;/li&gt;&lt;li&gt;Patients receiving thienopyridines chronically prior to PCI&lt;/li&gt;&lt;li&gt;Concurrent use of CYP P450 2C19 substrates, or inhibiting/ inducing medications with the exception of proton pump inhibitors&lt;/li&gt;&lt;li&gt;Illicit drug or alcohol abuse&lt;/li&gt;&lt;li&gt;Daily treatment with nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors&lt;/li&gt;&lt;li&gt;Allergy to St Johns wort or lactose&lt;/li&gt;&lt;li&gt;Patients expected to discontinue dual antiplatelet therapy prior to completion of the study protocol&lt;/li&gt;&lt;li&gt;Patients unable to adhere to the study protocol&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mean platelet reactivity (as measured in platelet reactivity units) on day 7 and day 21: the investigators are comparing the mean platelet reactivity (as measured in platelet reactivity units) within subjects (treatment effect) between placebo and St Johns Wort. In addition we will be assessing the period effect (difference between those getting treatment AB - placebo/St Johns Wort and those getting treatment BA - St Johns Wort/placebo)</Description><Timeframe>Day 7 and  21</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this prospective, randomized, double-blind, placebo-controlled, crossover study was to evaluate whether patients post PCI receiving &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; who      were carriers of at least one CYP2C19 loss-of-function allele might achieve improved      pharmacodynamic efficacy of &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; when treated with the CYP2C19 enzyme inducing      agent, St John's wort, as compared with placebo.&lt;br/&gt;Specific aims were:&lt;br/&gt;To identify the difference in platelet reactivity in patients receiving St John's wort           or placebo.&lt;br/&gt;To characterize the difference in platelet inhibition in patients receiving St John's           wort or placebo.&lt;/para&gt;&lt;para&gt;Hypotheses of the study were:&lt;br/&gt;Reduced platelet reactivity would be present in patients receiving St John's wort as           compared to placebo when utilized in combination with &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt;.&lt;br/&gt;The combination or St John's wort and &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; would result in enhanced platelet           inhibition.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients receiving &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; would be randomized as follows:&lt;/para&gt;&lt;para&gt;Arm 1: patients would receive placebo for 7 days, 7 days washout and 7 days of St Johns Wort (300 mg po, tid).&lt;br/&gt;Arm 2: patients would receive St Johns Wort (300 mg po , tid) for 7 days, 7 days washout and 7 days of placebo.&lt;/para&gt;&lt;para&gt;Patients identified as carriers of at least one CYP2C19 loss-of-function allele (ie, clopidogrel reduced-metabolizers) would remain in the study and be randomly assigned to receive placebo or St John's wort. Patients not carrying a CYP2C19 loss-of-function allele (ie, clopidogrel normal metabolizers) would not require any further follow-up as these patients would be considered to display a normal response to clopidogrel. On day 7 following the initiation of the study      drug, platelet function testing would be performed. Following a 7 day washout period,      patients would be crossed over into the other study group to receive 7 days of study      medication. On day 21, the patients would undergo platelet function testing and the study      medication would be discontinued. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;This study has been terminated due to inability to enroll subjects and changes in standard of care for PCI.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Lancaster General Hospital</Name><Address1>Lancaster</Address1><Address2>Pennsylvania</Address2><Address3>17604</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="201">Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="369">Subjects on /Indicated for/History of Cardiovascular Therapy</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Acute coronary syndrome</Disease><PatientSegments><PatientSegment><PatientSegment id="321">Subjects with History of Cardiac Intervention</PatientSegment><SubSegments><SubSegment id="323">PTCA alone </SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="373">Subjects with History of Treatment</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01330589</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2598"><Endpoint>Assessment of Platelet Function Tests (PFT) Findings</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Acute coronary syndrome" id="2904"><Endpoint>Assessment of Platelet Function Tests (PFT)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Acute coronary syndrome" id="46607"><Endpoint>Gene variants involved in outcome measures</Endpoint><SubEndpoints><SubEndpoint disease="Acute coronary syndrome" id="46770">CYP2C19_HUMAN_Mutation</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Coronary artery disease" id="46671"><Endpoint>Gene variants involved in outcome measures</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="46769">CYP2C19_HUMAN_Mutation</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1068"><Criterion>Subjects with Coronary Artery Disease (CAD)</Criterion></Inclusion><Inclusion disease="Coronary artery disease" id="1134"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1139">Antiplatelet drugs/Platelet glycoprotein IIb/IIIa antagonist</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1169"><Criterion>Subjects with History of /Scheduled for Coronary Revascularization Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1171">PTCA (percutaneous transluminal coronary angioplasty)/Stent placement</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Acute coronary syndrome" id="1321"><Criterion>Subjects with History of/Scheduled for Cardiac Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="1326">Percutaneous transluminal coronary angioplasty  (PTCA) alone</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Acute coronary syndrome" id="1384"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="1389">Subjects with history of antiplatelet therapy</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Coronary artery disease" id="1740"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1742">Subjects with bleeding disorders/bleeding diathesis/hemorrhagic diathesis /hematopoietic disease/coagulopathy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1780"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="5588">Subjects co-morbid with cerebrovascular/CNS disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1793"><Criterion>Subjects on Cardiovascular Treatment</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1806">Antiplatelet therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1857"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1859">Subjects with abnormal hematological tests</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1880"><Criterion>Subjects with Hypersensitivity/Contraindication to Therapy</Criterion></Exclusion><Exclusion disease="Acute coronary syndrome" id="2053"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Acute coronary syndrome" id="2065"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2066">Brain tumor/intracranial neoplasm</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acute coronary syndrome" id="2070"><Criterion>Subjects on  Other Systemic Medications</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2081">Analgesics/Anti-inflammatory drugs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acute coronary syndrome" id="2102"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2104">Subjects with bleeding disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acute coronary syndrome" id="2113"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2118">Subjects co-morbid with gastrointestinal bleeding</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acute coronary syndrome" id="2119"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2122">Hepatic disease/hepatic insufficiency/hepatocellular insufficiency</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acute coronary syndrome" id="2131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2142">Anticoagulants</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acute coronary syndrome" id="2141"><Criterion>Subjects on Antithrombotic Agents</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2143">Antiplatelets </SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acute coronary syndrome" id="2162"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2172">Hemoglobin level</SubCriterion><SubCriterion disease="Acute coronary syndrome" id="2176">Low platelet count </SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acute coronary syndrome" id="2179"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2181">Study medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Acute coronary syndrome" id="2195"><Criterion>Subjects with History of Other Procedure/Intervention</Criterion><SubCriteria><SubCriterion disease="Acute coronary syndrome" id="2203">General Surgery/Organ transplantation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="5591"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="25865"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="5589">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="26158"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1805">Anticoagulant therapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2015-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2011-03-28T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-06-13T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="196577"><TitleDisplay>Nasal Irrigation in Infants With Bronchiolitis</TitleDisplay><TitleOfficial>Randomized, Controlled Trial to Evaluate the Efficacy of Nasal Irrigation in Infants With Bronchiolitis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02162745</Identifier><Identifier type="Organisational Study">RC 35/12</Identifier></Identifiers><Indications><Indication id="2976">Bronchiolitis</Indication></Indications><BiomarkerNames><BiomarkerName id="1913" role="Therapeutic effect marker" type="Physiological">Arterial oxygen saturation</BiomarkerName><BiomarkerName id="10260" role="Therapeutic effect marker" type="Physiological">Respiratory frequency</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>hypertonic saline</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>isotonic saline</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1080730" type="Company"><TargetEntity id="5039061504" type="organizationId">Istituto di Ricovero e Cura a Carattere Scientifico Materno Infantile Burlo Garofolo</TargetEntity></SourceEntity><SourceEntity id="2976" type="ciIndication"><TargetEntity id="10006448" type="MEDDRA"/><TargetEntity id="D001988" type="MeSH"/><TargetEntity id="-414497616" type="omicsDisease"/><TargetEntity id="276" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1080730">IRCCS Burlo Garofolo</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>133</PatientCountEnrollment><DateStart>2012-10-31T00:00:00Z</DateStart><DateEnd type="actual">2014-05-31T00:00:00Z</DateEnd><DateChangeLast>2018-01-22T22:09:32Z</DateChangeLast><DateAdded>2014-07-11T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>IRCCS Burlo Garofolo, Trieste, Italy</Affiliation><Name>Dino Barbi, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>IRCCS Burlo Garofolo, Trieste, Italy</Affiliation><Name>Silvana Schreiber, RN</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Infants&amp;lt; 1 year&lt;/li&gt;&lt;li&gt;Diagnosis of bronchiolitis with respiratory distress, rhinitis, cough&lt;/li&gt;&lt;li&gt;Oxygen saturation between 88 and 94%&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Previous treatments (nasal irrigation or suctioning, oxygen, nebulized drugs, nebulized hypertonic solution, antipyretics up to 6 h before the study entry, oral steroids at any time before study entry)&lt;/li&gt;&lt;li&gt;Chronic illness&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Oxygen saturation (%): measurement of  arterial oxygen saturation (SpO2) of hemoglobin with digital pulse oximeter</Description><Timeframe>Up to 50 min after allocation</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Respiratory effort (WARME score): evaluation of the respiratory effort using the validated WARME score (evaluation of:  respiratory rate; prolonged expiration;  wheezing; air exchange; muscle use)</Description><Timeframe>5, 15, 20, 50 min after allocation</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this randomized, controlled trial was to compare normal saline and hypertonic      solution for nasal irrigation versus simple supportive care in infants admitted to emergency      department with bronchiolitis and mild desaturation.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be asisgned to one of the three arms.&lt;br/&gt;Arm 1: patients would receive single nasal irrigation with 1 ml of isotonic solution (NaCl 0.9%) per each nostril.&lt;br/&gt;Arm 2: patients would receive single nasal irrigation with 1 ml of hypertonic solution (NaCl 3%) per each nostril.&lt;br/&gt;Arm 3:  patients would receive supportive care including  wiping the nose, positioning the child, changing a wet diaper, feeding.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Italy"><Sites><Site><Name>Emergency Department, IRCCS Burlo Garofolo</Name><Address1>Trieste</Address1><Address2>Friuli Venezia Giulia</Address2><Address3>34137</Address3><CountrySubDivision>Friuli Venezia Giulia</CountrySubDivision><Contacts/></Site><Site><Name>Pediatria, Azienda Ospedaliera Santa Maria Degli Angeli</Name><Address1>Pordenone</Address1><Address2>Friuli Venezia Giulia</Address2><Address3>33170</Address3><CountrySubDivision>Friuli Venezia Giulia</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02162745</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2014-05-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2014-06-11T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-07-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="201380"><TitleDisplay>Mass Balance Recovery, Metabolite Profile and Metabolite Identification of (14C) NXL-104</TitleDisplay><TitleOfficial>An Open-Label, Single-Dose Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of (14C) NXL-104</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01448395</Identifier><Identifier type="Organisational Study">D4280C00008</Identifier></Identifiers><Indications/><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>avibactam sodium + ceftazidime (iv, urinary tract infection), AstraZeneca/Allergan</Name><Drug id="52209">avibactam sodium + ceftazidime (iv, urinary tract infection), AstraZeneca/Allergan</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="52209">avibactam sodium + ceftazidime (iv, urinary tract infection), AstraZeneca/Allergan</Drug><IndicationsPioneer/><Companies><Company><Company id="18767">Pfizer Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="52209" type="Drug"><TargetEntity id="316823" type="siDrug">Avibactam sodium</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="86" type="Action"><TargetEntity id="501" type="Mechanism">beta-Lactamase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="18767">Pfizer Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="86">Beta lactamase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1535">Beta lactam antibiotic</Class><Class id="1537">Cephalosporin</Class><Class id="1594">Antibacterial</Class><Class id="7293">Synergist</Class></Class><Technologies><Technology id="66">Antibiotic</Technology><Technology id="175">Drug combination</Technology><Technology id="898">Formulation powder</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>6</PatientCountEnrollment><PatientCountEvaluable>6</PatientCountEvaluable><DateStart>2011-10-31T00:00:00Z</DateStart><DateEnd type="actual">2011-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-11-22T03:44:55Z</DateChangeLast><DateAdded>2014-07-02T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>AstraZeneca</Affiliation><Name>Paul Newell, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Provision of informed consent prior to any study specific procedures&lt;/li&gt;&lt;li&gt;Healthy male subjects aged 30 to 65 years inclusive&lt;/li&gt;&lt;li&gt;Male subjects should be willing to use an adequate method of contraception from the day of dosing until 3 months after dosing with the investigational product&lt;/li&gt;&lt;li&gt;Have a body mass index (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg&lt;/li&gt;&lt;li&gt;Clinically normal physical examination and laboratory findings as judged by the investigator, including negative test results for drug abuse, alcohol, -CO breath test and negative test results for Hepatitis B surface antigen, antibodies to Hepatitis C&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any clinically significant disease or disorder (eg, cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment)&lt;/li&gt;&lt;li&gt;Any clinically relevant abnormal findings in physical examination, vital signs, clinical chemistry, hematology, urinalysis, which, in the opinion of the investigator, may put the subject at risk because of his participation in the study&lt;/li&gt;&lt;li&gt;QTc&amp;gt; 450 ms or QT &amp;gt; 500 ms or other ECG abnormality making interpretation more difficult, as judged by the investigator, or a history of additional risk factors for Torsades de Points (eg heart failure, hypokalemia, family history of long QT syndrome)&lt;/li&gt;&lt;li&gt;Radiation exposure from clinical studies, including that from the present study, excluding background radiation but including diagnostic X-rays and other medical exposures, exceeding 5 mSv in the last twelve months or 10 mSv in the last five years&lt;/li&gt;&lt;li&gt;Participation in another clinical study with an investigational product during the last 3 months&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mass balance after a single intravenous (IV) dose of [14C] NXL-104 as generated from recovery of total radioactivity excreted in feces</Description><Timeframe>168 h</Timeframe></Measure><Measure><Description>Mass balance after a single intravenous (IV) dose of [14C] NXL-104 as generated from recovery of total radioactivity excreted in urine</Description><Timeframe>168 h</Timeframe></Measure><Measure><Description>Routes of [14C] NXL-104 metabolism and excretion measured through total radioactivity concentrations in faeces</Description><Timeframe>168 h</Timeframe></Measure><Measure><Description>Routes of [14C] NXL-104 metabolism and excretion measured through total radioactivity concentrations in urine</Description><Timeframe>168 h</Timeframe></Measure><Measure><Description>Whole blood and plasma partitioning of total radioactivity through measurement of total radioactivy levels in blood</Description><Timeframe>168 h</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Intravenous  pharmacokinetics (PK) of [14C] NXL-104 through calculation of Cmax, Tmax, AUC0-infinity, T1/2, MRT, terminal elimination rate constant, amount of NXL-104 (Ae), % excreted, will be calculated from NXL-104 concentrations in urine and feces: explanations for abbreviations: Cmax = Maximum concentration Tmax = Time taken to reach maximum concentration AUC 0-Infinity = Area under the plasma concentration-time curve 0-Infinity T1/2 = Terminal half-life MRT = Mean Residence Time</Description><Timeframe>Predose,  0.25, 0.5, 1,1.25,1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120, 144, 168 h</Timeframe></Measure><Measure><Description>Metabolites of [14C] NXL-104 in plasma, whole blood, urine and feces calculated from plasma, urine and feces concentration levels. Identification of major metabolites in plasma, urine and feces where possible</Description><Timeframe>Whole blood: predose,  0.25, 0.5, 1,1.25,1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120, 144, 168 hoursUrine and Faeces samples Predose-144 h</Timeframe></Measure><Measure><Description>Safety and tolerability of NXL-104 as number of patients with adverse events and assessment of Electrocardiogram (ECG) and vital signs results</Description><Timeframe>Electrocardiogram (ECG) recordings at Screening Pre-dose, 1 ,24 and 168 h. Continuous ECG  monitoring 0-1 h. Vital signs measurements screening pre-dose, 0.5, 1, 2, 24 and 168 h</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In February 2015,  results were presented.  One  subject reported a mild AE (headache) after dosing with [14C]-avibactam approximately 4 days following discharge from the clinical unit. Subject took paracetamol for the headache, and it resolved within 2 h of onset. No other AEs were reported after dosing with [14C]-avibactam. No significant safety findings were reported in patients who were treated  with 500 mg [14C]-avibactam [&lt;ulink linkType="Reference" linkID="2017994"&gt;2017994&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was an open-label, single-dose study in healthy male subjects designed to assess the mass balance recovery, metabolite profile and metabolite identification of [14C]NXL-104 (&lt;ulink linkType="Drug" linkID="52209"&gt;Avycaz&lt;/ulink&gt;)  [&lt;ulink linkType="Reference" linkID="2017994"&gt;2017994&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2096571"&gt;2096571&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The primary objectives of the trial were:&lt;br/&gt;To determine the mass balance after a single iv dose of [14C]-avibactam.&lt;br/&gt;To determine the routes of [14C]-avibactam metabolism and excretion.&lt;br/&gt;To estimate the whole blood and plasma partitioning of total radioactivity.&lt;br/&gt;To determine the urine and fecal recovery of radioactivity determine the urine and fecal recovery of radioactivity [&lt;ulink linkType="Reference" linkID="2017994"&gt;2017994&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The secodary objectives were:&lt;br/&gt;To assess the pharmacokinetics of [14C]-avibactam.&lt;br/&gt;To identify and characterize the metabolites of [14C]-avibactam in plasma, whole blood, urine and feces.&lt;br/&gt;To provide additional safety and tolerability information for avibactam [&lt;ulink linkType="Reference" linkID="2017994"&gt;2017994&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In February 2015,  results were presented. All mean hematology and clinical chemistry values were within the normal reference range at admission and discharge, and there were no notable mean changes from baseline for any parameter. There were no clinically significant findings from physical exam or from any vital signs or ECG parameters   [&lt;ulink linkType="Reference" linkID="2017994"&gt;2017994&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive 500 mg/100 ml iv solution of (14C) NXL-104.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Subjects received 500 mg avibactam in 100 ml of saline over 60 min and a target dose of radioactivity of no more than 300 microCi (11.1 MBq) [14C]-avibactam in a fasted state [&lt;ulink linkType="Reference" linkID="2017994"&gt;2017994&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>avibactam sodium + ceftazidime (iv, urinary tract infection), AstraZeneca/Allergan</Name><Drug id="52209">avibactam sodium + ceftazidime (iv, urinary tract infection), AstraZeneca/Allergan</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="148">Headache</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="458963">avibactam sodium + ceftazidime (iv, urinary tract infection), AstraZeneca/Allergan</Intervention><Treatments><Treatment><Dose>500 milligram</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Study site</Name><Address1>Ruddington</Address1><Address2>Nottingham</Address2><CountrySubDivision>Nottingham</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01448395</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2011-11-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2011-09-30T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-07-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-04-03T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="Added"><Date>2018-04-03T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change></ChangeHistory></Trial><Trial id="205905"><TitleDisplay>A Study Of Immunogenicity Of A Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliomyelitis Vaccine Used to Reconstitute a Freeze-Dried Hemophilus Influenze Type B Vaccine (DTaP-IPV//PRP-T) Administered Simultaneously With a Hepatitis B Vaccine at 2, 3 and 4 Months of Life</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications/><BiomarkerNames><BiomarkerName id="5849" role="Therapeutic effect marker" type="Genomic;Proteomic">Hepatitis B large envelope protein</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>DTaP-IPV//PRP-T</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Recombivax HB</Name><Drug id="6748">Recombivax HB</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6748">Recombivax HB</Drug><IndicationsPioneer/><Companies><Company><Company id="1009547">Sanofi SA</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6748" type="Drug"><TargetEntity id="280501" type="siDrug">Recombivax HB</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1009547">Sanofi SA</Company><Company id="18077">Merck &amp; Co Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="12372">Protein subunit vaccine</Class><Class id="12378">Prophylactic vaccine</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="745">Suspension</Technology></Technologies><TermsPatientSelection><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Prevention</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>162</PatientCountEnrollment><PatientCountEvaluable>162</PatientCountEvaluable><DateEnd type="actual">1999-12-10T00:00:00Z</DateEnd><DateChangeLast>2017-07-19T16:09:52Z</DateChangeLast><DateAdded>2014-08-07T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;A total of 162 healthy infants, aged 8 to 10 weeks, were enrolled in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Seroconversion Rates</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Immunogenicity</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In December 1999, results were published. The simultaneous administration of DTaP-IPV//PRP-T and hepatitis B vaccines gave a good safety profile and no vaccine-related serious adverse events were reported [&lt;ulink linkType="Reference" linkID="1579003"&gt;1579003&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to assess the immunogenicity of a vaccine combining diphtheria and tetanus toxoids, acellular pertussis vaccine, and inactivated poliovirus vaccine reconstituting Hemophilus influenze type b polysaccharide conjugated to tetanus protein (DTaP-IPV//PRP-T, Pasteur Merieux Connaught, Lyon, France) administered simultaneously in association with hepatitis B vaccine (&lt;ulink linkType="Drug" linkID="6748"&gt;RECOMBIVAX&lt;/ulink&gt; &lt;ulink linkType="Company" linkID="1059823"&gt;Merck Sharp &amp;amp; Dohme&lt;/ulink&gt;, West Point, PA, USA) for the primary immunization of infants [&lt;ulink linkType="Reference" linkID="1579003"&gt;1579003&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 1999, results were published. The percentages of infants fulfilling seroconversion criteria 4 weeks after the third immunization were 98.9% for pertussis toxin, 95.9% for filamentous hemagglutinin, 100.0% for tetanus, 100.0% for diphtheria, 99.3% for poliovirus type 1, 100.0% for both poliovirus types 2 and 3, 98.0% for Hemophilus influenze type b, and 100% for hepatitis B surface antigen. The simultaneous administration of DTaP-IPV//PRP-T and hepatitis B vaccines yielded clinically satisfactory immune responses to all antigens compared with historical controls [&lt;ulink linkType="Reference" linkID="1579003"&gt;1579003&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Infants received DTaP-IPV//PRP-T  administered simultaneously in association with hepatitis B vaccine (&lt;ulink linkType="Drug" linkID="6748"&gt;RECOMBIVAX&lt;/ulink&gt;) at 2, 3 and 4 months of age. Blood samples were taken before the first dose and 4 weeks after the third dose. The infants were observed for 15 min after vaccination for any immediate reaction [&lt;ulink linkType="Reference" linkID="1579003"&gt;1579003&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="DTP Vaccine" id="10965"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="DTP Vaccine" id="10966">Assessment of anti-diphtheria antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10967">Assessment of anti-tetanus antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10968">Assessment of anti-pertussis antibody concentration (PT)</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10969">Assessment of anti-filamentous haemagglutinin antibody concentration (FHA)</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10971">Assessment of anti-hepatitis B antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="10973">Assessment of anti-polio virus antibody concentration</SubEndpoint><SubEndpoint disease="DTP Vaccine" id="11137">Assessment of anti-influenza antibody concentration</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="DTP Vaccine" id="11003"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="DTP Vaccine" id="11007">Assessment of serious adverse events</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Polio Vaccine" id="18508"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Polio Vaccine" id="18509">Assessment of anti-polio antibody concentration</SubEndpoint><SubEndpoint disease="Polio Vaccine" id="18511">Immunogenic response to other antigens</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Polio Vaccine" id="18513"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Polio Vaccine" id="18514">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Haemophilus Influenzae Type B Vaccine" id="19080"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Haemophilus Influenzae Type B Vaccine" id="19081">Assessment of anti-polyribosyl-ribitol-phosphate antibody concentration (PRP)</SubEndpoint><SubEndpoint disease="Haemophilus Influenzae Type B Vaccine" id="19082">Assessment of anti-diphtheria antibody concentration</SubEndpoint><SubEndpoint disease="Haemophilus Influenzae Type B Vaccine" id="19083">Assessment of anti-tetanus antibody concentration</SubEndpoint><SubEndpoint disease="Haemophilus Influenzae Type B Vaccine" id="19084">Assessment of anti-pertussis antibody concentration (PT)</SubEndpoint><SubEndpoint disease="Haemophilus Influenzae Type B Vaccine" id="19085">Assessment of anti-filamentous haemagglutinin antibody concentration (FHA)</SubEndpoint><SubEndpoint disease="Haemophilus Influenzae Type B Vaccine" id="19088">Assessment of anti-hepatitis B antibody concentration</SubEndpoint><SubEndpoint disease="Haemophilus Influenzae Type B Vaccine" id="19090">Assessment of anti-polio virus antibody concentration</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Haemophilus Influenzae Type B Vaccine" id="19099"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Haemophilus Influenzae Type B Vaccine" id="19100">Adverse events/reactogenicity</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="DTP Vaccine" id="34524"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="DTP Vaccine" id="22461">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Haemophilus Influenzae Type B Vaccine" id="34720"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Haemophilus Influenzae Type B Vaccine" id="17709">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Polio Vaccine" id="34748"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Polio Vaccine" id="16829">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-08-07T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="207762"><TitleDisplay>Effect of Exercise on coronary artery disease risk factors</TitleDisplay><TitleOfficial>The effect of resistance exercise on coronary artery disease risk factors in the patients referred to Isfahan Cardiovascular Research center</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2013022112551N1</Identifier><Identifier type="Secondary Organisational">392058</Identifier></Identifiers><Indications><Indication id="80">Coronary artery disease</Indication></Indications><BiomarkerNames><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="2095" role="Therapeutic effect marker" type="Physiological">Mean arterial pressure</BiomarkerName><BiomarkerName id="14767" role="Therapeutic effect marker" type="Biochemical">Lipids</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>resistance exercises</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>routine exercise</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>routine rehabilitation</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1082077" type="Company"><TargetEntity id="5039610465" type="organizationId">Isfahan Cardiovascular Research Center</TargetEntity></SourceEntity><SourceEntity id="80" type="ciIndication"><TargetEntity id="10011078" type="MEDDRA"/><TargetEntity id="D003327" type="MeSH"/><TargetEntity id="-1572475765" type="omicsDisease"/><TargetEntity id="221" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1082077">Isfahan Cardiovascular Research Center</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Infants (6-23 months)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2013-04-09T00:00:00Z</DateStart><DateChangeLast>2017-10-10T09:51:41Z</DateChangeLast><DateAdded>2014-08-11T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Isfahan University of Medical Sciences,Hezar Jerib Ave ; Isfahan ; Isfahan ; Iran, Islamic Republic Of</Affiliation><Email>z_salehi@nm.mui.ac.ir ;</Email><Name>Zahra Salehi</Name><Phone>00983342432929 ; 00989132357250 ;</Phone></Contact><Contact type="Public contact"><Affiliation>Isfahahan University of Medical Sciences</Affiliation><Email>Webmaster@nm.mui.ac.ir</Email><Name>Dr Peyman Adibi</Name><Phone>00983116687153</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients referring to the Isfahan Cardiovascular Research Center&lt;/li&gt;&lt;li&gt;Being pre-hypertensive&lt;/li&gt;&lt;li&gt;Stage 1 hypertensive&lt;/li&gt;&lt;li&gt;Taking lowering blood pressure drugs&lt;/li&gt;&lt;li&gt;History of myocardial infarction prior 2 months&lt;/li&gt;&lt;li&gt;After 10 days  of coronary angioplasty and 3 months after heart bypass surgery&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Smoking&lt;/li&gt;&lt;li&gt;Professional in exercise&lt;/li&gt;&lt;li&gt;Participation in an exercise program during the last 3 months&lt;/li&gt;&lt;li&gt;Absence for more than three consecutive meetings rehabilitation program&lt;/li&gt;&lt;li&gt;Incidence of acute conditions associated with health&lt;/li&gt;&lt;li&gt;Limitations to exercise&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mean blood pressure: mmHg- Sphygmomanometer</Description><Timeframe>At beginning and at the end of the intervention</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Fasting blood sugar: mg/dl. Laboratory measuerments</Description><Timeframe>At beginning and at the end of the intervention</Timeframe></Measure><Measure><Description>Lipid profile: mg/dl. Iaboratory measuerments</Description><Timeframe>At beginning and at the end of the intervention</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to investigate the effect of resistance exercise on mean blood pressure in the cardiovascular patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A total of 40 patients who had coronary artery disease or history of coronary artery bypass graft surgery will be randomly assigned to intervention and control groups. &lt;br/&gt;Intervention group: patients will participate in two exercise sessions that would last for 45 to 60 min/week for a study period of 8 weeks. In addition to routine exercise, resistance exercise will be performed.&lt;br/&gt;Control group: patients will participate in two exercise sessions that would last for 45 to 60 min/week for a study period of 8 weeks. Patients will follow the routine rehabilitation unit protocol that will be  aerobic exercise.&lt;br/&gt;On  day 1 before the beginning of the intervention, demographic data, blood pressure, fasting blood sugar and lipid profile measurement will be done. On day 1 after the end of the intervention, blood pressure, fasting blood sugar and lipid profile would be controlled. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Isfahan Cardiovascular Research Center</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="173">Subjects with Unstable Coronary Artery Disease</PatientSegment><SubSegments><SubSegment id="174">Acute onset/new onset myocardial infarction (MI)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="201">Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="207">Subjects Undergoing /Underwent Major Cardiac Intervention</PatientSegment><SubSegments><SubSegment id="213">On pump coronary artery bypass grafting (CABG)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="224">Subjects with High Cardiovascular Risk Profile</PatientSegment><SubSegments><SubSegment id="231">Subjects with hypertension</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2013022112551N1</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2708"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Coronary artery disease" id="2763"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2764">Assessment of blood glucose</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1076"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="3883">Subjects with hypertension as a risk factor</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1078"><Criterion>Subjects with Myocardial Infarction (MI)</Criterion></Inclusion><Inclusion disease="Coronary artery disease" id="1106"><Criterion>Subjects with Arterial Hypertension</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1107">Mild hypertension</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1134"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1138">Subjects with history of/scheduled to receive anti-hypertensive medications</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1163"><Criterion>Subjects with History of/Scheduled for Cardiac Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1174">Subjects with history of/undergoing coronary artery bypass graft surgery (CABG)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1169"><Criterion>Subjects with History of /Scheduled for Coronary Revascularization Therapy</Criterion></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2014-10-01T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>17.77 Months</EnrollmentPeriod><EnrollmentRate>2.25 Patients/Month</EnrollmentRate><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-08-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="217689"><TitleDisplay>Evaluation of iron dosing according to iron demand in hemodialysis patients treated with darbepoetin alfa</TitleDisplay><TitleOfficial>Evaluation of iron dosing according to iron demand in hemodialysis patients treated with darbepoetin alfa</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000015869</Identifier></Identifiers><Indications><Indication id="17">Anemia</Indication></Indications><BiomarkerNames><BiomarkerName id="1236" role="Therapeutic effect marker" type="Biochemical">Hemoglobin</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>darbepoetin alfa</Name><Drug id="7413">darbepoetin alfa</Drug></Intervention><Intervention type="InterventionPrimary"><Name>iron (Fesin)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="7413">darbepoetin alfa</Drug><IndicationsPioneer/><Companies><Company><Company id="1103734">Yokodai Central Clinic</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1103735">Houshin-kai Medical Corp</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="7413" type="Drug"><TargetEntity id="236400" type="siDrug">Darbepoetin alfa</TargetEntity><TargetEntity id="672479" type="siDrug">Darbepoetin alfa</TargetEntity><TargetEntity id="705130" type="siDrug">Darbepoetin alfa</TargetEntity></SourceEntity><SourceEntity id="1103734" type="Company"><TargetEntity id="5044171334" type="organizationId">Yokodai Central Clinic</TargetEntity></SourceEntity><SourceEntity id="1103735" type="Company"><TargetEntity id="5044171333" type="organizationId">Houshinkai Inc</TargetEntity></SourceEntity><SourceEntity id="17" type="ciIndication"><TargetEntity id="10002034" type="MEDDRA"/><TargetEntity id="D000740" type="MeSH"/><TargetEntity id="-201701473" type="omicsDisease"/><TargetEntity id="988" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1103734">Yokodai Central Clinic</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1103735">Houshin-kai Medical Corp</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="12162">Erythropoietin ligand</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="610">Hematopoietic stimulator</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="74">Glycoprotein</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2014-12-08T00:00:00Z</DateStart><DateChangeLast>2017-08-03T22:06:20Z</DateChangeLast><DateAdded>2014-12-13T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Yokodai Central Clinic ; Director /Director of hemodialysis clinic</Affiliation><Email>t.kuji@houshinkai.or.jp</Email><Name>Tadashi Kuji</Name><Phone>045-830-5511</Phone></Contact><Contact type="Public contact"><Affiliation>Yokodai Central Clinic ; Director /Director of hemodialysis clinic</Affiliation><Email>t.kuji@houshinkai.or.jp</Email><Name>Tadashi Kuji</Name><Phone>045-830-5511</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with maintenance hemodialysis&lt;/li&gt;&lt;li&gt;Patients with renal anemia, who are treated with rHuEPO or iron&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with chronic inflammation, malignant disorder, severe congestive heart failure, respiratory organs, and liver disorder&lt;/li&gt;&lt;li&gt;Patients who are receiving dialysis modalities other than hemodialysis&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Hemoglobin and erythropoiesis-related indexes</Description></Measure><Measure><Description>Blood chemical examination including iron-related, inflammation, nutrition indexes</Description></Measure><Measure><Description>Required dose of darbepoetin alfa</Description></Measure><Measure><Description>Hemodynamic parameters</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this study  was to evaluate the effect of iron supplementation on &lt;ulink linkType="Drug" linkID="7413"&gt;darbepoetin alfa&lt;/ulink&gt; efficacy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would  be randomized to two arms:&lt;br/&gt;Arm A: patients would receive iron supplementation after darbepoetin alfa administration (Fesin 10 mg x 3 in a week).&lt;br/&gt;Arm B:  no iron supplementation.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Tomodori dialysis clinic</Name><Address1>Kanagawa Prefecture</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>End stage renal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7704">Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7716">Subjects with Anemia of Chronic Kidney Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000015869</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="End stage renal disease" id="22544"><Endpoint>Hematological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22545">Assessment of hemoglobin levels</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22559"><Endpoint>Assessment of Nutritional Status</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22564">Assessment of other nutritional markers</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22562"><Endpoint>Assessment of iron status</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22598"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22604">Other laboratory assessment</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="End stage renal disease" id="17648"><Criterion>Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</Criterion></Inclusion><Inclusion disease="End stage renal disease" id="17676"><Criterion>Subjects with Anemia of Chronic Kidney Disease</Criterion></Inclusion><Inclusion disease="End stage renal disease" id="17690"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17694">Subjects on erythropoietin/iron supplements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="End stage renal disease" id="17508"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17519"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17520"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17522"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17533"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17535"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17555"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2015-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>6.77 Months</EnrollmentPeriod><EnrollmentRate>14.77 Patients/Month</EnrollmentRate><FundersType><Type>Company</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-12-13T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-12-08T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-08-07T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="221254"><TitleDisplay>Single-Dose, Phase I Study of FYU-981</TitleDisplay><TitleOfficial>Single-Dose, Clinical, Pharmacological Study of FYU-981 Administered to Healthy Male Adults (Phase I Study)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02348307</Identifier><Identifier type="Organisational Study">FYU-981-001</Identifier></Identifiers><Indications/><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>dotinurad</Name><Drug id="84057">dotinurad</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="84057">dotinurad</Drug><IndicationsPioneer/><Companies><Company><Company id="16252">Fuji Yakuhin Co Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="84057" type="Drug"><TargetEntity id="808390" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="16252" type="Company"><TargetEntity id="5000004251" type="organizationId">Fujiyakuhin Co Ltd</TargetEntity></SourceEntity><SourceEntity id="48912" type="Action"><TargetEntity id="3015" type="Mechanism">Urate Transporter 1 (URAT1) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="16252">Fuji Yakuhin Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="48912">Urate anion exchanger 1 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1808">Uric acid modulator</Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Japanese Ancestry</Term><Term>Male</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>54</PatientCountEnrollment><DateStart>2013-03-31T00:00:00Z</DateStart><DateEnd type="actual">2013-08-31T00:00:00Z</DateEnd><DateChangeLast>2015-04-13T07:12:38Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts/><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pharmacokinetics (Cmax: maximum plasma concentration)</Description><Timeframe>48 h</Timeframe></Measure><Measure><Description>Pharmacokinetics (Tmax: time to reach the peak plasma concentration)</Description><Timeframe>48 h</Timeframe></Measure><Measure><Description>Pharmacokinetics (T1/2: elimination half-life of plasma concentration)</Description><Timeframe>48 h</Timeframe></Measure><Measure><Description>Pharmacokinetics (AUC: area under the plasma concentration-time curve)</Description><Timeframe>48 h</Timeframe></Measure><Measure><Description>Pharmacokinetics (CLtot/F: total clearance/fraction of dose absorbed)</Description><Timeframe>48 h</Timeframe></Measure><Measure><Description>Pharmacokinetics (kel: elimination rate constant)</Description><Timeframe>48 h</Timeframe></Measure><Measure><Description>Pharmacokinetics (MRT: mean residence time)</Description><Timeframe>48 h</Timeframe></Measure><Measure><Description>Pharmacokinetics (Ae: amount of drug excreted in urine)</Description><Timeframe>48 h</Timeframe></Measure><Measure><Description>Pharmacokinetics (fe: fraction of dose excreted in urine)</Description><Timeframe>48 h</Timeframe></Measure><Measure><Description>Pharmacokinetics (CLr: renal clearance)</Description><Timeframe>48 h</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Japan</Name><Address1>Tokyo</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02348307</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2013-06-30T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="223198"><TitleDisplay>Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations</TitleDisplay><TitleOfficial>A Study to Evaluate the Efficacy of Rh-Endostatin (Endostar) in Combination With Icotinib for Advanced Non-Small Cell Lung Cancer With EGFR Mutations</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02375022</Identifier><Identifier type="Organisational Study">ZYTOP1501</Identifier></Identifiers><Indications><Indication id="1262">Non-small-cell lung cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="8" role="Therapeutic effect marker" type="Genomic;Proteomic">Epidermal growth factor receptor</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>icotinib hydrochloride</Name><Drug id="64299">icotinib hydrochloride</Drug></Intervention><Intervention type="InterventionPrimary"><Name>recombinant human endostatin (cancer), Shandong Simcere Medgenn (Endostar)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="64299">icotinib hydrochloride</Drug><IndicationsPioneer/><Companies><Company><Company id="1004107">Beta Pharma Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="1098582">Zhejiang Provincial Government</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1100608">Jiangsu Simcere Pharmaceutical Co Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="64299" type="Drug"><TargetEntity id="655532" type="siDrug">Icotinib hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1004107" type="Company"><TargetEntity id="4297900536" type="organizationId">Beta Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1098582" type="Company"><TargetEntity id="5001076917" type="organizationId">Zhejiang, Province of</TargetEntity></SourceEntity><SourceEntity id="1100608" type="Company"><TargetEntity id="4297416368" type="organizationId">Jiangsu Simcere Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"/><TargetEntity id="D002289" type="MeSH"/><TargetEntity id="-1730468577" type="omicsDisease"/><TargetEntity id="612" type="siCondition"/></SourceEntity><SourceEntity id="3754" type="Action"><TargetEntity id="1222" type="Mechanism">HER (erbB) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1098582">Zhejiang Provincial Government</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1004107">Beta Pharma Inc</Company><Company id="1100608">Jiangsu Simcere Pharmaceutical Co Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3754">EGFR family tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="62255">Anticancer protein kinase inhibitor</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>10</PatientCountEnrollment><DateStart>2015-03-31T00:00:00Z</DateStart><DateEnd type="estimated">2016-03-31T00:00:00Z</DateEnd><DateChangeLast>2016-04-26T15:30:39Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histological documentation of NSCLC, with activating EGFR (defined as deletion 19 or exon 21 L858R mutation)&lt;/li&gt;&lt;li&gt;Stage IV disease according to the 7th edition of the American Joint Committee on Cancer staging system&lt;/li&gt;&lt;li&gt;Measureable disease&lt;/li&gt;&lt;li&gt;Life expectancy of&amp;gt;/= 12 months&lt;/li&gt;&lt;li&gt;Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1&lt;/li&gt;&lt;li&gt;Absolute neutrophil count (ANC)&amp;gt;/= 1500/mm3, platelet count &amp;gt;/= 100000/mm3, hemoglobin &amp;gt;/= 9.0 g/dl&lt;/li&gt;&lt;li&gt;Total bilirubin =/&amp;lt; 1.5 x upper limit of normal (ULN), serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =/&amp;lt; 2.5 x ULN in patients without liver or bone metastases; &amp;lt; 5 x ULN in patients with liver or bone metastases, cockcroft-Gault calculated creatinine clearance of &amp;gt;/= 45 ml/min or creatinine =/&amp;lt; 1.5 x ULN&lt;/li&gt;&lt;li&gt;Prothrombin time (PT) =/&amp;lt; 1.5 x ULN, partial thromboplastin time (PTT) =/&amp;lt; ULN&lt;/li&gt;&lt;li&gt;Urine dipstick proteinuria&amp;lt; 2+. Patients discovered to have &amp;gt;/= 2 + proteinuria on dipstick urinalysis at baseline should undergo a 24-h urine collection and must demonstrate &amp;lt; 1 g of protein in 24 h&lt;/li&gt;&lt;li&gt;Negative pregnancy test done =/&amp;lt; 7 days prior to randomization, for women of childbearing potential only&lt;/li&gt;&lt;li&gt;Provide informed written consent&lt;/li&gt;&lt;li&gt;Willing to return to enrolling institution for follow-up&lt;/li&gt;&lt;li&gt;Willing to provide tissue and blood samples for correlative research purposes&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Evidence of bleeding diathesis or coagulopathy&lt;/li&gt;&lt;li&gt;Evidence of central nervous system involvement or brain metastases confirmed by head CT or brain MRI within 28 days prior to being registered for protocol therapy&lt;/li&gt;&lt;li&gt;Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration for protocol therapy&lt;/li&gt;&lt;li&gt;Anticipation of need for major surgical procedure during the course of the study&lt;/li&gt;&lt;li&gt;Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to registration for protocol therapy&lt;/li&gt;&lt;li&gt;History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to registration for protocol therapy&lt;/li&gt;&lt;li&gt;Serious, non-healing wound, ulcer, or bone fracture&lt;/li&gt;&lt;li&gt;History of hemoptysis&lt;/li&gt;&lt;li&gt;Clinically significant infections as judged by the treating investigator&lt;/li&gt;&lt;li&gt;Other active malignancy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Objective response rate</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Progression free survival</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Safety: number of participants with adverse events: number of participants with adverse events as a measure of safety and tolerability</Description><Timeframe>12 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this open-label, single-arm pilot study is to invesitgate how well  &lt;ulink linkType="Drug" linkID="64299"&gt;icotinib&lt;/ulink&gt; with &lt;ulink linkType="Drug" linkID="53252"&gt;recombinant human endostatin      &lt;/ulink&gt;(Endostar) works in treating patients with advanced stage NSCLC with EGFR activating mutations. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects are treated with combination therapy of endostar and icotinib. endostar: 15 mg continuous iv, day1 to 10, q3w and icotinib: 125 mg tid po. If no progressive disease observed, combination treatment will continue until unacceptable toxicity or progressive disease.&lt;br/&gt;Before starting study treatment, computed tomography scans of the chest, B ultrasound           of abdomen, 12-lead electrocardiogram, MRI scan of brain, and a bone scan are required.&lt;br/&gt;Tumor response, based on investigator-assessed Response Evaluation Criteria in Solid           Tumors (RECIST v.1.1), is evaluated every 6 weeks during treatment. Exploratory evaluation will be performed using dynamic contrast enhanced MRI (DCE-MRI). QoL is assessed using the core module, which will be completed by patients at           baseline and before each cycle during treatment.    All patients who prematurely discontinue treatment for any reason will be followed for           survival.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Zhejiang University</Name><Address1>Hangzhou</Address1><Address2>Zhejiang</Address2><Address3>310000</Address3><CountrySubDivision>Zhejiang</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>doczq.2008@gmail.com</Email><Name>Qiong Zhao</Name><Phone>0571-87236802</Phone></Contact><Contact type="Facility contact backup"><Email>Drpengling@gmail.com</Email><Name>Ling Peng</Name><Phone>0571-87236800</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lung tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3617">Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3623">Subjects with Advanced Stage Lung Cancer</PatientSegment><SubSegments><SubSegment id="3634">Subjects with metastatic/stage IV lung cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="10129">Subjects with EGFR Positive Lung Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12810">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-493205386" id="12935">EGFR_HUMAN_rs121434568(G)</SubSegment><SubSegment genevariantId="-2105073555" id="14654">EGFR_HUMAN_Mutation(GOF)</SubSegment><SubSegment genevariantId="-1012574192" id="14655">EGFR_HUMAN_delex19</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02375022</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lung tumor" id="8504"><Endpoint>Assessment of Objective Response</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8505">Assessment of objective response rate(ORR)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lung tumor" id="8489"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lung tumor" id="8639"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Lung tumor" id="8563"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></OtherEndpoint><OtherEndpoint disease="Lung tumor" id="8576"><Endpoint>Assessment of Tumor Related Parameters</Endpoint></OtherEndpoint><OtherEndpoint disease="Lung tumor" id="8593"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8595">Evaluation by MRI/CT scan</SubEndpoint><SubEndpoint disease="Lung tumor" id="9153">Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Lung tumor" id="8677"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8705">Assessment of subject withdrawals</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lung tumor" id="3913"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3925"><Criterion>Subjects with Protocol Specified Stages of Lung Cancer(TNM staging)</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3936">Subjects with stage IV lung cancer</SubCriterion><SubCriterion disease="Lung tumor" id="3938">Subjects with advanced stage lung cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3956"><Criterion>Subjects Confirmed of Lung Cancer by Specific Modes</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3957">Subjects with cytologically/histologically confirmed diagnosis of lung cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3968"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3971">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3975"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3976">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Lung tumor" id="3977">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="4073"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="22381">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="33317"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4024">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Lung tumor" id="4041">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34001"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4032">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34344"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="32043">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34925"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4074">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lung tumor" id="5121"><Criterion>Subjects with Evidence of Metastasis</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5125">Subjects with central nervous system metastases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="5149"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5193"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Lung tumor" id="20281"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5176">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="26890"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5285">Subjects with history of/scheduled for surgery</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2016-03-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="228570"><TitleDisplay>Efficacy, Safety and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure</TitleDisplay><TitleOfficial>A Study on the Efficacy, Safety and Tolerability of Perhexiline Maleate in Subjects With Hypertrophic Cardiomyopathy and Moderate-To-Severe Heart Failure</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02431221</Identifier><Identifier type="Organisational Study">HM-PHX-003</Identifier></Identifiers><Indications><Indication id="1578">Hypertrophic cardiomyopathy</Indication><Indication id="55">Cardiac failure</Indication></Indications><BiomarkerNames><BiomarkerName id="147" role="Therapeutic effect marker" type="Physiological">Six-minute walk distance</BiomarkerName><BiomarkerName id="2265" role="Therapeutic effect marker" type="Physiological">Maximal oxygen uptake</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>perhexiline maleate (hypertrophic cardiomyopathy), Heart Metabolics</Name><Drug id="79373">perhexiline maleate (hypertrophic cardiomyopathy), Heart Metabolics</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="79373">perhexiline maleate (hypertrophic cardiomyopathy), Heart Metabolics</Drug><IndicationsPioneer/><Companies><Company><Company id="1016623">Heart Metabolics Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1016623" type="Company"><TargetEntity id="5019437375" type="organizationId">HMBL Ltd</TargetEntity></SourceEntity><SourceEntity id="1578" type="ciIndication"><TargetEntity id="10020871" type="MEDDRA"/><TargetEntity id="D002312" type="MeSH"/><TargetEntity id="-1205434426" type="omicsDisease"/><TargetEntity id="1510" type="siCondition"/></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"/><TargetEntity id="10007554" type="MEDDRA"/><TargetEntity id="D006333" type="MeSH"/><TargetEntity id="-1323949873" type="omicsDisease"/><TargetEntity id="237" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason></ReasonForTrialDiscontinuation><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1016623">Heart Metabolics Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="53443">Carnitine palmitoyltransferase IA inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="965">Cardiovascular agent</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateChangeLast>2019-01-24T17:31:39Z</DateChangeLast><DateAdded>2015-05-13T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Adult, at least 18 years of age&lt;/li&gt;&lt;li&gt;Able and willing to give written informed consent Cardiomyopathy-related Criteria -Hypertrophic cardiomyopathy (HCM) with moderate-to-severe heart failure as defined as meeting all of the following criteria:&lt;ul&gt;&lt;li&gt;HCM meeting the 2011 ACCF/AHA Criteria for the Diagnosis of Hypertrophic Cardiomyopathy&lt;/li&gt;&lt;li&gt;Left ventricular hypertrophy (LVH) with maximum LV wall thickness&amp;gt; 15 mm by echocardiography or cardiac magnetic resonance imaging without an alternative explanation &lt;/li&gt;&lt;li&gt;Left ventricular ejection fraction (LVEF)&amp;gt; 40% &lt;/li&gt;&lt;li&gt;Able to perform exercise testing but unable to &gt; 75% of the predicted age-adjusted maximum level(as determined by METs achieved during exercise testing-eligibility is not based on VO2max)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Normal sinus rhythm at Screening and Baseline (atrial fibrillation pattern acceptable for subjects with known chronic atrial fibrillation)&lt;/li&gt;&lt;li&gt;If taking any medications for the treatment of HCM (including beta-blockers, calcium channel blockers, disopyramide, diuretics), the medication has been taken a stable dose for at least 60 days prior to enrollment and will be continued at the same dose throughout the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;Pregnant women, women who intend to become pregnant, or woman who are not practicing contraception, either pharmacologically or with a barrier methodLactating women &lt;ul&gt;&lt;li&gt;CYP2D6 Poor Metabolizer (PM) status, based on genotype known prior to Screening, or as predicted by genotype assessed at Screening  CYP2D6 Poor Metabolizer (PM) status is defined as having no functional CYP2D6 alleles by genotyping (exclusively having allele combinations of *3, *4, *5, *6, *7, *8, *12, *14)&lt;/li&gt;&lt;li&gt;Any subject who regularly takes a medication known to be a strong inhibitor of CYP2D6 (bupropion, fluoxetine, paroxetine, quinidine, or ritonavir)&lt;/li&gt;&lt;li&gt;Any concomitant disease, condition, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the investigator or sponsor, pose an unacceptable risk to subjects and/or interfere with the interpretation of study data, including but not limited to:&lt;ul&gt;&lt;li&gt;History of a known toxic or inflammatory peripheral neuropathy, such as mononeuritis multiplex, acute or chronic inflammatory demyelinating polyneuropathy (AIDP or CIDP), axonal sensorimotor neuropathies, drug-related neuropathy or neuritis, or diabetic neuropathy (history of a compression neuropathy, such as carpal tunnel syndrome, is acceptable)&lt;/li&gt;&lt;li&gt;Poorly controlled diabetes mellitus (e.g., HbA1c&amp;gt; 8.5%) &lt;/li&gt;&lt;li&gt;Clinically severe chronic obstructive pulmonary disease (i.e. COPD requiring home oxygen or history of IV or oral steroid use)&lt;/li&gt;&lt;li&gt;History of a known chronic liver disease including cirrhosis of any cause, or chronic hepatitis B or hepatitis C&lt;/li&gt;&lt;li&gt;History of porphyria&lt;/li&gt;&lt;li&gt;History of recurrent hypoglycemia&lt;/li&gt;&lt;li&gt;Active infection requiring antibiotics&lt;/li&gt;&lt;li&gt;Life expectancy of less than two years&lt;/li&gt;&lt;li&gt;Evidence of an active or suspected cancer or a history of malignancy, except for skin squamous cell or basal cell carcinomas that did not require systemic therapy and are considered to be cured&lt;/li&gt;&lt;li&gt;History of substance abuse, including alcohol or illicit drugs within the past 12 months&lt;/li&gt;&lt;li&gt;Abnormal safety studies of clinical significance at Screening such as:&lt;ul&gt;&lt;li&gt;Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, or lactate dehydrogenase&amp;gt; 1.5 x upper limit of normal (ULN)&lt;/li&gt;&lt;li&gt;Glucose&amp;lt; 70 mg/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Prolonged QTc (&amp;gt; 450 ms) l. Known hypersensitivity to perhexiline maleate&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Unable or unwilling to comply with the protocol&lt;/li&gt;&lt;li&gt;Enrolled in another therapeutic trial for hypertrophic cardiomyopathy Cardiomyopathy-related Exclusion Criteria&lt;/li&gt;&lt;li&gt;Asymptomatic subjects or subjects whose symptoms are controlled with medications&lt;/li&gt;&lt;li&gt;Resting LVOT gradient&amp;gt; 50 mmHg or known exercise-induced LVOT gradient &amp;gt; 80 mmHg &lt;/li&gt;&lt;li&gt;Absence of an implanted, operational ICD if there is a history of frequent non-sustained ventricular tachycardia, or a first degree relative having had sudden cardiac death or ICD implant&lt;/li&gt;&lt;li&gt;Known coronary artery disease (&amp;gt; 50% arterial luminal narrowing of a major epicardial vessel) &lt;/li&gt;&lt;li&gt;History of cardiac transplantation&lt;/li&gt;&lt;li&gt;Cardiac surgery or septal reduction surgery planned or having occurred within past 6 months&lt;/li&gt;&lt;li&gt;HCM believed to be caused by infiltrative disorders, glycogen storage disorders, and hypertensive heart disease (including genotypic or phenotypic evidence of Fabry's Disease)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Subject Outcome Variable: the subject Outcome variable is a rank-ordered, hierarchical classification of outcome variables followed by a rank ordering of change from baseline in Maximum oxygen consumption</Description><Timeframe>6 months after randomization</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Functional Assessment During Randomized Phase: change in 6-min walk test (6MWT) from baseline (pre-Part 1 run-in, prior to receiving any perhexiline) to 6 months after randomization during the Randomized Treatment (Part 2)</Description><Timeframe>6 months after Randomization</Timeframe></Measure><Measure><Description>Functional Assessment During Randomized Withdrawal Phase: change in 6-min walk test (6MWT) from the beginning of the Randomized Withdrawal (Part 4) to the end of the Randomized Withdrawal (Part 4)</Description><Timeframe>6 months after initiation of open-label period, and 3 months after randomized withdrawal period initiated</Timeframe></Measure><Measure><Description>Functional Assessment During Randomized Withdrawal Phase: change of CPEX-VO2max from the beginning of the Randomized Withdrawal phase to the end of the Randomized Withdrawal phase (Part 4).  The change in CPEX-VO2max in the placebo group will be compared to the change in CPEX-VO2max in the continued perhexiline (non-withdrawal) group.</Description><Timeframe>6 months after initiation of open-label period, and 3 months after randomized withdrawal period initiated</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to study the efficacy, safety, and tolerability of &lt;ulink linkType="Drug" linkID="79373"&gt;perhexiline maleate&lt;/ulink&gt; in subjects with      hypertrophic cardiomyopathy and moderate-to-severe heart failure.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study was an international, multicenter, randomized, double-blind, placebo-controlled      clinical trial of the effects of perhexiline maleate on a rank-ordered, hierarchical      variable consisting of outcome and functional measures in 350 subjects with hypertrophic      cardiomyopathy and symptoms of moderate to severe congestive heart failure.  &lt;/para&gt;&lt;para&gt;The study was      designed in four parts: &lt;br/&gt;An open-label run-in period of 2 weeks&lt;br/&gt;Blinded, randomized      phase of variable duration (anticipated between 6 months and 18 months depending on      enrollment rate)&lt;br/&gt;An open-label period of 3 months, and &lt;br/&gt;A randomized withdrawal period      of 3 months.  &lt;/para&gt;&lt;para&gt;Subjects who did not experience an adverse outcome (death or resuscitated      ventricular arrhythmia, stroke, need for surgical intervention, cardiovascular      hospitalization, occurrence of atrial fibrillation, or study dropout) would undergo      cardiopulmonary exercise testing in order to determine change from baseline in maximum      oxygen consumption.&lt;/para&gt;&lt;para&gt;Perhexiline maleate would be supplied in 100  and 25 mg tablets.  It would be initially administered with either placebo or  perhexiline maleate at a dose of 200 mg qd in tablet form for at least 6 months. After initiation of dosing, perhexiline dosing would be determined using plasma level guided dose adjustment. Dosing decisions would be made by an unblinded dose control center. Whenever initiating PHM therapy, subjects would receive a loading regimen of PHM as indicated in in the Heart Metabolics Dose Justification document. Drug levels would be measured first on day 4 +/- 1 day, with an initial dose adjustment performed on day 7 +/- 1 day, as needed. The next sampling would occur on day 21 +/- 1 day for potential dose adjustment, as advised by the DCC, on or about day 24. Subsequent dosing would be monitored and advised by a Dose Control Center.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;This sttudy has been withdrawn due to lack of efficacy in a preceeding study.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cardiac failure</Disease><PatientSegments><PatientSegment><PatientSegment id="150">Subjects with History of Treatment</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="151">Subjects at risk of developing disease</PatientSegment><SubSegments><SubSegment id="146">Subjects with cardiomyopathy</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02431221</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Cardiac failure" id="732"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="750">Assessment of peak oxygen consumption (VO2 max)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cardiac failure" id="28679"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="28727">Other patient reported outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Cardiac failure" id="732"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="750">Assessment of peak oxygen consumption (VO2 max)</SubEndpoint><SubEndpoint disease="Cardiac failure" id="753">Six-minute walk test (6MWT)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="1031"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Cardiac failure" id="1031"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="1062">Efficacy parameter - unspecified</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Cardiac failure" id="1321"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cardiac failure" id="258"><Criterion>Subjects with Congestive Heart Failure (CHF)</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="266">Moderate heart failure</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="282"><Criterion>Subjects with Ventricular Structural/Functional Abnormality</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="286">Left ventricular hypertrophy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="293"><Criterion>Subjects with Normal Ejection Fraction</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="294">LVEF = or &gt; 45% (Normal)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="297"><Criterion>Subjects with Cardiomyopathy</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="361"><Criterion>Subjects with Ability to Perform Protocol Specified Exercise Capacity Tests</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="367"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="370">Subjects with history/scheduled to receive beta blockers</SubCriterion><SubCriterion disease="Cardiac failure" id="378">Subjects with history of/scheduled to receive diuretics</SubCriterion><SubCriterion disease="Cardiac failure" id="383">Vasodilators</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="447"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="368">Subjects receiving/scheduled to receive stable medication</SubCriterion><SubCriterion disease="Cardiac failure" id="480">Normal sinus rhythm</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="34444"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="485">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cardiac failure" id="412"><Criterion>Subjects with Congestive Heart Failure (CHF)</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="413">Asymptomatic heart failure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="437"><Criterion>Subjects with  Coronary Artery Disease (CAD)/Ischemic Heart Disease (IHD)</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="448"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="455">Ventricular tachycardia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="464"><Criterion>Subjects with Left Ventricular Dysfunction</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="468">Left ventricular outflow obstruction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="481"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="483">Cardiac transplantation</SubCriterion><SubCriterion disease="Cardiac failure" id="485">Subjects with implanted/scheduled to receive pacemakers/device</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="525"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="526">Subjects with history of/scheduled to receive antibiotics for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="543"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="737">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="556"><Criterion>Subjects co-morbid with hypertension</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="605"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="640"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="642">Subjects co-morbid with hepatitis B virus infection</SubCriterion><SubCriterion disease="Cardiac failure" id="643">Subjects co-morbid with hepatitis C virus infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="679"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="697">Any medical/surgical condition interfering with participation in the study</SubCriterion><SubCriterion disease="Cardiac failure" id="698">Conditions that prohibit completion of study</SubCriterion><SubCriterion disease="Cardiac failure" id="699">Conditions/co-morbidity that limit survival or Limited Life expectancy</SubCriterion><SubCriterion disease="Cardiac failure" id="700">Conditions/Medication affecting patient safety/study outcome</SubCriterion><SubCriterion disease="Cardiac failure" id="755">Participated in an investigational drug/device study within the last 3 months</SubCriterion><SubCriterion disease="Cardiac failure" id="820">Unsuitable to participate as per the investigator's opinion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="681"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="582">Abnormal liver function test</SubCriterion><SubCriterion disease="Cardiac failure" id="1404">Abnormalities on echocardiogram</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="25073"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="581">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion><SubCriterion disease="Cardiac failure" id="597">Subjects with neurologic/psychiatric disorders</SubCriterion><SubCriterion disease="Cardiac failure" id="660">Subjects co-morbid with chronic inflammatory disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="25725"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="735">Intend to become pregnant during the trial</SubCriterion><SubCriterion disease="Cardiac failure" id="740">Lactating women</SubCriterion><SubCriterion disease="Cardiac failure" id="744">Men without  adequate contraception</SubCriterion><SubCriterion disease="Cardiac failure" id="750">Positive serum/urine pregnancy test</SubCriterion><SubCriterion disease="Cardiac failure" id="792">Pregnant women</SubCriterion><SubCriterion disease="Cardiac failure" id="827">Women of child bearing potential without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="25881"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="671">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="26247"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="688">Subjects co-morbid with alcohol and/or drug/substance abuse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27058"><Criterion>Subjects co-morbid with vascular disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="564">Subjects co-morbid with peripheral vascular disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27060"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="572">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27844"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="823">Unwillingness/inability to comply with study requirements/protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-07-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2015-04-27T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-05-13T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-07-20T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="231572"><TitleDisplay>Comparing Pain After Laparoscopic Hernia Repair Using Two Different Types of Mesh Fixation</TitleDisplay><TitleOfficial>A Clinical Study of Postoperative Pain Following Laparoscopic Transabdominal Preperitoneal Inguinal Hernioplasty. Comparing Parietex ProGrib With Tacks for Mesh Fixation</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02467140</Identifier><Identifier type="Organisational Study">2307PG</Identifier></Identifiers><Indications/><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Parietex ProGrib self-fixating mesh</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Tack fixation (AbsorbaTack)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1097361" type="Company"><TargetEntity id="5043331632" type="organizationId">Medtronic PLC</TargetEntity></SourceEntity><SourceEntity id="DOL1000133" type="Company"><TargetEntity id="5001204002" type="organizationId">Aarhus University</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="DOL1000133">Aarhus University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1097361">Medtronic plc</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>500</PatientCountEnrollment><DateStart>2015-05-31T00:00:00Z</DateStart><DateEnd type="estimated">2017-05-31T00:00:00Z</DateEnd><DateChangeLast>2015-06-12T06:19:39Z</DateChangeLast><DateAdded>2015-09-15T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>maledine@rm.dk</Email><Name>Malene O Dinesen, MD PhD</Name><Phone>+45 42 29 00 23</Phone></Contact><Contact type="Scientific contact"><Name>Michael F Nielsen, MD PhD</Name></Contact><Contact type="Public contact"><Email>mariekirk@dadlnet.dk</Email><Name>Marie K Christensen, MD</Name><Phone>+45 40 79 54 59</Phone></Contact></Contacts><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of patients experiencing acute postoperative pain, using the NRS pain score</Description><Timeframe>3 months</Timeframe></Measure><Measure><Description>Number of patients with recurrent hernia</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number of patients experiencing chronic postoperative pain, using the NRS pain score</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Quality of life before and after surgery, using the Carolina Comfort Scale</Description><Timeframe>6 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Denmark"><Sites><Site><Name>Hospitalsenheden Midt</Name><Address1>Viborg</Address1><Address2>Region Midt</Address2><Address3>8800</Address3><CountrySubDivision>Region Midt</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8386">Subjects with Acute Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8387">Subjects with Chronic Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8424">Subjects with Post-Operative Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02467140</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25875">Based on Numerical Rating Scale [NRS]</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25934"><Endpoint>Assessment of Post-operative Pain</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26058"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25875">Based on Numerical Rating Scale [NRS]</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25934"><Endpoint>Assessment of Post-operative Pain</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="34984">Assessment by Carolina Comfort Scale</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22087"><Criterion>Subjects Based on Duration of Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22088">Subjects with acute pain</SubCriterion><SubCriterion disease="Pain" id="22090">Subjects with chronic pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22142"><Criterion>Subjects with Peri-operative Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22143">Subjects with post operative pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22148"><Criterion>Subjects Based on Pain Scale Ratings</Criterion></Inclusion><Inclusion disease="Pain" id="22172"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Pain" id="22173">Subjects with pre-specified physical status</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34371"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22263">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20174">Subjects with history/scheduled to receive other drug therapies</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2016-05-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-09-15T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="232707"><TitleDisplay>Safety and pharmacokinetics of CIGB-552</TitleDisplay><TitleOfficial>Evaluation of the safety and pharmacokinetics and determining the maximum tolerable dose with the use of antitumor peptide CIGB-552 in solid tumors</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">RPCEC00000196</Identifier><Identifier type="Other">IG/CIGB-552I/TS/1301</Identifier><Identifier type="Trial Acronym">ARGOS-1</Identifier></Identifiers><Indications><Indication id="725">Solid tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>CIGB-552</Name><Drug id="62892">CIGB-552</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="62892">CIGB-552</Drug><IndicationsPioneer/><Companies><Company><Company id="15353">Center for Genetic Engineering and Biotechnology</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="15353" type="Company"><TargetEntity id="5035523591" type="organizationId">Centro de Ingenieria Genetica y Biotecnologia</TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="15353">Center for Genetic Engineering and Biotechnology</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class><Class id="59620">Unspecified drug target</Class><Class id="695">Metastasis inhibitor</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>No Control</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>42</PatientCountEnrollment><DateChangeLast>2019-06-03T11:30:00Z</DateChangeLast><DateAdded>2015-06-28T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>National Institute of Oncology and Radiobiology</Affiliation><Email>brauliofdez@infomed.sld.cu</Email><Name>Braulio Mestre Fernandez</Name><Phone>+53-78382576</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Patients who meet the diagnostic criteria&lt;/li&gt;&lt;li&gt;Values normal blood glucose values according institucionales&lt;/li&gt;&lt;li&gt;General status ECOG 0-2&lt;/li&gt;&lt;li&gt;Patients who have normal functioning of organs and bone marrow defined by the following parameters: - *Hemoglobin &gt;/= 9 g /l&lt;ul&gt;&lt;li&gt;Leukocytes &gt;/=  3 x 10(9) /l&lt;/li&gt;&lt;li&gt;Absolute neutrophil count &gt;/= 1.5 x 10(9) /l&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Platelet count &gt;/= 150 to 250 x 10(9)/l&lt;/li&gt;&lt;li&gt;Total bilirubin: Within normal limits as institutional values. - TGP and TGO&amp;lt;/= 2.5 x the institutional upper limit of normal&lt;/li&gt;&lt;li&gt;Creatinine: Within normal limits as institutional values&lt;/li&gt;&lt;li&gt;Voluntary patient by signing the informed consent model&lt;/li&gt;&lt;li&gt;Life expectancy greater than 3 months&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who are of childbearing potential not using adequate contraceptive method (IUDs, barrier methods, hormones or tubal ligation) for men (vasectomy, condom use) prior to their inclusion in the study and / or while participating in the clinical trial&lt;/li&gt;&lt;li&gt;Patients with a positive pregnancy test, breastfeeding and postpartum women&lt;/li&gt;&lt;li&gt;Patients suffering from severe allergic diseases&lt;/li&gt;&lt;li&gt;Diabetic patients&lt;/li&gt;&lt;li&gt;That have been treated with other biological therapy six months preceding the date of inclusion&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Adverse events of intensity III and IV (Common Toxicity Criteria (Common Toxicity Criteria) (CTC) version 4.0 of the National Cancer Institute USA)</Description><Timeframe>After each administration, 4 weeks after the last administration of the product and at 12 weeks after inclusion</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Adverse Events (AE) :  Intensity of AE (Common Toxicity Criteria-CTC) . Gravity (Grave, Not serious) . Result ( Recovered,  Improved, Persists or Squeals) . Attitude respect to EA ( Temporal interruption,  Definitive interruption, Without change, Other)</Description><Timeframe>After each administration, 4 weeks after treatment and 12 weeks after inclusion</Timeframe></Measure><Measure><Description>Causality relationship of AE (Very Likely / Safe, Likely, Possible, Unlikely Not related, Unknown) . Lot of antitumor peptide (lot identification)</Description></Measure><Measure><Description>Laboratory tests. Hematology (hemoglobin, Leucogram with differential, hematocrit, platelet count).</Description><Timeframe>At baseline, four weeks after treatment and at 12 weeks after inclusion</Timeframe></Measure><Measure><Description>Biochemistry (transaminases, glucose, bilirubin, alkaline phosphatase, creatinine, total and fractionated proteins)</Description><Timeframe>At baseline, four weeks after treatment and at 12 weeks after inclusion</Timeframe></Measure><Measure><Description>Immunology (CD4 and CD8 levels)</Description><Timeframe>At baseline, four weeks after treatment and at 12 weeks after inclusion</Timeframe></Measure><Measure><Description>Tumor assessment -Objective response (RECIST criteria. Progression, Complete response, Partial response y stable disease, progression)</Description><Timeframe>4 weeks after treatment and 3 months after inclusion</Timeframe></Measure><Measure><Description>CIGB peptide plasma concentration-552, only three dose levels 2.8 , 4.7, 9.8 mg.</Description><Timeframe>At baseline, 10, 20 and 40 min and at 1, 1.5, 3, 6, 12 and 24 h after administration of the product</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to evaluate the safety and pharmacokinetics and determining the maximum tolerable dose with the use of antitumor peptide &lt;ulink linkType="Drug" linkID="62892"&gt;CIGB-552&lt;/ulink&gt; in solid tumors.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Study group (CIGB-552): The product will be repeated dose administered subcutaneously in six dose levels of scale: 1.4 , 2.8 , 4.7 , 7.0 , 9.8  and 13 mg. The appropriate dose is given  tiw for 2 weeks (six doses).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Cuba"><Sites><Site><Name>National Institute of Oncology and Radiobiology</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1013">Cuban Public Registry of Clinical Trials (RPCEC)</Name><Identifiers><Identifier>RPCEC00000196</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Solid tumor" id="15285"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15288">Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Solid tumor" id="15209"><Endpoint>Assessment of Disease Progression</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15211"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15212">Assessment of objective response rate (ORR)</SubEndpoint><SubEndpoint disease="Solid tumor" id="15214">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Solid tumor" id="15215">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Solid tumor" id="15216">Assessment of Stable Disease</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15245"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15249">Assessment of lymphocytes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15254"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15276"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="26827">Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15285"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15288">Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15287"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15309"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15310">Assessment of biochemical parameters</SubEndpoint><SubEndpoint disease="Solid tumor" id="15311">Serum assessment</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15312"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15315"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15325">Assessment of hematological status</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Solid tumor" id="13102"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13105">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13109"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13110">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Solid tumor" id="13111">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Solid tumor" id="13112">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13130"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13131">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Solid tumor" id="13132">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13155"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Solid tumor" id="34030"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13133">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34423"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13138">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Solid tumor" id="10704"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10743"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10753">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="26830"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10734">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="26970"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10754">Subjects without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-06-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-06-04T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="241536"><TitleDisplay>Phase II Study of Tefinostat in Chronic Myelomonocytic Leukemia (CMML)</TitleDisplay><TitleOfficial>A Phase II Study of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN17394489</Identifier><Identifier type="Other">2015-002281-23</Identifier><Identifier type="Other">Spon1345-14</Identifier><Identifier type="Trial Acronym">MONOCLE</Identifier></Identifiers><Indications><Indication id="6833">Chronic myelomonocytic leukemia</Indication></Indications><BiomarkerNames><BiomarkerName id="1453" role="Therapeutic effect marker" type="Genomic;Proteomic">Liver carboxylesterase 1 </BiomarkerName><BiomarkerName id="10684" role="Therapeutic effect marker" type="Cellular">Blood cells</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tefinostat</Name><Drug id="59093">tefinostat</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="59093">tefinostat</Drug><IndicationsPioneer><Indication id="6833">Chronic myelomonocytic leukemia</Indication></IndicationsPioneer><Companies><Company><Company id="1057645">Leukaemia and Lymphoma Research</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23495">Cardiff University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="59093" type="Drug"><TargetEntity id="650217" type="siDrug">Tefinostat</TargetEntity></SourceEntity><SourceEntity id="1057645" type="Company"><TargetEntity id="5035526716" type="organizationId">Bloodwise</TargetEntity></SourceEntity><SourceEntity id="23495" type="Company"><TargetEntity id="4296902902" type="organizationId">Cardiff University</TargetEntity></SourceEntity><SourceEntity id="6833" type="ciIndication"><TargetEntity id="10009018" type="MEDDRA"/><TargetEntity id="D015477" type="MeSH"/><TargetEntity id="98823" type="ORPHANET"/><TargetEntity id="-1293987798" type="omicsDisease"/><TargetEntity id="692" type="siCondition"/></SourceEntity><SourceEntity id="2574" type="Action"><TargetEntity id="1213" type="Mechanism">Histone Deacetylase (HDAC) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23495">Cardiff University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1057645">Leukaemia and Lymphoma Research</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="2574">Histone deacetylase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class><Class id="7293">Synergist</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2015-03-01T00:00:00Z</DateStart><DateEnd type="estimated">2019-07-26T00:00:00Z</DateEnd><DateChangeLast>2018-10-27T10:35:14Z</DateChangeLast><DateAdded>2015-10-01T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Institute of Cancer &amp; Genetics at Cardiff University</Affiliation><Email>knappers@cardiff.ac.uk</Email><Name>Dr Knapper</Name><Phone>+44 (0)292 074 5379</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;All CMML-2 patients are eligible&lt;/li&gt;&lt;li&gt;For patients classified as CMML-1, the following must be present:&lt;ul&gt;&lt;li&gt;Symptomatic bone marrow failure/myeloproliferation defined as one or more of: red cell transfusion dependence with pre-transfusion Hb&amp;lt; 90 g/l, symptomatic anemia (Hb &amp;lt; 115 g/l), thrombocytopenia (platelets &amp;lt; 50 x 10(9)/l), symptomatic bleeding due to platelet function defect or DIC/fibrinolysis, white blood cell count &amp;gt; 50 x 10(9)/l&lt;/li&gt;&lt;li&gt;CMML-specific Prognostic Score (CPSS) of intermediate-2 or high risk&lt;/li&gt;&lt;li&gt;Systemic symptoms including weight loss with no alternative explanation (10% of baseline weight within previous 6 months)&lt;/li&gt;&lt;li&gt;Symptomatic splenomegaly&lt;/li&gt;&lt;li&gt;Symptomatic extrameduallary involvement, eg. skin infiltration, serous effusions&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Subject is able and willing to sign the informed consent form&lt;/li&gt;&lt;li&gt;Age &gt;/= 18 years at the time of signing the informed consent form&lt;/li&gt;&lt;li&gt;Willingness to undergo scheduled assessments as per the study protocol including bone marrow assessments&lt;/li&gt;&lt;li&gt;ECOG performance status of 0 to 2 at study entry&lt;/li&gt;&lt;li&gt;Women of childbearing potential must have a negative urine pregnancy test within 7 days prior to starting study drug&lt;/li&gt;&lt;li&gt;Women of childbearing potential must use at least two effective contraceptive methods throughout the study and for three months following the date of the last dose of study drug&lt;/li&gt;&lt;li&gt;Men whose partner is a woman of childbearing potential must use at least two effective contraceptive&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;CMML with eosinophillia and 5q33 abnormality&lt;/li&gt;&lt;li&gt;Previous chemotherapy for CMML except Hydroxycarbamide and 5-azacitidine&lt;/li&gt;&lt;li&gt;Creatinine concentration&amp;gt; 2 x the institutional upper limit of normal range&lt;/li&gt;&lt;li&gt;Liver transaminases (AST/ALT)&amp;gt; 3 x the institutional upper limit of normal range or serum bilirubin &amp;gt; 4 x the institutional upper limit of normal range&lt;/li&gt;&lt;li&gt;Pregnant or lactating females&lt;/li&gt;&lt;li&gt;Use of experimental drug or therapy within 28 days of registration&lt;/li&gt;&lt;li&gt;Other malignancy within the last three years other than curatively-treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated non-metastatic prostate cancer with negative prostate-specific antigen, in situ breast carcinoma after complete surgical resection, or superficial transitional cell bladder carcinoma&lt;/li&gt;&lt;li&gt;Known seropositivity for HIV infection or infectious hepatitis (type B or C)&lt;/li&gt;&lt;li&gt;Uncontrolled inter-current illness including, but not limited to, ongoing infection, psychiatric illness or social situation that the treating physician judges would limit compliance with study requirements&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Safety and tolerability of tefinostat defined as the proportion of patients experiencing CTC grade 3 to 4 non-hematological toxicity or death thought to be at least possibly related to tefinostat</Description><Timeframe>Primary outcome measures will be assessed continuously over this period, including fortnightly peripheral blood assessment (full blood count, blood film/differential) and bone marrow assessments performed after 12 and 24 weeks of therapy</Timeframe></Measure><Measure><Description>Overall clinical response rate (according to Wattel and modified IWG criteria)</Description><Timeframe>Primary outcome measures will be assessed continuously over this period, including fortnightly peripheral blood assessment (full blood count, blood film/differential) and bone marrow assessments performed after 12 and 24 weeks of therapy</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Achievement of red blood cell and platelet transfusion independence</Description><Timeframe>Secondary outcome measures will be assessed continuously over this period, including fortnightly peripheral blood assessment (full blood count, blood film/differential) and bone marrow assessments performed after 12 and 24 weeks of therapy</Timeframe></Measure><Measure><Description>Biological correlates including hCE-1 expression, changes in protein acetylation</Description><Timeframe>Secondary outcome measures will be assessed continuously over this period, including fortnightly peripheral blood assessment (full blood count, blood film/differential) and bone marrow assessments performed after 12 and 24 weeks of therapy</Timeframe></Measure><Measure><Description>Duration of tefinostat therapy</Description><Timeframe>Secondary outcome measures will be assessed continuously over this period, including fortnightly peripheral blood assessment (full blood count, blood film/differential) and bone marrow assessments performed after 12 and 24 weeks of therapy</Timeframe></Measure><Measure><Description>Incidence and duration of CR/PR/hematological improvement/clinical benefit (according to International Consortium MDS/MPN Response Criteria)</Description><Timeframe>Secondary outcome measures will be assessed continuously over this period, including fortnightly peripheral blood assessment (full blood count, blood film/differential) and bone marrow assessments performed after 12 and 24 weeks of therapy</Timeframe></Measure><Measure><Description>Incidence of transformation of CMML to acute myeloid leukemia (AML), and the time to AML transformation</Description><Timeframe>Secondary outcome measures will be assessed continuously over this period, including fortnightly peripheral blood assessment (full blood count, blood film/differential) and bone marrow assessments performed after 12 and 24 weeks of therapy</Timeframe></Measure><Measure><Description>Overall survival</Description><Timeframe>Secondary outcome measures will be assessed continuously over this period, including fortnightly peripheral blood assessment (full blood count, blood film/differential) and bone marrow assessments performed after 12 and 24 weeks of therapy</Timeframe></Measure><Measure><Description>Progression-free survival</Description><Timeframe>Secondary outcome measures will be assessed continuously over this period, including fortnightly peripheral blood assessment (full blood count, blood film/differential) and bone marrow assessments performed after 12 and 24 weeks of therapy</Timeframe></Measure><Measure><Description>Quality of life</Description><Timeframe>Patients will be followed up for 18 months to gather all data to effectively assess end points</Timeframe></Measure><Measure><Description>Biological correlates including hCE-1 expression and changes in protein acetylation</Description><Timeframe>Patients will be followed up for 18 months to gather all data to effectively assess end points</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The dual primary objectives of this simple, single-arm, phase II trial were:&lt;br/&gt;To evaluate the safety and tolerability of &lt;ulink linkType="Drug" linkID="59093"&gt;tefinostat&lt;/ulink&gt; (CHR-2845) in chronic myelomonocytic leukemia.&lt;br/&gt;To evaluate the overall clinical response rate to tefinostat in patients with chronic myelomonocytic leukemia (according to Wattel and modified IWG criteria).&lt;/para&gt;&lt;para&gt;In February 2017, the trial was initiated [&lt;ulink linkType="Reference" linkID="1899075"&gt;1899075&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Main objective of the trial:&lt;br/&gt;Is tefinostat (CHR-2845) safe and tolerable for patients with CMML?&lt;br/&gt;Is tefinostat clinically effective in CMML? (primary efficacy endpoint will be overall clinical response rate according to the International Consortium MDS/MPN Response Criteria). &lt;/para&gt;&lt;para&gt;Secondary objectives of the trial:&lt;br/&gt;Is tefinostat clinically effective in CMML? (Secondary efficacy endpoint will include the incidences of complete remission, partial remission and 'haematological improvement', overall survival, progression-free survival, and time to transformation to acute myeloid leukaemia).&lt;br/&gt;Do clinical responses to tefinostat correlate with biological measures (including baseline hCE-1 expression level [Human carboxylesterase], differential effects on protein acetylation between monocytes and other haematological cell lineages and molecular mutational profile including targeted gene sequencing?).&lt;br/&gt;&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive tefinostat (CHR-2845) continuously for six continuous 4-week cycles (24 weeks).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Contacts/></Site><Site><Name>Aberdeen Royal Infirmary</Name><Contacts/></Site><Site><Name>Beatson West of Scotland Cancer Centre</Name><Contacts/></Site><Site><Name>Bristol Haematology and Oncology Centre</Name><Contacts/></Site><Site><Name>Cardiff University</Name><Contacts/></Site><Site><Name>Castle Hill Hospital</Name><Contacts/></Site><Site><Name>Churchill Hospital</Name><Contacts/></Site><Site><Name>Freeman Hospital</Name><Contacts/></Site><Site><Name>Guy's Hospital</Name><Contacts/></Site><Site><Name>Kent and Canterbury Hospital</Name><Contacts/></Site><Site><Name>Nottingham City Hospital</Name><Contacts/></Site><Site><Name>St James's University Hospital</Name><Contacts/></Site><Site><Name>The Christie Hospital</Name><Contacts/></Site><Site><Name>University Hospital of Wales</Name><Contacts/></Site><Site><Name>Ysbyty Gwynedd</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Leukemia</Disease><PatientSegments><PatientSegment><PatientSegment id="3978">Subjects with Chronic Myeloid Leukemia (CML)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2015-002281-23</Identifier></Identifiers></Registry><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN17394489</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8089">Assessment of toxicity</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8109"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Leukemia" id="7879"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7891"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7906"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7907">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Leukemia" id="7908">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Leukemia" id="7909">Assessment of Overall/Objective Response Rate (ORR)</SubEndpoint><SubEndpoint disease="Leukemia" id="7916">Assessment of hematologic/bone marrow response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7935"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7942">Assessment of time to leukemic transformation</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8015"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8049"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8136"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8140">Assessment of Clinical Efficacy</SubEndpoint><SubEndpoint disease="Leukemia" id="8142">Assessment of hematopoietic suppression</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8149"><Endpoint>Assessment of use of Rescue Medication</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="44052"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="9407">Assessment of transfusion requirements</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Leukemia" id="4982"><Criterion>Subjects with Chronic Myeloid Leukemia (CML)</Criterion></Inclusion><Inclusion disease="Leukemia" id="5019"><Criterion>Subjects with Symptomatic Disease</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5020">Subjects with anemia as disease symptom</SubCriterion><SubCriterion disease="Leukemia" id="5029">Subjects with splenomegaly</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5031"><Criterion>Subjects with Other Bone Marrow Disorders</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5033">Subjects co-morbid with myeloproliferative disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5071"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5077">Subjects with normal/adequate hematopoietic function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5085"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5086">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Leukemia" id="5087">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Leukemia" id="5088">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5187"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5206">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="33205"><Criterion>Subjects with Chronic Myelomonocytic Leukemia (CMML)</Criterion></Inclusion><Inclusion disease="Leukemia" id="33935"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5412">Subjects with protocol specified body weights</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34143"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5196">Men with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34442"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5190">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34918"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5189">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Leukemia" id="6534"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Leukemia" id="6546"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Leukemia" id="6554"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Leukemia" id="6706"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6719">Subjects with physical abnormality or laboratory abnormality which would make it inappropriate to participate in the study</SubCriterion><SubCriterion disease="Leukemia" id="6720">Subjects with previous exposure to study drug</SubCriterion><SubCriterion disease="Leukemia" id="6723">Protocol specified exclusion criteria for females</SubCriterion><SubCriterion disease="Leukemia" id="6725">Subjects not suitable to take part in study according to investigator's opinion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="8709"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6618">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2017-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>25.00 Months</EnrollmentPeriod><EnrollmentRate>1.60 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-10-01T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-10-26T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="242202"><TitleDisplay>Clinical utility of robotic surgery for the treatment of lung and mediastinal disease</TitleDisplay><TitleOfficial>Clinical utility of robotic surgery (the da Vinci surgical system; standard and S) for the treatment of lung and mediastinal disease</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000004328</Identifier></Identifiers><Indications><Indication id="283">Lung disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>da Vinci Surgical System</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>robotic surgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1083926" type="Company"><TargetEntity id="5039925159" type="organizationId">Tokyo Medical Nuversity</TargetEntity></SourceEntity><SourceEntity id="283" type="ciIndication"><TargetEntity id="10025082" type="MEDDRA"/><TargetEntity id="D008171" type="MeSH"/><TargetEntity id="-1582153652" type="omicsDisease"/><TargetEntity id="3451" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1083926">Tokyo Medical University, JAPAN</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2009-10-01T00:00:00Z</DateStart><DateChangeLast>2017-10-12T06:45:36Z</DateChangeLast><DateAdded>2015-10-08T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Tokyo medical university ; surgery 1</Affiliation><Email>surgery1@tokyo-med.ac.jp</Email><Name>Ikeda Norihiko</Name><Phone>03-3342-6111</Phone></Contact><Contact type="Public contact"><Affiliation>surgeru 1 ; thoracic surgery</Affiliation><Email>kajiwara@tokyo-med.ac.jp</Email><Name>Kajiwara Naohiro</Name><Phone>03-3342-6111</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;General condition good (possible of open thoracotomy)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;General condition poor&lt;/li&gt;&lt;li&gt;Past history of the open thoracotomy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Robotic surgery is an effective surgical method</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Investigators will use the da Vinci Surgical System for thoracic diseases and review future possibilities and problems of robotic surgery for thoracic surgery fields in Japan.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will undergo  robotic surgery using da Vinci Surgical System.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Tokyo Medical University Hospital</Name><Address1>Tokyo</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000004328</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><DateEnrollmentEnd type="actual">2017-10-10T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>96.32 Months</EnrollmentPeriod><EnrollmentRate>0.31 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-10-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-10-12T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="246744"><TitleDisplay>Effect of high Iron/Zinc Pearl Millet on growth, ability of the body to resist infections (immunity), and mental functioning (cognition) in children aged 12 to 18 months in India</TitleDisplay><TitleOfficial>Effect of Iron and Zinc biofortified Pearl Millet (ICTP8203-Fe) Consumption on Growth, Immune competence, and Cognitive Function in Children Aged 12 to 18 Months in Urban Slums of Mumbai, India</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">CTRI/2015/11/006376</Identifier></Identifiers><Indications><Indication id="2736">Hypozincemia</Indication><Indication id="683">Nutritional deficiency</Indication></Indications><BiomarkerNames><BiomarkerName id="907" role="Therapeutic effect marker" type="Genomic;Proteomic">Transferrin receptor protein 1</BiomarkerName><BiomarkerName id="1051" role="Therapeutic effect marker" type="Genomic;Proteomic">Ferritin</BiomarkerName><BiomarkerName id="9842" role="Therapeutic effect marker" type="Anthropomorphic">Birth weight</BiomarkerName><BiomarkerName id="17664" role="Therapeutic effect marker" type="Anthropomorphic">Arm circumference</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName><BiomarkerName id="22801" role="Therapeutic effect marker" type="Structural (imaging)">Head circumference</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>conventional pearl millet diet</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>iron and zinc biofortified pearl millet (ICTP8203-Fe)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="24136" type="Company"><TargetEntity id="5000024077" type="organizationId">Cornell University</TargetEntity></SourceEntity><SourceEntity id="2736" type="ciIndication"><TargetEntity id="E60" type="ICD10"/><TargetEntity id="10021148" type="MEDDRA"/><TargetEntity id="3769" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="24136">Cornell University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1077911">HarvestPlus</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>700</PatientCountEnrollment><DateStart>2016-01-20T00:00:00Z</DateStart><DateChangeLast>2015-12-12T16:00:35Z</DateChangeLast><DateAdded>2015-11-26T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>SNDT Womens University</Affiliation><Email>drshobhaudipi@gmail.com</Email><Name>Dr Shobha A Udipi</Name><Phone>26608855</Phone></Contact><Contact type="Scientific contact"><Affiliation>Saint Johns Research Institute</Affiliation><Email>a.kurpad@sjri.res.in</Email><Name>Anura Kurpad</Name></Contact><Contact type="Scientific contact"><Affiliation>Centre for the Study of Social Change (CSSC)</Affiliation><Email>rdpotdar@snehamrc.com</Email><Name>Dr Ramesh Potdar</Name><Phone>919820183454</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age 9 to 15 months (at time of pre-screening)&lt;/li&gt;&lt;li&gt;Serum ferritin&amp;lt; 20 microg/dl&lt;/li&gt;&lt;li&gt;Plasma zinc&amp;lt; 105 microg/dl&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;lt;  10 months or older than 15 months (at time of pre-screening)&lt;/li&gt;&lt;li&gt;Hemoglobin&amp;lt; 9 g/dl and/or hemoglobinapathy&lt;/li&gt;&lt;li&gt;Presence of severe malnutrition according to Wellcome Classification (marasmus, marasmic kwashiorkor, kwashiorkor, weight-for-height z-score&amp;lt; -3)&lt;/li&gt;&lt;li&gt;Prior known or current diagnoses of HIV/AIDS, Malaria, dengue fever, thrice, tuberculosis&lt;/li&gt;&lt;li&gt;Children who do not have a caretaker to bring him/her to feeding center twice per day&lt;/li&gt;&lt;li&gt;Possibility of migrating out of the slum dwelling&lt;/li&gt;&lt;li&gt;Prior or current consumption of iron or zinc supplements&lt;/li&gt;&lt;li&gt;Any known dietary allergies&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Biomarkers iron and zinc status determined by serum ferritin, sTfR, serum zinc, and total body iron</Description><Timeframe>At screening (prior to enrolment), baseline (prior to intervention), midline (during months 2 to 8), and endline (post-intervention)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Immune function tests: measurement of both growth capacity of bacterial strain in whole blood and killing capacity of macrophages</Description><Timeframe>Baseline, midline, and endline (9 months)</Timeframe></Measure><Measure><Description>Anthropometric measurements as determined by length/height, weight, head circumference, and mid-upper-arm circumference</Description><Timeframe>Baseline, midline, and endline (9 months)</Timeframe></Measure><Measure><Description>Cognitive outcomes: Bayley III test will be performed to determine specific aspects of memory, attention, and processing speed as well as assessment of higher integrative cognitive abilities that require multiple specific functions</Description><Timeframe>Baseline, midline, and endline (9 months)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The main objectives of this study is  to determine the effect of consumption of biofortified pearl millet on the biomarkers of iron and zinc status, functional consequences of growth, immune and cognitive outcomes of children between the ages 12 to 18 months. The long-term goal of this study is to determine if iron and zinc biofortification of pearl millet is an effective and sustainable strategy to reduce iron and zinc deficiency and their adverse effects on child health and development in developing countries.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects will be assigned to one of the two arms.&lt;br/&gt;Arm 1: iron and zinc biofortified pearl millet (ICTP8203-Fe) will be consumed (oral ingestion) three times per day, 6 days per week, for 9 months. Children are anticipated to consume 25 to 30 g of the pearl millet at each feeding for a total of 60 g per day.The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits. &lt;br/&gt;Arm 2: conventional pearl millet will be consumed three times per day, 6 days per week, for 9 months. Children are anticipated to consume 25 to 30 g of the pearl millet at each feeding for a total of 60 g per day. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>Centre for the Study of Social Change (CSSC)</Name><Address1>Mumbai</Address1><Address2>MAHARASHTRA</Address2><Address3>400 051</Address3><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts/></Site><Site><Name>Shreemati Nathibai Damodar Thackersey Womens University</Name><Address1>Mumbai</Address1><Address2>MAHARASHTRA</Address2><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts/></Site><Site><Name>St Johns Research Research Institute</Name><Address1>Bangalore</Address1><Address2>KARNATAKA</Address2><CountrySubDivision>KARNATAKA</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2015/11/006376</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-11-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="251247"><TitleDisplay>Effect of oxycodone to general anesthesia patients's safety and degree of comfort during perioperative period undergoing laparoscope abdominal surgery</TitleDisplay><TitleOfficial>Effect of oxycodone to general anesthesia patients's safety and degree of comfort during perioperative period undergoing laparoscope abdominal surgery</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR-IPR-16007775</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames><BiomarkerName id="175" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-10</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="274" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor</BiomarkerName><BiomarkerName id="364" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-1 beta</BiomarkerName><BiomarkerName id="1664" role="Therapeutic effect marker" type="Genomic;Proteomic">Cytochrome P450 3A4</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="1886" role="Therapeutic effect marker" type="Genomic;Proteomic">Cytochrome P450 3A5</BiomarkerName><BiomarkerName id="2095" role="Therapeutic effect marker" type="Physiological">Mean arterial pressure</BiomarkerName><BiomarkerName id="2534" role="Therapeutic effect marker" type="Biochemical">Hydrocortisone</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="5088" role="Therapeutic effect marker" type="Genomic">Mu-Type opioid receptor</BiomarkerName><BiomarkerName id="10260" role="Therapeutic effect marker" type="Physiological">Respiratory frequency</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>oxycodone</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sufentanil</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1054418" type="Company"><TargetEntity id="5035550177" type="organizationId">Changzheng Hospital</TargetEntity></SourceEntity><SourceEntity id="1074324" type="Company"><TargetEntity id="5035311718" type="organizationId">Science and Technology Commission of Shanghai Municipality</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1054418">Shanghai Changzheng Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1074324">Shanghai Committee of Science and Technology</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2016-01-01T00:00:00Z</DateStart><DateEnd type="estimated">2016-06-30T00:00:00Z</DateEnd><DateChangeLast>2019-02-07T03:56:05Z</DateChangeLast><DateAdded>2016-01-25T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Department of Anesthesiology, Changzheng Hospital, Second Military Medical University</Affiliation><Email>pujuan1984@hotmail.com</Email><Name>Pu Jun</Name><Phone>+86 13764500596</Phone></Contact><Contact type="Public contact"><Email>jfjccyy@163.com</Email><Name>Yuan Hongbin</Name><Phone>+86 13795229316</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Approved by the hospital ethics committee, 100 cases of laparoscopic gastric cancer and colorectal cancer surgery were selected (surgery time 2 to 4 h)&lt;/li&gt;&lt;li&gt;Age between 18 to 65, ASA I to II&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Allergic to oxycodone or Other ingredients in the preparation of oxycodone&lt;/li&gt;&lt;li&gt;Patients with history of respiratory disease&lt;/li&gt;&lt;li&gt;A long history of smoking&lt;/li&gt;&lt;li&gt;There were upper respiratory tract infection in the last 2 weeks&lt;/li&gt;&lt;li&gt;Use of hormones, bronchial dilation agent in the last 2 weeks&lt;/li&gt;&lt;li&gt;Patients with heart ,brain, liver and kidney disease&lt;/li&gt;&lt;li&gt;Morbidly obese patients&lt;/li&gt;&lt;li&gt;The history of mental and neurological diseases was diagnosed before operation&lt;/li&gt;&lt;li&gt;Long term use of diazepam or opioid drug&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Blood pressure: arterial blood pressure</Description><Timeframe>Before anesthesia induction, the endotracheal intubation before, immediately, after 0.5, 5 min; tracheal catheter removal before, immediately, after 5, 30 min; postoperative 6, 12, 24, 48 h</Timeframe></Measure><Measure><Description>Emergence agitation: restlessness score</Description><Timeframe>Anesthesia recovery period</Timeframe></Measure><Measure><Description>Level of sedation: Ramsay score</Description><Timeframe>Tracheal catheter removal before, immediately, after 5, 30 min; postoperative 6,12, 24, 48 h</Timeframe></Measure><Measure><Description>The degree of pain: VAS: visual analog scale</Description><Timeframe>Tracheal catheter removal before, immediately, after 5, 30 min; postoperative 6,12, 24, 48 h</Timeframe></Measure><Measure><Description>Cough reflex: choking cough strength score</Description><Timeframe>Anesthesia induction period</Timeframe></Measure><Measure><Description>Respiratory depression: respiratory rate</Description><Timeframe>Tracheal catheter removal before, immediately, after 5, 30 min; postoperative 6,12, 24, 48 h</Timeframe></Measure><Measure><Description>Blood glucose: method of glucose oxidase</Description><Timeframe>Before operation, operation start after 30 min, pulling the endotracheal tube after 1 h, postoperative 6, 12, 24 h</Timeframe></Measure><Measure><Description>The plasma cortisol concentration: radioimmunoassay</Description><Timeframe>Before operation, operation start after 30 min, pulling the endotracheal tube after 1 h, postoperative 6, 12, 24 h</Timeframe></Measure><Measure><Description>TNF-alpha: ELISA method</Description><Timeframe>Before operation, operation start after 30 min, pulling the endotracheal tube after 1 h, postoperative 6, 12, 24 h</Timeframe></Measure><Measure><Description>IL-1beta: ELISA method</Description><Timeframe>Before operation, operation start after 30 min, pulling the endotracheal tube after 1 h, postoperative 6, 12, 24 h</Timeframe></Measure><Measure><Description>IL-6: ELISA method</Description><Timeframe>Before operation, operation start after 30 min, pulling the endotracheal tube after 1 h, postoperative 6, 12, 24 h</Timeframe></Measure><Measure><Description>IL-10: ELISA method</Description><Timeframe>Before operation, operation start after 30 min, pulling the endotracheal tube after 1 h, postoperative 6, 12, 24 h</Timeframe></Measure><Measure><Description>OPRM1 A118G gene polymorphism: PCR-RFLP method</Description><Timeframe>Before operation</Timeframe></Measure><Measure><Description>CYP3A4 gene polymorphism: PCR-RFLP method</Description></Measure><Measure><Description>CYP3A5 gene polymorphism: PCR-RFLP method</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this trial is to comprehensively evaluate the influence of the safety, degree of comfort, stress reaction and immunosuppression of the patients during perioperative period and to analyze the correlation between the gene polymorphism and the efficacy of opioid drugs in patients with colon/gastric tumor. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will receive perioperative analgesia with oxycodone or sufentanil.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Shanghai changzheng hosptial</Name><Address2>Shanghai</Address2><CountrySubDivision>Shanghai</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8424">Subjects with Post-Operative Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR-IPR-16007775</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25929"><Endpoint>Assessment of Procedural Analgesia/Anesthesia</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25932">Assessment of sedation level</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26009"><Endpoint>Assessment of Vital Signs</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26014"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26024">Assessment of Inflammatory/Immunological Markers</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26017"><Endpoint>Assessment of Pulmonary Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="37192"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="46656"><Endpoint>Gene variants involved in outcome measures</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="47184">CYP3A5_HUMAN_Mutation</SubEndpoint><SubEndpoint disease="Pain" id="47352">OPRM1_HUMAN_rs1799971(G)</SubEndpoint><SubEndpoint disease="Pain" id="47363">CYP3A4_HUMAN_Mutation</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Pain" id="26032"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22142"><Criterion>Subjects with Peri-operative Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22143">Subjects with post operative pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22172"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Pain" id="22173">Subjects with pre-specified physical status</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22189"><Criterion>Conditions Associated with Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22206">Subjects with malignancy associated pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion><SubCriterion disease="Pain" id="20121">Subjects co-morbid with respiratory disorders/disease</SubCriterion><SubCriterion disease="Pain" id="20123">Subjects with infectious disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20115"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20117"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20132">Subjects with history/scheduled to receive opioids</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20174">Subjects with history/scheduled to receive other drug therapies</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20129">Hypersensitivity/ contraindication to investigational drug/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26044"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Pain" id="20116">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-01-25T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="252446"><TitleDisplay>Renal Denervation for the Treatment of Hypertension: A Pilot, Safety and Efficacy Study</TitleDisplay><TitleOfficial>The Safety and Efficacy of a Renal Denervation System in Treating Patients With Hypertension: A Pilot Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02672462</Identifier><Identifier type="Organisational Study">GL-CT-20150301</Identifier></Identifiers><Indications><Indication id="178">Hypertension</Indication></Indications><BiomarkerNames><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>radiofrequency renal sympathetic denervation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1099502" type="Company"><TargetEntity id="5043440875" type="organizationId">Shanghai Golden Leaf Med Tec Co Ltd</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"/><TargetEntity id="D006973" type="MeSH"/><TargetEntity id="-369992864" type="omicsDisease"/><TargetEntity id="240" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1099502">Shanghai Golden Leaf Med Tec Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2015-12-31T00:00:00Z</DateStart><DateChangeLast>2016-03-18T06:47:34Z</DateChangeLast><DateAdded>2016-03-01T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Name>Gengshan Ma, MD</Name><Phone>(86)13002580569</Phone></Contact><Contact type="Scientific contact"><Affiliation>Cardiovascular division, Dept. of Internal Medicine, Zhongda Hospital</Affiliation><Name>Gengshan Ma, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Ages of 18 to 75, male or female&lt;/li&gt;&lt;li&gt;Main renal artery, with or without accessary renal arteries, with length &gt;/= 20 mm&lt;/li&gt;&lt;li&gt;Patients who have not taken any anti-hypertensive drugs or have been off drugs for &gt;/= 2 weeks, with mean SBP &gt;/= 150 mmHg and&amp;lt;/= 180 mmHg based on &gt;/=  3 office blood pressure measurments, or ASBP &gt;/= 135 mmHg and &amp;lt;/= 170 mmHg based on 24 h blood pressure monitoring&lt;/li&gt;&lt;li&gt;Agrees to take part in the trial and signs the written, informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Renal artery abnormalities that are inappropriate for the procedure&lt;/li&gt;&lt;li&gt;Pregnant or plan to become pregnant&lt;/li&gt;&lt;li&gt;History of orthostatic hypotension&lt;/li&gt;&lt;li&gt;Type I diabetes&lt;/li&gt;&lt;li&gt;Estimated GFR&amp;lt; 40 ml/min/1.73m2&lt;/li&gt;&lt;li&gt;Only one kidney or prior kindney transplantation&lt;/li&gt;&lt;li&gt;Bleeding tendency or other coagulation related diseases&lt;/li&gt;&lt;li&gt;Acute or severe systemic infection&lt;/li&gt;&lt;li&gt;Prior renal artery interventional procedures or prior RDN treatment&lt;/li&gt;&lt;li&gt;History of stroke or TIA&lt;/li&gt;&lt;li&gt;Malignant tumor or end-stage illnesses&lt;/li&gt;&lt;li&gt;Secondary hypertension&lt;/li&gt;&lt;li&gt;Acute coronary events within 2 weeks&lt;/li&gt;&lt;li&gt;Other conditions that deem unsuitable for the procedure, in the opinions of investigators&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Blood pressure</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This single-center, self-controlled, pilot study is to check  safety and efficacy of radiofrequency renal sympathetic denervation in      treatment of hypertension.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will undergo radiofrequency renal sympathetic denervation for treatment of hypertension.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Zhongda Hospital</Name><Address1>Nanjing</Address1><Address2>Jiangsu</Address2><CountrySubDivision>Jiangsu</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Gengshan Ma, MD</Name><Phone>(86)13002580569</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02672462</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hypertension" id="1"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Hypertension" id="261"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hypertension" id="34342"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="154">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hypertension" id="9"><Criterion>Subjects with Secondary Hypertension</Criterion></Exclusion><Exclusion disease="Hypertension" id="36"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="40">Subjects co-morbid with stroke</SubCriterion><SubCriterion disease="Hypertension" id="42">Subjects co-morbid with transient ischemic attack</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="51"><Criterion>Subjects with Hypotension</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="52">Orthostatic hypotension</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="84"><Criterion>Subjects with Current/History of Antihypertensive Treatment</Criterion></Exclusion><Exclusion disease="Hypertension" id="167"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Hypertension" id="183"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Hypertension" id="203"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Hypertension" id="220"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="221">Subjects with bleeding disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="271"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="310">Not suitable to take part in the trial as per the physician/investigator</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="351"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="43">Subjects co-morbid with coronary artery disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="385"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="254">Subjects with history/scheduled to undergo organ transplantation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="25139"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="60">Subjects co-morbid with type 1 diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypertension" id="25724"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="326">Pregnant women</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2016-06-30T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-03-01T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="25783"><TitleDisplay>Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer</TitleDisplay><TitleOfficial>A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum (Per 04/99 Amendment); Old Title: A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum Confined to the Liver</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CDR0000066991</Identifier><Identifier type="NCT">NCT00003834</Identifier><Identifier type="Secondary Organisational">NCCTG-974651</Identifier></Identifiers><Indications><Indication id="3658">Metastatic colorectal cancer</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>fluorouracil</Name></Intervention><Intervention type="InterventionPrimary"><Name>leucovorin</Name></Intervention><Intervention type="InterventionPrimary"><Name>oxaliplatin</Name><Drug id="3792">oxaliplatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3792">oxaliplatin</Drug><IndicationsPioneer/><Companies><Company><Company id="1040381">Cancer and Leukemia Group B</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3792" type="Drug"><TargetEntity id="108094" type="siDrug">Oxaliplatin</TargetEntity></SourceEntity><SourceEntity id="1040381" type="Company"><TargetEntity id="5035559663" type="organizationId">Alliance for Clinical Trials in Oncology Foundation</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="3658" type="ciIndication"><TargetEntity id="10052358" type="MEDDRA"/><TargetEntity id="595" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>21</NumberOfSites><CompaniesSponsor><Company id="1040381">Cancer and Leukemia Group B</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20519">National Cancer Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="50">Anticancer alkylating agent</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>44</PatientCountEnrollment><PatientCountEvaluable>42</PatientCountEvaluable><DateStart>1999-03-31T00:00:00Z</DateStart><DateEnd type="actual">2005-12-31T00:00:00Z</DateEnd><DateChangeLast>2016-11-28T10:35:09Z</DateChangeLast><DateAdded>2008-09-10T12:36:16Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Mayo Clinic</Affiliation><Name>Steven Alberts</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Disease characteristics:&lt;ul&gt;&lt;li&gt;History of carcinoma of the colon or rectum in which the primary site has been completely resected&lt;/li&gt;&lt;li&gt;Measurable or evaluable unresectable liver metastases with one or more of the following: Involvement of all three major hepatic veins, the portal vein bifurcation, or the retrohepatic vena cava&lt;/li&gt;&lt;li&gt;Involvement of the main right or the main left portal vein and the main hepatic vein of the opposite lobe&lt;/li&gt;&lt;li&gt;Disease requiring more than a right or left trisegmentectomy&lt;/li&gt;&lt;li&gt;Six or more metastatic lesions distributed diffusely in both lobes of the liver&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patient characteristics:&lt;ul&gt;&lt;li&gt;Age &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Performance status: ECOG 0 to 2&lt;/li&gt;&lt;li&gt;Life expectancy: not specified&lt;/li&gt;&lt;li&gt;Hematopoietic:&lt;ul&gt;&lt;li&gt;WBC at least 3500/mm(3)&lt;/li&gt;&lt;li&gt;Platelet count at least 100,000/mm(3)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Hepatic:&lt;ul&gt;&lt;li&gt;Bilirubin normal&lt;/li&gt;&lt;li&gt;SGOT no greater than three times upper limit of normal (ULN)&lt;/li&gt;&lt;li&gt;No chronic hepatic disease (eg, chronic active hepatitis, cirrhosis)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Renal: creatinine&amp;lt; 1.5 times ULN&lt;/li&gt;&lt;li&gt;Cardiovascular:&lt;ul&gt;&lt;li&gt;No history of myocardial infarction within the past 6 months&lt;/li&gt;&lt;li&gt;No congestive heart failure&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Other:&lt;ul&gt;&lt;li&gt;No other malignancy within the past five years except basal cell or squamous cell skin cancer or carcinoma in situ of any organ or other tumor associated with &gt; 10% probability of death from malignant disease within five years of diagnosis&lt;/li&gt;&lt;li&gt;Adequate oral nutrition including estimated intake of at least 1500 calories per day&lt;/li&gt;&lt;li&gt;No severe anorexia or frequent nausea and/or vomiting&lt;/li&gt;&lt;li&gt;Able to withstand a major operative procedure&lt;/li&gt;&lt;li&gt;No neuropathy&lt;/li&gt;&lt;li&gt;Not pregnant or nursing&lt;/li&gt;&lt;li&gt;Negative pregnancy test&lt;/li&gt;&lt;li&gt;Fertile patients must use effective contraception&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Prior concurrent therapy:&lt;ul&gt;&lt;li&gt;Biological therapy:&lt;ul&gt;&lt;li&gt;No concurrent immunotherapy&lt;/li&gt;&lt;li&gt;Concurrent filgrastim or epoetin alfa allowed&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Chemotherapy:&lt;ul&gt;&lt;li&gt;At least one year since prior adjuvant systemic fluorouracil with or without levamisole or leucovorin&lt;/li&gt;&lt;li&gt;No prior systemic or hepatic artery infusion chemotherapy for metastatic disease in patients&lt;/li&gt;&lt;li&gt;No other concurrent chemotherapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Endocrine therapy: not specified&lt;/li&gt;&lt;li&gt;Radiotherapy:&lt;ul&gt;&lt;li&gt;No prior radiotherapy to the liver&lt;/li&gt;&lt;li&gt;At least one year since radiotherapy to &gt; 25% of bone marrow&lt;/li&gt;&lt;li&gt;No concurrent radiotherapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Surgery:&lt;ul&gt;&lt;li&gt;At least 21 days since abdominal exploration with or without intestinal resection&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Other:&lt;ul&gt;&lt;li&gt;Oral cryotherapy allowed only on day 2 of each course&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Response rate</Description><Timeframe>Up to four years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Patients were periodically reassessed for resectability</Description></Measure><Measure><Description>Surgical response was classified as completely resectable (S-CR), partially resectable (S-PR), or unresectable (S-UR)</Description></Measure><Measure><Description>Efficacy</Description></Measure><Measure><Description>Toxicity</Description></Measure><Measure><Description>Overall survival</Description><Timeframe>Up to four years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This phase II trial was designed to study the effectiveness of combination chemotherapy in treating patients with liver metastases from colorectal cancer. The drugs used in the study were &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt;, leucovorin and, fluorouracil.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 2005, results were published. Tumor reduction was observed in 60% of patients by serial imaging. Eleven recurrences have occurred in the 15 S-CR and S-PR patients with a median postsurgical follow-up of 22 months. Median survival time was 26 months [&lt;ulink linkType="Reference" linkID="1477870"&gt;1477870&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Objectives of this study were to:  &lt;br/&gt;Evaluate the efficacy of treatment with &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt;, fluorouracil, and leucovorin calcium in terms of the resectability rate in patients with unresectable advanced colorectal carcinoma confined to the liver.&lt;br/&gt;Assess this regimen in terms of response rate, toxicity, and overall survival in these patients.&lt;/para&gt;&lt;para&gt;Patients would receive &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; iv over 2 h on day 1, then leucovorin iv over 2 h with fluorouracil iv bolus, followed by fluorouracil iv over 22 h on days 1 and 2.  Courses repeat every 2 weeks.  Patients with stable disease would continue treatment in the absence of disease progression or unacceptable toxicity or until disease is resectable.  Patients who would achieve complete response (CR), partial response (PR) with unresectable disease, or PR but are not surgical candidates would continue treatment in the absence of disease progression or unacceptable toxicity.&lt;/para&gt;&lt;para&gt;Patients who would demonstrate a response as  treated until best response or until disease is deemed resectable. Patients who would achieve a CR or PR and are resected would receive two to four additional courses of therapy at the discretion of the investigator.Patients would followed every 3 months for one year and then every 6 months for two years.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received fluorouracil, leucovorin, and oxaliplatin [&lt;ulink linkType="Reference" linkID="1477870"&gt;1477870&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Allan Blair Cancer Centre</Name><Address1>Regina</Address1><Address2>Saskatchewan</Address2><Address3>S4T 7T1</Address3><CountrySubDivision>Saskatchewan</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>CCOP - Scottsdale Oncology Program</Name><Address1>Scottsdale</Address1><Address2>Arizona</Address2><Address3>85259-5404</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Carle Cancer Center</Name><Address1>Urbana</Address1><Address2>Illinois</Address2><Address3>61801</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Illinois Oncology Research Association</Name><Address1>Peoria</Address1><Address2>Illinois</Address2><Address3>61602</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Cedar Rapids Oncology Project</Name><Address1>Cedar Rapids</Address1><Address2>Iowa</Address2><Address3>52403-1206</Address3><CountrySubDivision code="IA">Iowa</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Iowa Oncology Research Association</Name><Address1>Des Moines</Address1><Address2>Iowa</Address2><Address3>50309-1016</Address3><CountrySubDivision code="IA">Iowa</CountrySubDivision><Contacts/></Site><Site><Name>Siouxland Hematology-Oncology</Name><Address1>Sioux City</Address1><Address2>Iowa</Address2><Address3>51101-1733</Address3><CountrySubDivision code="IA">Iowa</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Wichita</Name><Address1>Wichita</Address1><Address2>Kansas</Address2><Address3>67214-3882</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Ochsner</Name><Address1>New Orleans</Address1><Address2>Louisiana</Address2><Address3>70121</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Ann Arbor Regional</Name><Address1>Ann Arbor</Address1><Address2>Michigan</Address2><Address3>48106</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Duluth</Name><Address1>Duluth</Address1><Address2>Minnesota</Address2><Address3>55805</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Metro-Minnesota</Name><Address1>Saint Louis Park</Address1><Address2>Minnesota</Address2><Address3>55416</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>CentraCare Clinic</Name><Address1>Saint Cloud</Address1><Address2>Minnesota</Address2><Address3>56303</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>Mayo Clinic Cancer Center</Name><Address1>Rochester</Address1><Address2>Minnesota</Address2><Address3>55905</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Missouri Valley Cancer Consortium</Name><Address1>Omaha</Address1><Address2>Nebraska</Address2><Address3>68131</Address3><CountrySubDivision code="NE">Nebraska</CountrySubDivision><Contacts/></Site><Site><Name>Altru Health Systems</Name><Address1>Grand Forks</Address1><Address2>North Dakota</Address2><Address3>58201</Address3><CountrySubDivision code="ND">North Dakota</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Merit Care Hospital</Name><Address1>Fargo</Address1><Address2>North Dakota</Address2><Address3>58122</Address3><CountrySubDivision code="ND">North Dakota</CountrySubDivision><Contacts/></Site><Site><Name>Medcenter One Health System</Name><Address1>Bismarck</Address1><Address2>North Dakota</Address2><Address3>58501</Address3><CountrySubDivision code="ND">North Dakota</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Toledo Community Hospital Oncology Program</Name><Address1>Toledo</Address1><Address2>Ohio</Address2><Address3>43623-3456</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Geisinger Clinic and Medical Center</Name><Address1>Danville</Address1><Address2>Pennsylvania</Address2><Address3>17822-2001</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Sioux Community Cancer Consortium</Name><Address1>Sioux Falls</Address1><Address2>South Dakota</Address2><Address3>57105-1080</Address3><CountrySubDivision code="SD">South Dakota</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Colorectal tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3813">Subjects with Rectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3814">Subjects with Colon Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3824">Subjects with TNM  stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00003834</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Colorectal tumor" id="8440"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8447">Assessment of tumor resectability</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Colorectal tumor" id="8205"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8207">Assessment of time to recurrence</SubEndpoint><SubEndpoint disease="Colorectal tumor" id="8209">Assessment of sites of recurrence</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="8219"><Endpoint>Assessment of Metastasis</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8222">Assessment of hepatic metastasis</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="8429"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8430">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="8449"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8462">Change in burden of illness and treatment over time</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="9370"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8187">Assessment of Objective/Overall Response Rate (ORR)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Colorectal tumor" id="8151"><Endpoint>Assessment of Overall Survival (OS)</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8160">Assessment of median overall survival</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="8182"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8183">Assessment of time to disease progression (TTP)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="8205"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="8211"><Endpoint>Assessment of Tumor Related Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8216">Assessment of shrinkage of tumor</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="8409"><Endpoint>Assessment of Mortality/Morbidity</Endpoint></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="8440"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8453">Efficacy/feasibility Assessment</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="8449"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8477">Clinical outcomes</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="9370"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="9368">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Colorectal tumor" id="9369">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Colorectal tumor" id="9376">Assessment of Stable Disease</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Colorectal tumor" id="4467"><Criterion>Subjects with Rectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4468"><Criterion>Subjects with Colon Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4483"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4518"><Criterion>Subjects with Unresectable Colorectal  Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4526"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4527">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Colorectal tumor" id="4528">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Colorectal tumor" id="4529">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="4544"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4545">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Colorectal tumor" id="4549">Subjects with history of/ scheduled for surgery</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="32554"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4564">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Colorectal tumor" id="4569">Subjects with normal/acceptable hematopoetic/marrow function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="33970"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4565">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Colorectal tumor" id="5841"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5848"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5864"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5879"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5886">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5928"><Criterion>Subjects with History of/Scheduled to Receive Colorectal Cancer Therapy</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5945"><Criterion>Subjects with history of/scheduled to receive biological therapy</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5949"><Criterion>Subjects with history of/scheduled to receive radiation therapy</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2005-12-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-09-10T12:36:16Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2013-09-17T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="258278"><TitleDisplay>Relationship Between Diabetes and Cognitive Impairment Based on Olfactory Function Assessment and Functional MRI</TitleDisplay><TitleOfficial>The Cross-sectional and Longitudinal Study of Relationship Between Diabetes and Cognitive Impairment by Olfactory Function Assessment and Functional MRI in Obese and Normal Weight Diabetic Patients</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02738671</Identifier><Identifier type="Organisational Study">ZZ2016</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication><Indication id="353">Cognitive disorder</Indication><Indication id="836">Insulin dependent diabetes</Indication><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bariatric surgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cognitive assessment</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>functional magnetic resonance imaging</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>olfactory function measurement</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1057007" type="Company"><TargetEntity id="5035551100" type="organizationId">Nanjing Drum Tower Hospital</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"/><TargetEntity id="10029883" type="MEDDRA"/><TargetEntity id="D009765" type="MeSH"/><TargetEntity id="-1640888899" type="omicsDisease"/><TargetEntity id="985" type="siCondition"/></SourceEntity><SourceEntity id="353" type="ciIndication"><TargetEntity id="10057668" type="MEDDRA"/><TargetEntity id="D019965" type="MeSH"/><TargetEntity id="-1363718134" type="omicsDisease"/><TargetEntity id="98" type="siCondition"/></SourceEntity><SourceEntity id="836" type="ciIndication"><TargetEntity id="E10" type="ICD10"/><TargetEntity id="10067584" type="MEDDRA"/><TargetEntity id="D003922" type="MeSH"/><TargetEntity id="-686743471" type="omicsDisease"/><TargetEntity id="507" type="siCondition"/></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"/><TargetEntity id="10067585" type="MEDDRA"/><TargetEntity id="D003924" type="MeSH"/><TargetEntity id="-1888632793" type="omicsDisease"/><TargetEntity id="509" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1057007">Nanjing Drum Tower Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Cross-sectional</Term><Term>Cohort</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>150</PatientCountEnrollment><DateStart>2016-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2018-05-31T00:00:00Z</DateEnd><DateChangeLast>2017-03-30T17:18:03Z</DateChangeLast><DateAdded>2016-04-20T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>zhudldr@gmail.com</Email><Name>Da long Zhu, MD, PhD</Name><Phone>86-25-83-105302</Phone></Contact><Contact type="Public contact"><Email>biyan@nju.edu.cn</Email><Name>Yan Bi, MD, PhD</Name><Phone>86-25-83-105302</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Have a certain level of education (at least six years), able to complete the cognitive assessment&lt;/li&gt;&lt;li&gt;Disease duration greater than  one year&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Control participants would be excluded if they had a fasting blood glucose level＞7.0 mmol/l; glucose level＞7.8 mmol/l after oral glucose tolerance test (OGTT)&lt;/li&gt;&lt;li&gt;Montreal Cognitive Assessment (MoCA,Beijing edition) score of ＜ 20&lt;/li&gt;&lt;li&gt;History of neurological or psychological illness&lt;/li&gt;&lt;li&gt;History of cardiovascular or cerebrovascular disease&lt;/li&gt;&lt;li&gt;Abnormal results of thyroid hormones, vitamin B12, and folate&lt;/li&gt;&lt;li&gt;Metal implants, unable to complete the MR examinations or evidence of cortical infarcts, hemorrhage, or structural brain disease other than atrophy, lacunes, or white matter lesions&lt;/li&gt;&lt;li&gt;Left-handed&lt;/li&gt;&lt;li&gt;Partial or complete olfactory dysfunction associated with sinusitis,allergic rhinitis, and deviated nasal septum&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Participants' personal information: self-reported information (education in years)</Description><Timeframe>1 day</Timeframe></Measure><Measure><Description>Glycemic control measured by blood test: HbA1c</Description><Timeframe>1 day</Timeframe></Measure><Measure><Description>Physical assessments: BMI (body mess index) in kg/m2</Description><Timeframe>1 day</Timeframe></Measure><Measure><Description>Olfactory threshold test: olfactory threshold test: the same odor with 2 different concentrations are given to the participant each time to find out which one is more intense. (Olfactory software will analyse and give threshold score depending on participant's choice.)</Description><Timeframe>1 day</Timeframe></Measure><Measure><Description>Olfactory memory test: part A: participants are shown four pictures for each odor (10 odors in total). They select what they sniffed. 10 min break. Part B: participants sniff 20 different odors , 10 of which are same odors in part A. They select the picture and figure out whether the odor is old or new</Description><Timeframe>1 day</Timeframe></Measure><Measure><Description>Montreal Cognitive Assessment (MoCA): the MoCA is a cognitive screening test designed to assist health professionals in detection of mild cognitive impairment</Description><Timeframe>1 day</Timeframe></Measure><Measure><Description>Functional MRI of the brain tracking testing</Description><Timeframe>1 day</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change form baseline glycemic control measured by blood test: HbA1c</Description><Timeframe>6 months after the bariatric surgery (for diabetic and non-diabetic obese patients)</Timeframe></Measure><Measure><Description>Change from baseline functional magnetic resonance imagine</Description><Timeframe>6 months after the bariatric surgery (for diabetic and non-diabetic obese patients)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to explore the relationship between diabetes and cognitive      impairment by olfactory function assessment and functional MRI.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In the cross-sectional study, biometric measurements, cognitive      assessment, olfactory function and fMRI results will be analyzed to explore the differences      among T1DM patients, T2DM patients and non-diabetic people. One the other hand, in the      longitudinal study, changes in olfactory function and fMRI results in diabetic and      non-diabetic obese patients both at baseline and 6 months after their bariatric surgery will be      collected to investigate whether better glucose and weight control benefit brain function.&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University</Name><Address1>Nanjing</Address1><Address2>Jiangsu</Address2><Address3>210008</Address3><CountrySubDivision>Jiangsu</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>zhudldr@gmail.com</Email><Name>Dalong Zhu, MD,PhD</Name><Phone>86-25-83-105302</Phone></Contact><Contact type="Facility contact backup"><Email>biyan@nju.edu.cn</Email><Name>Yan Bi, MD,PhD</Name><Phone>86-25-83-105302</Phone></Contact><Contact type="Facility investigator"><Name>Dalong Zhu, MD,PhD</Name></Contact><Contact type="Facility investigator"><Name>Yan Bi, MD,PhD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="7603">Subjects with Specified Duration of Disease</PatientSegment><SubSegments><SubSegment id="7605">Subjects with more than 1 year of diabetes mellitus</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7647">Others</PatientSegment><SubSegments><SubSegment id="7648">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02738671</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1358"><Endpoint>Assessment of Hemoglobin A1c (HbA1c) Levels</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="6727"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1502">Assessment of BMI</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="18111"><Endpoint>Assessment of HbA1c Levels</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other neurological disease" id="43051"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other neurological disease" id="43056"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other neurological disease" id="43215"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other neurological disease" id="43216">Assessment by Magnetic Resonance Imaging (MRI)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="44714"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18222">Assessment of BMI</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="45401"><Endpoint>Imaging/Radiological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="45406"><Endpoint>Imaging/Radiological Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1358"><Endpoint>Assessment of Hemoglobin A1c (HbA1c) Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18111"><Endpoint>Assessment of HbA1c Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="43051"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="43215"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other neurological disease" id="43216">Assessment by Magnetic Resonance Imaging (MRI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="45401"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="45406"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="16308"><Criterion>Subjects with Specified Duration with Type 1 Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16310">Subjects with more than 1 year of diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other neurological disease" id="33283"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="32746">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="34682"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16357">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="34698"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="692">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="34875"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16373">Subjects completing a specified study</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="34922"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="718">Subjects completing a specified study</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="35101"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16827">Subjects with Type 1 Diabetes Mellitus</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="831"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="891"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="916"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="928"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="945">Subjects with central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5070"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5078"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="5083">Subjects with increased blood glucose level/FBS not meeting the study requirement</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13773"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13785"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13817"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13825"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13835"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13837">Subjects with central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13850"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13860">Subjects with increased blood glucose level/FBS not meeting the study requirement</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="24386"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24389"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="26572"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24396">Subjects co-morbid with heart failure</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-05-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-02-25T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-04-20T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="261639"><TitleDisplay>Acthar SLE (Systemic Lupus Erythematosus)</TitleDisplay><TitleOfficial>Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematological Manifestations of Systemic Lupus Erythematosus</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02779153</Identifier><Identifier type="Organisational Study">15-00295</Identifier><Identifier type="Trial Acronym">Acthar SLE</Identifier></Identifiers><Indications><Indication id="318">Systemic lupus erythematosus</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>corticotropin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1085756" type="Company"><TargetEntity id="5038068684" type="organizationId">Mallinckrodt Plc</TargetEntity></SourceEntity><SourceEntity id="1086665" type="Company"><TargetEntity id="5016952605" type="organizationId">NYU School of Medicine</TargetEntity></SourceEntity><SourceEntity id="318" type="ciIndication"><TargetEntity id="M32" type="ICD10"/><TargetEntity id="10042945" type="MEDDRA"/><TargetEntity id="D008180" type="MeSH"/><TargetEntity id="-1461472531" type="omicsDisease"/><TargetEntity id="731" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1086665">New York University School of Medicine, US</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1085756">Mallinckrodt plc</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>25</PatientCountEnrollment><DateStart>2016-10-31T00:00:00Z</DateStart><DateEnd type="estimated">2019-03-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T15:29:35Z</DateChangeLast><DateAdded>2016-06-04T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>hmb307@nyumc.org</Email><Name>Hannah Bernstein</Name></Contact><Contact type="Scientific contact"><Affiliation>New York University Medical School</Affiliation><Name>Amit Saxena, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Able to provide informed consent&lt;/li&gt;&lt;li&gt;Diagnosis of SLE according to the American college of rheumatology revised criteria (fulfilled  &gt;/= 4 criteria)&lt;/li&gt;&lt;li&gt;Hematologic BILAG scores due to hemolytic anemia or thrombocytopenia of BILAG A (including hemolytic anemia with hemoglobin&amp;lt; 8.0 g/dl or platelet count &amp;lt; 25 x 10[9] l) or BILAG B (including hemolytic anemia with hemoglobin 8.0 to 9.9 g/dDl or platelet count 25 to 49 x 10[9] l) based on screening laboratory assessment&lt;/li&gt;&lt;li&gt;Currently taking prednisone &gt;/= 7.5 mg or equivalent for hematological SLE for at least 2 weeks prior to screening&lt;/li&gt;&lt;li&gt;Use of antimalarials and NSAIDs (stable regimen within the 4 weeks prior to screening), as well as methotrexate, azathioprine, and mycophenolate mofetil (stable regimen within the 4 weeks prior to screening) are permitted but not required. If used, the regimen must remain stable through the study. An increase or addition of SLE medication at any time during the study is not permitted&lt;/li&gt;&lt;li&gt;Ability to comply with study procedures, which include sc injections of study medication, adhering to concomitant medication restrictions, and attending scheduled office visits&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with a recent history (&amp;lt; 2 week prior to screening) of starting prednisone or equivalent&lt;/li&gt;&lt;li&gt;Patients with active nephritis, defined as serum creatinine&amp;gt; 2.5 mg/dl or protein/creatinine ratio (PCR) &amp;gt; 1.5 g/g, or patients that required hemodialysis within 3 months prior to screening&lt;/li&gt;&lt;li&gt;Active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, cerebrovascular accident, cerebritis, or CNS vasculitis), requiring therapeutic intervention within 3 months prior to screening&lt;/li&gt;&lt;li&gt;Type 1 or 2 diabetes mellitus (history of gestational diabetes is not an exclusion), or patients currently taking hypoglycemic medication&lt;/li&gt;&lt;li&gt;Patients with a history of concomitant medication use as follows:&lt;ul&gt;&lt;li&gt;Receipt of the following within 1 month prior to screening&lt;ul&gt;&lt;li&gt;Any steroid injection (intramuscular, intraarticular, or intravenous)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Receipt of any of the following within 3 months prior to screening&lt;ul&gt;&lt;li&gt;Cyclosporine&lt;/li&gt;&lt;li&gt;Any non-biological investigational drug&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Receipt of the following within 4 months prior to screening&lt;ul&gt;&lt;li&gt;IVIg&lt;/li&gt;&lt;li&gt;Plasmapheresis&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Receipt of cyclophosphamide within 6 months prior to screening&lt;/li&gt;&lt;li&gt;Receipt of the following within 12 months prior to screening&lt;ul&gt;&lt;li&gt;B cell targeted therapy (rituximab or other anti-CD20 agent, anti-CD22 [epratuzumab], anti-CD52 [alentuzumab], or belimumab)&lt;/li&gt;&lt;li&gt;Abatacept&lt;/li&gt;&lt;li&gt;Any biological investigational agent&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Contraindication per Acthar prescribing information: scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, or adrenal cortical hyperfunction&lt;ul&gt;&lt;li&gt;For the purposes of this study, osteoporosis is defined as evidence of vertebral or long bone fracture, or lumbar spine T-score&amp;gt; 2.0 standard deviations below the mean of the reference population&lt;/li&gt;&lt;li&gt;For the purposes of this study, history of peptic ulcer is defined as&amp;lt;/= 6 months prior to screening&lt;/li&gt;&lt;li&gt;For the purposes of this study, congestive heart failure is defined as New York Heart association functional class III to IV&lt;/li&gt;&lt;li&gt;For the purposes of this study, uncontrolled hypertension is defined as a mean systolic blood pressure &gt;/= 140 mmHg and/or diastolic blood pressure &gt;/= 90 mmHg on &gt;/= 3 seated readings taken at least 5 min apart during the screening period&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Reproductive status&lt;ul&gt;&lt;li&gt;Women who are pregnant&lt;/li&gt;&lt;li&gt;Women who are breastfeeding&lt;/li&gt;&lt;li&gt;Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period, as evaluated by the investigator (women of non-childbearing potential are those that have a history of hysterectomy, bilateral oophorectomy, or are postmenopausal with no history of menstrual flow for &gt;/= 12 months prior to screening)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Immune system: known immunocompromised status (not related to SLE or therapies for SLE), including individuals who have undergone organ transplantation or who are known to be positive for the human immunodeficiency virus&lt;/li&gt;&lt;li&gt;Patients with acute or chronic hepatitis C, or active hepatitis B infection, positive interferon gamma release assay (IGRA) or signs or symptoms concerning for active tuberculosis (TB); or use of antibiotics (antibacterial, antiviral, antifungal, or antiparasitic agent) within 4 weeks of randomization for treatment of an active infection&lt;/li&gt;&lt;li&gt;Presence of any other clinically significant disease or disorder which, in the opinion of the investigator (by its nature or by being inadequately controlled), might put the patient at risk due to participation in the study, or may influence the results of the study or the patient's ability to complete the study&lt;/li&gt;&lt;li&gt;Any clinically significant laboratory abnormality, based on the investigator's judgment. The following laboratory exclusions apply for all patients&lt;ul&gt;&lt;li&gt;AST&amp;gt; 2.5 x the upper limit of normal (ULN)&lt;/li&gt;&lt;li&gt;ALT&amp;gt; 2.5 x ULN&lt;/li&gt;&lt;li&gt;Hemoglobin A1c&amp;gt; 6.5%&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score: disease activity is based on 24 questions, weighted across nine organ systems, combined into a total score that can range from 0 to 105, but are generally &lt; 20, even with very active disease</Description><Timeframe>Baseline to week 24</Timeframe></Measure><Measure><Description>British Isles Lupus Assessment Group (BILAG) disease activity index score: items are rated as 0 (not present), 1 (improving), 2 (same), 3 (worse), or 4 (new) in the last 4 weeks compared with the previous 4 weeks. The numerical scores are used to categorize each organ system by an alphabetical score: 'A' reflecting severe disease requiring increases in prednisone to &gt; 20 mg daily and/or addition of immunosuppressive agents, 'B' indicated less active disease, requiring low-dose prednisone and/or symptomatic treatment with NSAIDs and/or antimalarials, 'C' reflecting mild disease requiring only symptomatic therapy, 'D' reflecting previous organ system involvement without current disease activity, and 'E' reflecting no prior or no current disease involvement in that organ system</Description><Timeframe>Baseline to week 24</Timeframe></Measure><Measure><Description>Physician's Global Assessment score: the Physician's Global Assessment is a 10 cm visual analogue scale (VAS) anchored at 0 (none) and 3 (severe) with intermediate lines at 1 (mild) and 2 (moderate). It is designed for the physician to indicate the patient's overall disease activity at a particular visit</Description><Timeframe>Baseline to week 24</Timeframe></Measure><Measure><Description>SELENA Flare Index score: the SELENA Flare Index categorizes SLE flare as 'mild or moderate' or 'severe' based on six variables : change in SLEDAI score from the most recent assessment to current, change in signs or symptoms of disease activity, change in prednisone dosage, use of new medication for disease activity or hospitalization, change in PGA score, hospitalization for SLE activity (severe flare only)</Description><Timeframe>Baseline to week 24</Timeframe></Measure><Measure><Description>SLICC/ACR Damage Index: the SLICC/ACR Damage Index measures irreversible organ damage from either the disease process or treatment, which has been present for &gt;/= 6 months, in 12 organ systems. It is an important predictor of long-term mortality and is an independent outcome measure separate from the SLEDAI</Description><Timeframe>Baseline to week 24</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>FACIT Fatigue scale: the FACIT-F scale is a 13-item questionnaire to evaluate self-reported fatigue and its impact upon daily activities and function. The responses are measured on a 4-point Likert scale, with the total score ranging from 0 to 52. The FACIT-F scale has been validated in SLE patients</Description><Timeframe>Baseline to week 24</Timeframe></Measure><Measure><Description>Medical Outcomes Survey Short Form-36: the SF-36 has been validated in SLE and includes eight domains: physical functioning, role physical, bodily pain, general health perceptions, vitality (which includes fatigue, energy and vigor), social functioning, role emotional and mental-health impact, combined into two summary scores (physical component summary scores [PCS] and mental component summary scores [MCS])</Description><Timeframe>Baseline to week 24</Timeframe></Measure><Measure><Description>Patient's Global Assessment: subjects rate their global assessment of SLE disease activity on each visit, in response to the question 'considering all the ways your SLE affects you, please mark a vertical line on the scale below for how are you feeling today?' using a 100mm visual analogue scale, where 0 is 'very good, no symptoms' and 100 is 'very poor, very severe symptoms'</Description><Timeframe>Baseline to week 24</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this randomized study is to  explore the efficacy, safety and steroid sparing ability of two      doses (40 and 80 U) of &lt;ulink linkType="Drug" linkID="84484"&gt;Acthar&lt;/ulink&gt; in SLE patients with immune-mediated hematological      manifestations requiring steroid use for a minimum of 2 weeks prior to screening.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study will consists of two arms:&lt;br/&gt;Arm 1: patients will receive 0.5 ml low dose (40 U) of Acthar qd. Patients will taper Acthar during week 2 through the remainder of the study and will administer 0.5 ml of Acthar biw. The stable Acthar regimen should be maintained for the remainder of the study.&lt;br/&gt;Arm 2: patients will receive 1.0 ml high dose (80 U) of Acthar every day. If a patient meets dose reduction criteria, their assigned volume will be adjusted from 1.0 ml to 0.5 ml. Patients will taper Acthar during week 2 through the remainder of the study.&lt;/para&gt;&lt;para&gt;However, dose adjustments will be implemented if needed based on safety.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>New York University School of Medicine</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10016</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>hmb307@nyumc.org</Email><Name>Hannah Bernstein</Name></Contact><Contact type="Facility investigator"><Name>Amit Saxena, MS</Name></Contact><Contact type="Facility investigator"><Name>Janine Sullivan, MD</Name></Contact><Contact type="Facility investigator"><Name>Jill Buyon, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Systemic lupus erythematosus</Disease><PatientSegments><PatientSegment><PatientSegment id="7560">Subjects with SLE According to American College of Rheumatology (ACR) Criteria</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7572">Subjects with History of Medication for SLE</PatientSegment><SubSegments><SubSegment id="7573">Subjects on NSAIDs</SubSegment><SubSegment id="7574">Subjects on immunosuppressive agents</SubSegment><SubSegment id="7577">Subjects on stable medication</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02779153</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Systemic lupus erythematosus" id="14526"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Systemic lupus erythematosus" id="14527">Assessment by systemic lupus erythematosus disease activity index (SLEDAI)</SubEndpoint><SubEndpoint disease="Systemic lupus erythematosus" id="14528">Assessment by British isles lupus assessment group (BILAG)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Systemic lupus erythematosus" id="14533"><Endpoint>Physician Global Assessment of Disease Activity</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Systemic lupus erythematosus" id="14534"><Endpoint>Assessment by Global Assessment Scales</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Systemic lupus erythematosus" id="14535"><Endpoint>Assessment of Flare(s)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Systemic lupus erythematosus" id="14539"><Endpoint>Assessment of Disease Damage</Endpoint><SubEndpoints><SubEndpoint disease="Systemic lupus erythematosus" id="14540">Assessment by SLICC/ACR damage Index</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Systemic lupus erythematosus" id="14627"><Endpoint>Assessment of hospitalization</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Systemic lupus erythematosus" id="44900"><Endpoint>Assessment of Clinical Symptoms</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Systemic lupus erythematosus" id="14534"><Endpoint>Assessment by Global Assessment Scales</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Systemic lupus erythematosus" id="14567"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Systemic lupus erythematosus" id="14569">Assessment by SF-36/SF-12</SubEndpoint><SubEndpoint disease="Systemic lupus erythematosus" id="14570">Assessment by functional assessment of chronic illness therapy (FACIT)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Systemic lupus erythematosus" id="13787"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="13788">Subjects with history of/scheduled to receive NSAIDs</SubCriterion><SubCriterion disease="Systemic lupus erythematosus" id="13789">Subjects with history of immunosuppressive therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Systemic lupus erythematosus" id="13793"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Systemic lupus erythematosus" id="13796"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="13792">Subjects receiving/scheduled to receive stable medication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Systemic lupus erythematosus" id="14965"><Criterion>Subjects with SLE According to American College of Rheumatology (ACR) Criteria</Criterion></Inclusion><Inclusion disease="Systemic lupus erythematosus" id="34813"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="15396">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Systemic lupus erythematosus" id="12621"><Criterion>Subjects with CNS Manifesation of Systemic Lupus Erythematosus (SLE)</Criterion></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12632"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="12640">Subjects co-morbid with metabolic diseases/disorders</SubCriterion><SubCriterion disease="Systemic lupus erythematosus" id="12642">Subjects with infectious disorder</SubCriterion><SubCriterion disease="Systemic lupus erythematosus" id="12643">Subjects with inflammatory joint disorders</SubCriterion><SubCriterion disease="Systemic lupus erythematosus" id="12645">Subjects with other auto-immune disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12633"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12634"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12639"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12648"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="12649">Subjects with abnormal cardiac function tests</SubCriterion><SubCriterion disease="Systemic lupus erythematosus" id="12651">Abnormal liver function test</SubCriterion><SubCriterion disease="Systemic lupus erythematosus" id="12652">Subjects with abnormal renal function tests</SubCriterion><SubCriterion disease="Systemic lupus erythematosus" id="12653">Subjects with abnormal hematologic values</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12658"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="12660">Subjects with history of/Scheduled for treatment with biologics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12668"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="13308">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="26071"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="12636">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-05-18T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-06-04T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-12-20T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="280291"><TitleDisplay>A study of tolerability, reactogenicity and safety of live allantoic influenza vaccines in volunteers aged 18 to 60 years</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">LIV-R-I-00-004/2016</Identifier></Identifiers><Indications><Indication id="191">Influenza virus infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>live allantoic influenza vaccine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1041266" type="Company"><TargetEntity id="5035525879" type="organizationId">NPO Mikrogen Minzdrava RF FGUP</TargetEntity></SourceEntity><SourceEntity id="191" type="ciIndication"><TargetEntity id="J09" type="ICD10"/><TargetEntity id="10022000" type="MEDDRA"/><TargetEntity id="D007251" type="MeSH"/><TargetEntity id="948" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1041266">Microgen State Scientific Industrial Company</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2017-03-01T00:00:00Z</DateStart><DateEnd type="estimated">2017-12-31T00:00:00Z</DateEnd><DateChangeLast>2016-11-28T16:00:13Z</DateChangeLast><DateAdded>2016-11-28T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Volunteers aged 18 to 60 years&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety and tolerability</Description></Measure><Measure><Description>Reactogenicity</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;A  study was conducted to evaluate the tolerability, reactogenicity and safety of live allantoic  influenza vaccines in healthy volunteers.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive a solution for intranasal administration of 0.5 ml/dose.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Russian Federation"><Sites><Site><Name>Federal State Institution "Research Institute of Influenza," the Ministry of Health and Social Development of the Russian Federation</Name><Address1>St. Petersburg</Address1><Address3>197376</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Influenza Vaccine</Disease><PatientSegments><PatientSegment><PatientSegment id="15283">Others</PatientSegment><SubSegments><SubSegment id="9842">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1030">Russian State Register of Medicines Clinical Trials Registry</Name><Identifiers><Identifier/></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><SecondaryEndpoints><SecondaryEndpoint disease="Influenza Vaccine" id="17037"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Influenza Vaccine" id="17038">Adverse events/reactogenicity</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Influenza Vaccine" id="34733"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Influenza Vaccine" id="16081">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-11-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="29276"><TitleDisplay>The Impact of Velcade on Antibody Secreting Cells in Sensitized Renal Allograft Candidates</TitleDisplay><TitleOfficial>The Impact of Velcade on Antibody Secreting Cells in Sensitized Renal Allograft Candidates</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">08-000556</Identifier><Identifier type="NCT">NCT00722722</Identifier></Identifiers><Indications><Indication id="2989">Kidney transplant rejection</Indication></Indications><BiomarkerNames><BiomarkerName id="3070" role="Therapeutic effect marker" type="Proteomic">Anti-HLA antibodies</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bortezomib</Name><Drug id="15954">bortezomib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="15954">bortezomib</Drug><IndicationsPioneer><Indication id="2989">Kidney transplant rejection</Indication></IndicationsPioneer><Companies><Company><Company id="21111">Mayo Clinic Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21991">Takeda Oncology</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="15954" type="Drug"><TargetEntity id="260757" type="siDrug">Bortezomib</TargetEntity></SourceEntity><SourceEntity id="21111" type="Company"><TargetEntity id="5035523907" type="organizationId">Mayo Foundation</TargetEntity></SourceEntity><SourceEntity id="21991" type="Company"><TargetEntity id="4295907189" type="organizationId">Millennium Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="2989" type="ciIndication"><TargetEntity id="T86.11" type="ICD10"/><TargetEntity id="10023439" type="MEDDRA"/><TargetEntity id="1136" type="siCondition"/></SourceEntity><SourceEntity id="4917" type="Action"><TargetEntity id="1125" type="Mechanism">Proteasome Inhibitors</TargetEntity><TargetEntity id="3073" type="Mechanism">Immunoproteasome Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21111">Mayo Clinic Foundation</Company></CompaniesSponsor><CompaniesCollaborator><Company id="21991">Takeda Oncology</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4917">Proteasome inhibitor</Action><Action id="76469">26S proteasome complex inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class></Class><Technologies><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>18</PatientCountEnrollment><PatientCountEvaluable>10</PatientCountEvaluable><DateStart>2008-06-30T00:00:00Z</DateStart><DateEnd type="actual">2014-04-30T00:00:00Z</DateEnd><DateChangeLast>2018-11-22T11:09:10Z</DateChangeLast><DateAdded>2008-10-27T07:06:02Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Mayo Clinic</Affiliation><Name>Mark D. Stegall</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care&lt;/li&gt;&lt;li&gt;Female subject is post-menopausal, surgically sterilized, or she and/or sexual partner are willing to use an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study&lt;/li&gt;&lt;li&gt;Male subject agrees to use an acceptable method for contraception for the duration of the study&lt;/li&gt;&lt;li&gt;Renal transplant candidates who otherwise meet our acceptance criteria&lt;/li&gt;&lt;li&gt;Evidence of alloantibody in their serum (panel reactive antibody &gt; 20% and specificities determined by single antigen flow bead assay)&lt;/li&gt;&lt;li&gt;Sensitized patients with no living donors or have donor-specific antibody levels too high to undergo successful transplantation using our current protocols (T or B cell crossmatch channel shift &gt; 500)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patient has a platelet count of&amp;lt; 30 x 10(9)/l within 14 days before enrollment.&lt;/li&gt;&lt;li&gt;Patient has an absolute neutrophil count of (ANC)&amp;lt; 1.0 x 10(9)/l within 14 days before enrollment. &lt;/li&gt;&lt;li&gt;Patient has &gt; grade 2 peripheral neuropathy within 14 days before enrollment.&lt;/li&gt;&lt;li&gt;Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any electrocardiogram (ECG) abnormality at screening has to be documented by the investigator as not medically relevant&lt;/li&gt;&lt;li&gt;Patient has hypersensitivity to&lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt;, boron or mannitol&lt;/li&gt;&lt;li&gt;Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women&lt;/li&gt;&lt;li&gt;Patient has received other investigational drugs within14 days before enrollment&lt;/li&gt;&lt;li&gt;Serious medical or psychiatric illness likely to interfere with participation in this clinical study&lt;/li&gt;&lt;li&gt;Diagnosed or treated for malignancy within five years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy&lt;/li&gt;&lt;li&gt;Contraindication to kidney transplantation:&lt;ul&gt;&lt;li&gt;Active infection&lt;/li&gt;&lt;li&gt;Comorbid medical conditions, etc&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Response to bortezomib monotherapy: response to treatment with bortezomib alone was defined as a reduction in serum donor specific alloantibody (DSA) levels following treatment. DSA levels were measured prior to treatment and after treatment. A good response occurred if all DSA were reduced. A partial response when a reduction was observed in at least one DSA, but not all DSA. No response occurred when no reduction of any DSA was attained</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In June 2017, results were published. Due to adverse events, 2 patients completely discontinued therapy [&lt;ulink linkType="Reference" linkID="1962041"&gt;1962041&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The  purpose of this study was to determine if the drug &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; (Velcade) can reduce donor specific alloantibodies to a      level that permits kidney transplantation without a high risk for rejection. The study was designed to assess the impact of in vivo treatment of &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; on anti-human leukocyte antigen (HLA)      production by normal antibody secreting cells (ASC) in sensitized renal allograft candidates.&lt;/para&gt;&lt;para&gt;The aim of this study was to determine the safety and efficacy of 32 doses of bortezomib [&lt;ulink linkType="Reference" linkID="1962041"&gt;1962041&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2017, results were published. In a total of 2 patients, dose reduction was needed. Prior to bortezomib, anti-HLA antibodies mean fluorescence intensity (MFI) values were stable (p = 0.96) but after therapy, they decreased (mean decrease of 1916 MFI, p &amp;lt; 0.01). Against their original intended donor, no patient developed a negative crossmatch, and in all patients the calculated panel-reactive antibodies based on MFI of 2000, 4000, and 8000 was unchanged [&lt;ulink linkType="Reference" linkID="1962041"&gt;1962041&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The design would involve  treatment of patients with &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; using one of three dosing regimens (4 [1.3 mg/m2 of body surface area], 16 [1.3 mg/m2 of body surface area] or 32 [1.3 mg/m2 of body surface area] doses of bortezomib) that would be given   in four-dose cycles intravenously (through a vein).  The design would involve treatment of patients with bortezomib using one of three dosing regimens (4, 16  or 32 doses of bortezomib). Using novel assays, anti-HLA production would be  determined by measuring the bone marrow derived ASC at baseline (prior to therapy) and after treatment (at day 14, 3 days after the last bortezomib dose).  Paired data would be used with patients serving as their own controls.  Finally, the      safety of &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; would be evaluated by monitoring total serum antibody levels and the incidence      of side effects (primarily neuropathy) at 1 month, the final follow-up point.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received 32 doses of bortezomib (1.3 mg/m of body surface area) [&lt;ulink linkType="Reference" linkID="1962041"&gt;1962041&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Mayo Clinic</Name><Address1>Rochester</Address1><Address2>Minnesota</Address2><Address3>55905</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Kidney transplantation</Disease><PatientSegments><PatientSegment><PatientSegment id="599">Subjects Awaiting Renal Transplant</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00722722</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Kidney transplantation" id="5170"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Kidney transplantation" id="5172">Anti-HLA antibodies (Class I and Class II)</SubEndpoint><SubEndpoint disease="Kidney transplantation" id="5175">Donor specific antibodies</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Kidney transplantation" id="2242"><Criterion>Subjects Awaiting Renal Transplantation</Criterion></Inclusion><Inclusion disease="Kidney transplantation" id="2335"><Criterion>Subjects at Immunological Risk</Criterion><SubCriteria><SubCriterion disease="Kidney transplantation" id="2338">Moderate immunological risk subjects</SubCriterion><SubCriterion disease="Kidney transplantation" id="2339">Positive donor specific antibodies (DSA) (HLA class I and class II antibodies)</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Kidney transplantation" id="3384"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Kidney transplantation" id="3412"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Kidney transplantation" id="3419">Neutropenia</SubCriterion><SubCriterion disease="Kidney transplantation" id="3420">Subjects co-morbid with thrombocytopenia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Kidney transplantation" id="3433"><Criterion>Subjects with history of cardiovascular disease/disorder</Criterion><SubCriteria><SubCriterion disease="Kidney transplantation" id="3437">Cardiac arrhythmias</SubCriterion><SubCriterion disease="Kidney transplantation" id="3438">Cardiac insufficiency/failure</SubCriterion><SubCriterion disease="Kidney transplantation" id="3443">Subjects with history of myocardial infarction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Kidney transplantation" id="3444"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Kidney transplantation" id="3469"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Kidney transplantation" id="3473"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Kidney transplantation" id="3491"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Kidney transplantation" id="3522"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Kidney transplantation" id="3533">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-04-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2014-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>67.06 Months</EnrollmentPeriod><EnrollmentRate>0.27 Patients/Month</EnrollmentRate><DateFirstReceived>2008-07-23T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-10-27T07:06:02Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-01-24T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>0006-06-16T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>0006-06-16T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-09-18T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="300972"><TitleDisplay>Arthroscopic Wafer and Ulnar Shortening in Ulnar Abutment</TitleDisplay><TitleOfficial>Comparative Study Between Arthroscopic Wafer and Ulnar Shortening Osteotomy in Ulnar Abutment Syndrome</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03168646</Identifier><Identifier type="Organisational Study">WAFER</Identifier></Identifiers><Indications><Indication id="3896">Upper limb fracture</Indication></Indications><BiomarkerNames><BiomarkerName id="19714" role="Therapeutic effect marker" type="Physiological">Muscle strength</BiomarkerName><BiomarkerName id="46527" role="Therapeutic effect marker" type="Physiological">Wrist motion</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Arthroscopy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Ulnar shortening osteotomy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Wafer procedure</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1025024" type="Company"><TargetEntity id="5035537586" type="organizationId">Assiut University</TargetEntity></SourceEntity><SourceEntity id="3896" type="ciIndication"><TargetEntity id="10061394" type="MEDDRA"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1025024">Assiut University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2017-06-30T00:00:00Z</DateStart><DateEnd type="estimated">2020-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-16T16:18:58Z</DateChangeLast><DateAdded>2017-06-14T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>amrelmicro@YAHOO.com</Email><Name>Amr El-Sayed Ali</Name><Phone>00201099021770</Phone></Contact><Contact type="Public contact"><Email>wareethrs@yahoo.com</Email><Name>waleed riad saleh</Name><Phone>00201142123037</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Obvious ulnar abutment syndrome with ulnar side wrist pain&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Ulnar minus or neutral variance&lt;/li&gt;&lt;li&gt;Central and radial wrist pain&lt;/li&gt;&lt;li&gt;Osteoarthritis of the wrist&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mayo scoring system: follow up of the pain (nonpain, mild occasional, moderate and sever graded as 1, 2, 3 and 4 respectively)</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Mayo scoring system: range of motion of the wrist compared to the normal side( 100, 75 to 99, 50 to 74, 25 to 9, 0 to 24%)</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Mayo scoring system: grip strength</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study is to compare     arthroscopic wafer and ulnar shortening osteotomy in ulnar abutment syndrome.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study consists of two groups:&lt;br/&gt;Wafer group: patients will undergo wrist arthroscopy and debridement of triangular fibrocartilage and shortening of the head ulna by burr, wafer procedure using an arthroscope through portal (radial to extensor carpi ulnaris, debridement of triangular fibro-cartilage complex 3 to 4 mm is shaved from the dome of the ulna by 2.9 bur.&lt;br/&gt;Ulnar shortening group:  patients will undergo wrist arthroscopy, debride debridement of triangular fibrocartilage and shortening of the ulna by osteotomy and plat, this is the most logical technique, dorsoulnar incision is made on the distal one-third of the forearm then a 6 hole 3.5 mm Dcp plate is position, osteotomy using oscillating saw in z-shaped manner.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other musculoskeletal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18266">Subjects with specific disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03168646</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other musculoskeletal disease" id="42994"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other musculoskeletal disease" id="43039"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other musculoskeletal disease" id="46368"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other musculoskeletal disease" id="46369">Pain scores</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Other musculoskeletal disease" id="46386"><Endpoint>Assessment of Physical Examination</Endpoint><SubEndpoints><SubEndpoint disease="Other musculoskeletal disease" id="46392">Muscle strength/activity</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other musculoskeletal disease" id="32681"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other musculoskeletal disease" id="35079"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other musculoskeletal disease" id="24023"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24089"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-05-16T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-06-14T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="322215"><TitleDisplay>A retrospective study to evaluate the diagnostic value of 18F-FDG positron emission tomography/computed tomography versus magnetic resonance imaging in the setting of antibody-specific autoimmune encephalitis</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="781">Encephalitis</Indication></Indications><BiomarkerNames><BiomarkerName id="56386" role="Disease marker" type="Proteomic">Anti-N-methyl-D-aspartate receptor antibodies</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>18F-FDG</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Magnetic resonance imaging (MRI)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Positron emission tomography/computed tomography (PET/CT)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="24056" type="Company"><TargetEntity id="5035523841" type="organizationId">Johns Hopkins University School of Medicine</TargetEntity></SourceEntity><SourceEntity id="781" type="ciIndication"><TargetEntity id="10014581" type="MEDDRA"/><TargetEntity id="D004660" type="MeSH"/><TargetEntity id="-943037247" type="omicsDisease"/><TargetEntity id="877" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="24056">Johns Hopkins University School of Medicine</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>23</PatientCountEnrollment><PatientCountEvaluable>23</PatientCountEvaluable><DateChangeLast>2018-02-02T22:03:02Z</DateChangeLast><DateAdded>2017-12-21T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with antibody-specific autoimmune encephalitis&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Areas of cortical lobar hypo (hyper)-metabolism in the cerebrum that were 2 SDx from the mean were recorded as abnormal</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this retrospective study was to examine the role of neuroimaging in the setting of autoimmune encephalitides, comparing the utility of 18F-FDG positron emission tomography/computed tomography (PET/CT) versus conventional brain imaging with magnetic resonance imaging (MRI) [&lt;ulink linkType="Reference" linkID="1990620"&gt;1990620&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In August 2017, results were published. All patients were identified as having an abnormal pattern of 18F-FDG uptake on visual inspection. In 22 of 23 (95.6%) patients, at least one region of interest with metabolic change was identified using a discriminating z score of 2 in semiquantitative analysis. Compared to MRI, 18F-FDG PET/CT was more often found to be abnormal during the diagnostic period. In 21 of 23 (91.3%) patients, the predominant finding on brain 18F-FDG PET/CT imaging was found to be lobar hypometabolism. In the parietal lobe, hypometabolism was most commonly observed followed by the occipital lobe. Normal MRI results and abnormal 18F-FDG PET/CT findings were observed in an entire subset of antibody-positive patients and anti-N-methyl-d-aspartate receptor (n = 5). Whereas, a greater heterogeneity was observed in the other subsets [&lt;ulink linkType="Reference" linkID="1990620"&gt;1990620&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who underwent MRI versus 18F-FDG PET/CT were included and observed [&lt;ulink linkType="Reference" linkID="1990620"&gt;1990620&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-12-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="341557"><TitleDisplay>Efficacy of Alirocumab in the arteriosclerotic biomarker changes after percutaneous coronary angioplasty (PCI)</TitleDisplay><TitleOfficial>Efficacy of Alirocumab in the arteriosclerotic biomarker changes after percutaneous coronary angioplasty (PCI)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000032843</Identifier></Identifiers><Indications><Indication id="80">Coronary artery disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>alirocumab</Name><Drug id="65085">alirocumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="65085">alirocumab</Drug><IndicationsPioneer/><Companies><Company><Company id="1016096">University of Fukui</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="65085" type="Drug"><TargetEntity id="687774" type="siDrug">Alirocumab</TargetEntity></SourceEntity><SourceEntity id="1016096" type="Company"><TargetEntity id="4298193768" type="organizationId">University of Fukui</TargetEntity></SourceEntity><SourceEntity id="80" type="ciIndication"><TargetEntity id="10011078" type="MEDDRA"/><TargetEntity id="D003327" type="MeSH"/><TargetEntity id="-1572475765" type="omicsDisease"/><TargetEntity id="221" type="siCondition"/></SourceEntity><SourceEntity id="48843" type="Action"><TargetEntity id="3596" type="Mechanism">Proprotein Convertase Subtilisin/Kexin-Type 9 (PCSK9) Inhibitors</TargetEntity><TargetEntity id="3673" type="Mechanism">Anti-PCSK9 (Proprotein Convertase Subtilisin/Kexin-Type 9)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1016096">University of Fukui</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="48843">Proprotein convertase PC9 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="399">Hypoglycemic agent</Class><Class id="71">Antihypercholesterolemic agent</Class><Class id="72">Antihyperlipidemic agent</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="128">Cell culture technique</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="168">Monoclonal antibody human</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2017-06-01T00:00:00Z</DateStart><DateChangeLast>2018-06-06T09:16:00Z</DateChangeLast><DateAdded>2018-06-04T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Faculty of Medical Sciences, University of Fukui ; Department of Cardiovascular Medicine</Affiliation><Email>huzui@u-fukui.ac.jp</Email><Name>Hiroyasu Uzui</Name><Phone>0776-61-8800</Phone></Contact><Contact type="Scientific contact"><Affiliation>Faculty of Medical Sciences, University of Fukui ; Department of Cardiovascular Medicine</Affiliation><Email>huzui@u-fukui.ac.jp</Email><Name>Hiroyasu Uzui</Name><Phone>0776-61-8800</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with acute myocarial infarction having:&lt;ul&gt;&lt;li&gt;Dyslipidemia undergoing treatment with HMG-CoA reductase inhibition&lt;/li&gt;&lt;li&gt;LDL-C &gt;/= 100 mg/dl  in conventional therapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;HMG-CoA reductase inhibitor is not used at the time of introduction&lt;/li&gt;&lt;li&gt;At the time of introduction of research drugs, patients with LDL-C&amp;lt; 100 mg/dl&lt;/li&gt;&lt;li&gt;Contraindicated patients with HMG-CoA reductase inhibitors&lt;/li&gt;&lt;li&gt;Hypersensitivity to the study drug&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Assessment of myocardial remodering suppression effect</Description><Timeframe>After 32 to 40 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Assessment of coronary plaque imaging, serum biomarkers and coronary microcirculation</Description><Timeframe>After 32 to 40 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to explore the efficay of &lt;ulink linkType="Drug" linkID="65085"&gt;alirocumab&lt;/ulink&gt; in patients with acute myocardial infarction after percutaneous coronary angioplasty (PCI).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this study, the patients will receive alirocumab 75 mg, q2w for 32 to 40 weeks&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Faculty of Medical Sciences, University of Fukui ; Department of Cardiovascular Medicine</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="173">Subjects with Unstable Coronary Artery Disease</PatientSegment><SubSegments><SubSegment id="174">Acute onset/new onset myocardial infarction (MI)</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Lipid metabolism disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="11314">Subjects with Increased LDL-cholesterol Levels</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000032843</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2728"><Endpoint>Assessment of Cardiac Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Coronary artery disease" id="2656"><Endpoint>Assessment of Artery Plaque /Atheroma</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2797"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="43811"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="43875"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Coronary artery disease" id="2566"><Endpoint>Assessment of Atherosclerotic Changes/Markers</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1078"><Criterion>Subjects with Myocardial Infarction (MI)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1080">New or recent onset/Acute MI</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1134"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1146">Lipid modifying agents</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1240"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="2057">Lab values meeting inclusion criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lipid metabolism disorder" id="20010"><Criterion>Subjects with Dyslipidemia</Criterion></Inclusion><Inclusion disease="Lipid metabolism disorder" id="20024"><Criterion>Subjects with Increased LDL-cholesterol Levels</Criterion></Inclusion><Inclusion disease="Lipid metabolism disorder" id="20053"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Coronary artery disease" id="33634"><Criterion>Subjects with Dyslipidemia</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lipid metabolism disorder" id="17735"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Lipid metabolism disorder" id="17736"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="23442"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="24889"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1902">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion><SubCriterion disease="Coronary artery disease" id="1906">Hypersensitivity/contraindication to lipid lowering agents</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-06-04T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="344811"><TitleDisplay>Impact of active video game on adolescent health</TitleDisplay><TitleOfficial>Impact of exergame on cardiorespiratory function, macro and microcirculation of overweight adolescents: a randomized, intervention study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">RBR-2xn3g6</Identifier><Identifier type="Other">U1111-1209-0463</Identifier><Identifier type="Other">2.584.321</Identifier><Identifier type="Other">84019518.3.0000.518</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="133" role="Therapeutic effect marker" type="Biochemical">Total cholesterol</BiomarkerName><BiomarkerName id="217" role="Therapeutic effect marker" type="Biochemical">Triglycerides</BiomarkerName><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="5596" role="Therapeutic effect marker" type="Physiological">Blood flow</BiomarkerName><BiomarkerName id="12110" role="Therapeutic effect marker" type="Physiological">Maximal inspiratory mouth pressure</BiomarkerName><BiomarkerName id="12111" role="Therapeutic effect marker" type="Physiological">Maximal expiratory mouth pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>physical exercise (active videogame)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1138789" type="Company"><TargetEntity id="5052167973" type="organizationId">Universidade Estadual da Paraiba</TargetEntity></SourceEntity><SourceEntity id="CM28215" type="Company"><TargetEntity id="5035561052" type="organizationId">National Council for Scientific and Technological Development</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"/><TargetEntity id="10029883" type="MEDDRA"/><TargetEntity id="D009765" type="MeSH"/><TargetEntity id="-1640888899" type="omicsDisease"/><TargetEntity id="985" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1138789">Paraiba State University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="CM28215">Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>108</PatientCountEnrollment><DateChangeLast>2018-07-31T22:03:44Z</DateChangeLast><DateAdded>2018-07-03T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Universidade Estadual da Paraíba</Affiliation><Email>daniellefranklin6@gmail.com</Email><Name>Danielle Franklin de Carvalho</Name><Phone>+558333153300</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;To be enrolled and attending the classes from the 5th to the 9th year of the public school network of the urban area of Campina Grande-PB selected for the study&lt;/li&gt;&lt;li&gt;Being in the age group of 10 to 18 years&lt;/li&gt;&lt;li&gt;Have nutritional status characterized as being overweight or obese&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Present some motor (although temporary) or mental limitation that impedes the participation in the activities of the intervention and/or the accomplishment of the exams, as the pulmonary function tests&lt;/li&gt;&lt;li&gt;Have any severe metabolic changes that require the use of medications or specific treatment that alter the metabolism of the lipid profile&lt;/li&gt;&lt;li&gt;Have asthma with a recent crisis (2 months prior to data collection) and/or report of exercise-induced bronchospasm&lt;/li&gt;&lt;li&gt;Not being, at the time of the research, overweight treatment, and active video game users&lt;/li&gt;&lt;li&gt;For women, being pregnant or breastfeeding&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>mprovement of cardiorespiratory function: measured by heart rate (measured by heart monitor) and by pulmonary function (through inspiratory and expiratory pressure, frequency, spirometry and manuvacometry), with expected effect of 0.6 points for each outcome. Data will be collected 2 weeks before and 1 week after the intervention: the expected effect is 0.6 points</Description><Timeframe>Data collected 2 weeks before and 1 week after the intervention</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Improvement of macrocirculation: assessed by carotid doppler: the expected effect is 0.6 points</Description><Timeframe>Data collected 2 weeks before and 1 week after the intervention</Timeframe></Measure><Measure><Description>Improvement of the microcirculation, evaluated by maximum and resting blood flows, using the Laser Doppler flowmetry technique (LDF) with the VMS-LDF device (Moor Instruments, UK) with dual flow channel: the expected effect is 0.6 points</Description><Timeframe>Data collected 2 weeks before and 1 week after the intervention</Timeframe></Measure><Measure><Description>Nutritional status: assessed by body mass index, determined by weight ratio divided by the square of height: the expected effect is 0.6 points</Description><Timeframe>Data collected 2 weeks before and 1 week after the intervention</Timeframe></Measure><Measure><Description>Dyslipidemia: evaluated through biochemical markers for total cholesterol and fractions, and triglycerides, determined by colorimetric technique: the expected effect is 0.6 points</Description><Timeframe>Data collected 2 weeks before and 1 week after the intervention</Timeframe></Measure><Measure><Description>Blood pressure: measured by tensiometer: the expected effect is 0.6 points</Description><Timeframe>Data collected 2 weeks before and 1 week after the interventionTt</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial is to determine the impact of exergame on cardiorespiratory function, macro and microcirculation of overweight adolescents: a randomized, intervention study&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This is a a intervention study with two comparison groups: &lt;br/&gt;Control group: 54 adolescents who are overweight or obese will not receive treatment. &lt;br/&gt;Intervention group: 54 overweight or obese adolescents will practice physical exercise provided by the use of the active videogame, performed three times a week, with 50 min each session, associated with gamification.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Brazil"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7733">Overweight (pre-obese) Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7739">Pediatric Overweight Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7740">Pediatric Obese Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1020">Brazilian Clinical Trials Registry (ReBec)</Name><Identifiers><Identifier>RBR-2xn3g6</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20543"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20585"><Endpoint>Assessment of Vital Signs</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20786">Assessment of heart rate</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20599"><Endpoint>Assessment of Cardiac Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20660"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20661">Spirometry</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20709"><Endpoint>Assessment of Pulmonary Function</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20714">Assessment of pulmonary function test</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20715"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="44913"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Obesity" id="20415"><Endpoint>Assessment of Nutritional Status</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20446"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20452">Assessment of Triglycerides</SubEndpoint><SubEndpoint disease="Obesity" id="20458">Assessment of cholesterol</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20538"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20543"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20599"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20554">Assessment of blood pressure</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20634"><Endpoint>Assessment of Co-morbidity</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20660"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20715"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20723">Assessment of hemodynamic profile</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20400">Assessment of Body Weight</SubEndpoint><SubEndpoint disease="Obesity" id="20405">Assessment of BMI</SubEndpoint><SubEndpoint disease="Obesity" id="20726">Assessment of height</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="44913"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Obesity" id="44913"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20787">Efficacy</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19672"><Criterion>Obese Subjects</Criterion></Inclusion><Inclusion disease="Obesity" id="19787"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22428">Overweight Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19790"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Obesity" id="22431"><Criterion>Pediatric Overweight Subjects</Criterion></Inclusion><Inclusion disease="Obesity" id="22432"><Criterion>Pediatric Obese Subjects</Criterion></Inclusion><Inclusion disease="Obesity" id="34819"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19792">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15298"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Obesity" id="15325"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15327">Subjects with neuropathy/neurovasculopathy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15342"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15349">Subjects on lipid modifying agents</SubCriterion><SubCriterion disease="Obesity" id="15411">Subjects on/treated with weight loss medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15364"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Obesity" id="24974"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15397">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="27418"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Obesity" id="27904"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15402">Subjects unable to comply with the protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="29288"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion><Exclusion disease="Obesity" id="29804"><Criterion>Subjects with Abnormal Organ Function</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-07-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="55767"><TitleDisplay>Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder</TitleDisplay><TitleOfficial>Clinical Study of Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder After Surgical Management</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">LanZhou University</Identifier><Identifier type="NCT">NCT00343356</Identifier><Identifier type="Secondary Organisational">1996L01936</Identifier></Identifiers><Indications><Indication id="42">Bladder tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>BCG</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>epirubicin</Name><Drug id="13022">epirubicin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>BCG</Name></Intervention><Intervention type="InterventionPrimary"><Name>epirubicin</Name><Drug id="13022">epirubicin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="13022">epirubicin</Drug><IndicationsPioneer><Indication id="42">Bladder tumor</Indication></IndicationsPioneer><Companies><Company><Company id="1047491">LanZhou University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="13022">epirubicin</Drug><IndicationsPioneer><Indication id="42">Bladder tumor</Indication></IndicationsPioneer><Companies><Company><Company id="1047491">LanZhou University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="13022" type="Drug"><TargetEntity id="91069" type="siDrug">Epirubicin hydrochloride</TargetEntity><TargetEntity id="91069" type="siDrug">Epirubicin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1047491" type="Company"><TargetEntity id="5035546301" type="organizationId">LanZhou University</TargetEntity></SourceEntity><SourceEntity id="42" type="ciIndication"><TargetEntity id="10005056" type="MEDDRA"/><TargetEntity id="D001749" type="MeSH"/></SourceEntity><SourceEntity id="142" type="Action"><TargetEntity id="419" type="Mechanism">DNA Topoisomerase II Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1047491">LanZhou University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="142">Topoisomerase II inhibitor</Action><Action id="82444">DNA helicase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="750">DNA intercalator</Class></Class><Technologies><Technology id="66">Antibiotic</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>138</PatientCountEnrollment><PatientCountEvaluable>138</PatientCountEvaluable><DateStart>1996-06-30T00:00:00Z</DateStart><DateEnd type="actual">2003-07-31T00:00:00Z</DateEnd><DateChangeLast>2017-08-05T22:06:05Z</DateChangeLast><DateAdded>2009-05-28T13:01:21Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>the Second Hospital of LanZhou University</Affiliation><Name>Zhang Xiangbo</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Primary single or multiple (more than two tumors) pTa to pT1 transitional cell carcinoma, solitary or multiple grade Ⅲ tumors and primary or concomitant carcinoma in situ of the bladder were included in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Previous radiotherapy, intravesicial or systemic chemotherapy within 3 months of the study, presence of a second primary malignancy and transitional cell carcinoma of the upper urinary tract or prostatic urethra, invasion of periurethral prostatic ducts, prostatic gland or stroma&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Recurrence rate</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Side effect: local toxicity was defined as the occurrence of culture proved bacterial cystitis, chemical or drug-induced cystitis, or other local side effects, such as hematuria, prostatitis or epididymitis</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Biochemotherapy (combined immunotherapeutic drugs and chemotherapeutic drugs) has shown virtue than that use chemical or biological drugs alone in the treatment of some malignant tumor. In this study, the researchers would investigate the efficacy of sequential intravesical therapy with &lt;ulink linkType="Drug" linkID="13022"&gt;epirubicin&lt;/ulink&gt; and BCG to &lt;ulink linkType="Drug" linkID="13022"&gt;epirubicin&lt;/ulink&gt; or BCG alone in patients with transitional cell carcinoma of bladder cancer after surgical management.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results: after a median follow up of 36 months, the number of recurrences in group 1 was significantly reduced than group 2 and 3 (p &amp;lt; 0.05 versus group 2 and 3, x2-test). The frequency of bacterial, chemical cystitis and other local side effects was similar in group 1 and 2, whereas significant severe side effect was found in group 3 (p &amp;lt; 0.05 versus group 2 and 1, x2-test). Allergic reactions, including skin rash, were more frequent in group 3, and other systemic effects were more frequent in group 1.  Biochemotherapy by single dose EPI plus sequential BCG intravesical  markedly effect in preventing the recurrence of bladder cancer after surgical management. Its side effects are low. This method is of high clinical value.&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Methods: from July 1996 to November 2003, a total of 138 cases of bladder cancer underwent TURBT or partial cystectomy were entered the trail. They were  divided into three groups randomly: &lt;br/&gt;&lt;ulink linkType="Drug" linkID="13022"&gt;Epirubicin&lt;/ulink&gt;  plus BCG;&lt;br/&gt;Use BCG alone; and &lt;br/&gt;Use &lt;ulink linkType="Drug" linkID="13022"&gt;epirubicin&lt;/ulink&gt; alone.  &lt;/para&gt;&lt;para&gt;All the patients have been followed up for 28 to 40 months after surgery (average time was 36 months), and the frequency of bacterial, chemical cystitis and other local side effects were also observed. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Methods: from July 1996 to November 2003, a total of 138 cases of bladder cancer underwent TURBT or partial cystectomy were entered the trail. They were  divided into three groups randomly: &lt;br/&gt;&lt;ulink linkType="Drug" linkID="13022"&gt;Epirubicin&lt;/ulink&gt; (epi) plus BCG;&lt;br/&gt;Use BCG alone; and &lt;br/&gt;Use &lt;ulink linkType="Drug" linkID="13022"&gt;epirubicin&lt;/ulink&gt; alone. &lt;/para&gt;&lt;para&gt;All the patients have been followed up for 28 to 40 months after surgery (average time was 36 months), and the frequency of bacterial, chemical cystitis and other local side effects were also observed. &lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms><PatientSegmentByDisease><Disease>Bladder cancer</Disease><PatientSegments><PatientSegment><PatientSegment id="7813">Subjects with Histologic Grade 3 Bladder Cancer (G3)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8092">Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</PatientSegment><SubSegments><SubSegment id="8093">TNM Stage 0is or carcinoma in situ (Tis)</SubSegment><SubSegment id="8094">TNM Stage 0a or non-invasive papillary carcinoma (Ta)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8095">Subjects with Stage I Bladder Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00343356</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Bladder cancer" id="11789"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint><SubEndpoints><SubEndpoint disease="Bladder cancer" id="11791">Assessment of recurrence rate</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Bladder cancer" id="11772"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Bladder cancer" id="11774">Assessment of toxicity</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Bladder cancer" id="7436"><Criterion>Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</Criterion><SubCriteria><SubCriterion disease="Bladder cancer" id="7437">TNM Stage 0is or carcinoma in situ (Tis)</SubCriterion><SubCriterion disease="Bladder cancer" id="7438">TNM Stage 0a or non-invasive papillary carcinoma (Ta)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bladder cancer" id="7442"><Criterion>Subjects with Stage I Bladder Cancer</Criterion></Inclusion><Inclusion disease="Bladder cancer" id="7448"><Criterion>Subjects with Histologic Grade 3 Bladder Cancer (G3)</Criterion></Inclusion><Inclusion disease="Bladder cancer" id="7472"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Bladder cancer" id="7478">Subjects with history of/scheduled for surgery/procedure for bladder cancer</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Bladder cancer" id="9002"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Bladder cancer" id="9030"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateFirstReceived>2006-06-19T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-05-28T13:01:21Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="6398"><TitleDisplay>Evaluation of Atorvastatin on Atherosclerosis Composition</TitleDisplay><TitleOfficial>The Evaluation of Atorvastatin on Wall Shear Stress, Atherosclerosis Composition, and Microvascular Function in Patients With Moderate Coronary Disease</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">IRB00000701</Identifier><Identifier type="Organisational Study">Emory #07052168</Identifier><Identifier type="NCT">NCT00576576</Identifier><Identifier type="Secondary Organisational">GA2580TT</Identifier></Identifiers><Indications><Indication id="33">Atherosclerosis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>atorvastatin</Name><Drug id="2807">atorvastatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2807">atorvastatin</Drug><IndicationsPioneer/><Companies><Company><Company id="18767">Pfizer Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company><Company><Company id="20573">Emory University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2807" type="Drug"><TargetEntity id="180072" type="siDrug">Atorvastatin calcium</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="20573" type="Company"><TargetEntity id="4296863639" type="organizationId">Emory University</TargetEntity></SourceEntity><SourceEntity id="33" type="ciIndication"><TargetEntity id="I70" type="ICD10"/><TargetEntity id="440" type="ICD9"/><TargetEntity id="D050197" type="MeSH"/><TargetEntity id="-848966698" type="omicsDisease"/><TargetEntity id="208" type="siCondition"/></SourceEntity><SourceEntity id="205" type="Action"><TargetEntity id="437" type="Mechanism">HMG-CoA Reductase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20573">Emory University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="18767">Pfizer Inc</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="205">HMG CoA reductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2667">Antiarteriosclerotic</Class><Class id="71">Antihypercholesterolemic agent</Class><Class id="72">Antihyperlipidemic agent</Class></Class><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>27</PatientCountEnrollment><DateStart>2007-07-31T00:00:00Z</DateStart><DateEnd type="actual">2010-03-31T00:00:00Z</DateEnd><DateChangeLast>2018-07-14T11:27:06Z</DateChangeLast><DateAdded>2008-01-04T10:55:14Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Emory University</Affiliation><Name>Habib Samady, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients undergoing catheterization for stable angina or acute        coronary syndromes&lt;/li&gt;&lt;li&gt;At the time of catheterization the patient has a moderate coronary lesion in the proximal        60 mm of an epicardial coronary artery (moderate lesion is defined as a lesion deemed by the treating physician to be significant enough to warrant further        evaluation using coronary flow ratio and fractional flow reserve)        &lt;/li&gt;&lt;li&gt;Patient must have decision making capacity and consented prior to the catheterization&lt;/li&gt;&lt;li&gt;Performance status: all levels&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with coronary bypass grafts&lt;/li&gt;&lt;li&gt;Severe valvular heart disease&lt;/li&gt;&lt;li&gt;Patients presenting with an ST segment elevation myocardial infarction&lt;/li&gt;&lt;li&gt;Inability to provide informed consent prior to randomization&lt;/li&gt;&lt;li&gt;Creatinine&amp;gt; 1.5        &lt;/li&gt;&lt;li&gt;Patients who are on a statin with an LDL-C level&amp;lt; 130&lt;/li&gt;&lt;li&gt;Any patient on a maximum dose of statin (atorvastatin 80 mg, simvastatin 80 mg, rosuvastatin        20 mg, pravastatin 80 mg, or fluvastatin 80 mg)&lt;/li&gt;&lt;li&gt;Uncontrolled diabetes requiring intensification of therapy&lt;/li&gt;&lt;li&gt;Uncontrolled hypertension requiring the addition of angiotensin-converting enzyme inhibitors or angiotensin receptor blocking agents&lt;/li&gt;&lt;li&gt;A left main lesion greater than 50% stenosis&lt;/li&gt;&lt;li&gt;The moderate lesion is located beyond 60 mm&lt;/li&gt;&lt;li&gt;Collaterals&lt;/li&gt;&lt;li&gt;Coronary anatomy requiring coronary artery bypass graft&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in necrotic core volume</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in atheroma volume</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Change in fibrous plaque volume</Description><Timeframe>6 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to evaluate the effects of &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; on  coronary      atherosclerosis plaque morphology.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The primary goal of this project is to evaluate the effect of &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; on atherosclerosis plaque composition.  The hypothesis is that      &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; will reduce the number of vulnerable plaques and increase the number of      stable plaques seen by intravascular ultrasound.      Patients are evaluated by cardiac catheterization with intravascular ultrasound      analysis and then  treated with &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; for 6 months, followed by a repeat catheterization evaluation.      The secondary goal  is to evaluate the relationship between      coronary atherosclerosis and wall shear stress.   &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients receive 80 mg &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; qd.&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Emory University Hospital</Name><Address1>Atlanta</Address1><Address2>Georgia</Address2><Address3>30322</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Atherosclerosis</Disease><PatientSegments><PatientSegment><PatientSegment id="7237">Subjects with Coronary Atherosclerosis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7263">Subjects with History of/Undergoing Specified Procedures</PatientSegment><SubSegments><SubSegment id="7265">Subjects with history of/undergoing coronary angiogram</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="173">Subjects with Unstable Coronary Artery Disease</PatientSegment><SubSegments><SubSegment id="176">Non ST elevation myocardial infarction (NSTEMI)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="182">Subjects with Angina</PatientSegment><SubSegments><SubSegment id="188">Subjects with Stable Angina</SubSegment><SubSegment id="3729">Subjects with unstable angina</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="201">Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="207">Subjects Undergoing /Underwent Major Cardiac Intervention</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="367">Subjects with Stable Coronary Artery Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00576576</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2656"><Endpoint>Assessment of Artery Plaque /Atheroma</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2659">Change in necrotic core volume</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Atherosclerosis" id="9707"><Endpoint>Assessment of Atherosclerotic Plaque/Atheroma</Endpoint><SubEndpoints><SubEndpoint disease="Atherosclerosis" id="9709">Assessment of plaque volume</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Coronary artery disease" id="2656"><Endpoint>Assessment of Artery Plaque /Atheroma</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2658">Change in Atheroma/Plaque volume</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Atherosclerosis" id="9707"><Endpoint>Assessment of Atherosclerotic Plaque/Atheroma</Endpoint><SubEndpoints><SubEndpoint disease="Atherosclerosis" id="9709">Assessment of plaque volume</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Atherosclerosis" id="9707"><Endpoint>Assessment of Atherosclerotic Plaque/Atheroma</Endpoint><SubEndpoints><SubEndpoint disease="Atherosclerosis" id="9715">Assessment of plaque morphology</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1068"><Criterion>Subjects with Coronary Artery Disease (CAD)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="3871">Subjects with acute coronory syndrome</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1085"><Criterion>Subjects with angina</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1091">Subjects with stable angina / angina pectoris / exertional angina</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1169"><Criterion>Subjects with History of /Scheduled for Coronary Revascularization Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1170">Cardiac catheterization/coronary angiography</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1201"><Criterion>Coronary Angiogram Findings Suggestive of/Confirmed CAD/CHD</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1223">Stenosis or lesion of one major epicardial artery</SubCriterion><SubCriterion disease="Coronary artery disease" id="1433">Coronary flow reserve limitation</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Atherosclerosis" id="5710"><Criterion>Subjects with Diagnosis of Atherosclerosis</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="5711">Subjects with coronary atherosclerosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Atherosclerosis" id="5730"><Criterion>Subjects Diagnosed by Specific Methods</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="5731">Atherosclerosis diagnosed by angiography</SubCriterion><SubCriterion disease="Atherosclerosis" id="5732">Atherosclerosis diagnosed by radiology</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Atherosclerosis" id="5753"><Criterion>Subjects with History of/Undergoing Specified Procedures</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="5755">Subjects with history of/undergoing coronary angiogram</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Coronary artery disease" id="1602"><Criterion>Subjects with Myocardial Infarction (MI)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1606">Acute ST segment elevation myocardial infarction (STEMI)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1609"><Criterion>Subjects with Specific Coronary Angiographic Findings</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1621">Involvement of a side branch /compromised or sub-occluded branch</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1638"><Criterion>Subjects with Valvular Heart Diseases</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1651"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1664">Left main coronary artery(LMCA) occlusion /left main occlusion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1780"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1793"><Criterion>Subjects on Cardiovascular Treatment</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1795">Angiotensin II Receptor Blockers (ARB)</SubCriterion><SubCriterion disease="Coronary artery disease" id="1798">Antihypertensive drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1857"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1858">Subjects with abnormal renal function tests</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atherosclerosis" id="7297"><Criterion>Atherosclerosis with Defined Extent of Stenosis</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="7300">Subjects with greater than 50 % stenosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atherosclerosis" id="7313"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Atherosclerosis" id="7314"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Atherosclerosis" id="7355"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="7356">Hypersensitivity/contraindications to radioimaging procedures</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atherosclerosis" id="7357"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="7358">Subjects with history of/scheduled for cardiac surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atherosclerosis" id="7363"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="7559">Subjects with history of/scheduled for lipid lowering drugs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="26090"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1846">Subjects with CABG (Coronary artery bypass graft) surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="26158"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1796">Subjects with history/scheduled to receive angiotensin converting enzyme (ACE) inhibitors</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2007-12-17T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-01-04T10:55:14Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="78793"><TitleDisplay>Y- Shaped Pegylated Interferon (YPEG-IFN alpha-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C</TitleDisplay><TitleOfficial>Clinical Trial of the Efficacy, Dosing, Safety and Tolerability of Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CHT00234</Identifier><Identifier type="NCT">NCT01327729</Identifier></Identifiers><Indications><Indication id="153">Hepatitis C virus infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>YPEG-interferon alfa-2a (chronic hepatitis B/C virus infection), Amoytop/BioGeneric Phama</Name><Drug id="72168">YPEG-interferon alfa-2a (chronic hepatitis B/C virus infection), Amoytop/BioGeneric Phama</Drug></Intervention><Intervention type="InterventionPrimary"><Name>ribavirin</Name><Drug id="5369">ribavirin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="5369">ribavirin</Drug><IndicationsPioneer/><Companies><Company><Company id="1028796">Amoytop Biotech Co Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1034118">Biogenerics Pharma GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="72168">YPEG-interferon alfa-2a (chronic hepatitis B/C virus infection), Amoytop/BioGeneric Phama</Drug><IndicationsPioneer><Indication id="153">Hepatitis C virus infection</Indication></IndicationsPioneer><Companies><Company><Company id="1028796">Amoytop Biotech Co Ltd</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1034118">Biogenerics Pharma GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="72168" type="Drug"><TargetEntity id="734844" type="siDrug">Y-peginterferon alfa-2a</TargetEntity></SourceEntity><SourceEntity id="5369" type="Drug"><TargetEntity id="91288" type="siDrug">Ribavirin</TargetEntity></SourceEntity><SourceEntity id="1028796" type="Company"><TargetEntity id="5035558350" type="organizationId">Xiamen Amoytop Biotech Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1034118" type="Company"><TargetEntity id="5035541063" type="organizationId">Biogenerics Pharma GmbH</TargetEntity></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"/><TargetEntity id="D019698" type="MeSH"/><TargetEntity id="-776640207" type="omicsDisease"/><TargetEntity id="430" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1034118">Biogenerics Pharma GmbH</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1028796">Amoytop Biotech Co Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="214">Interferon alpha 2 ligand</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="439">RNA synthesis inhibitor</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="586">Capsule formulation</Technology><Technology id="701">Nucleoside synthesis</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="348">PEGylated formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="1652">Prodrug</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>300</PatientCountEnrollment><DateStart>2010-11-30T00:00:00Z</DateStart><DateEnd type="estimated">2013-05-31T00:00:00Z</DateEnd><DateChangeLast>2017-01-24T03:55:00Z</DateChangeLast><DateAdded>2011-07-01T07:01:20Z</DateAdded><Contacts><Contact type="Public contact"><Email>drmkarim@gmail.com</Email><Name>Mohamed Karim f Ashour, MD</Name><Phone>0020123130102</Phone></Contact><Contact type="Public contact"><Email>g_esmat@yahoo.com</Email><Name>Gamal Esmat, MD</Name><Phone>002012455468</Phone></Contact><Contact type="Scientific contact"><Affiliation>cairo university - Kasr alaini school of medicine</Affiliation><Name>Gamal Esmat, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Cairo university- Kasr Alaini school of medicine</Affiliation><Name>Mohamed Karim F Ashour, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;BioGeneric PharmaAge&amp;gt; 18 years and &amp;lt; 65 years&lt;/li&gt;&lt;li&gt;Chronic hepatitis C defined as: HCV antibodies using a third generation test; HCV-RNA             positive by PCR; liver biopsy in the past 12 months; METAVIR score of A1 and F0 or             higher&lt;/li&gt;&lt;li&gt;ALT&amp;gt; 1 ULN in the 24 weeks prior to inclusion (W-26; W-2)&lt;/li&gt;&lt;li&gt;Patients never treated with&lt;ulink linkType="Drug" linkID="5369"&gt;ribavirin&lt;/ulink&gt;,  Interferon or PEG-Interferon&lt;/li&gt;&lt;li&gt;Normal albumin, prothrombin time&amp;gt; 60%; normal bilirubin&lt;/li&gt;&lt;li&gt;Alpha-foeto-protein&amp;lt; 3 times the normal range for the laboratory reference&lt;/li&gt;&lt;li&gt;HBs antigen negative&lt;/li&gt;&lt;li&gt;Anti bilharzial antibodies if positive rectal snip shall be done.  The examination             may be repeated after praziquantel treatment for those with a positive test&lt;/li&gt;&lt;li&gt;Hemoglobin&amp;gt; 11g/dl,  leucocytes &amp;gt; 3000/mm3, neutrophils &amp;gt; 1500/mm3, platelets &amp;gt; 100             000/mm3, blood creatinin &amp;lt; 1.4 mg/dl&lt;/li&gt;&lt;li&gt;Normal TSH (subjects needing treatment to maintain TSH within a normal range may be             included if other eligibility criteria are respected)&lt;/li&gt;&lt;li&gt;Anti-nuclear antibodies&amp;lt; 1/160&lt;/li&gt;&lt;li&gt;Fasting blood sugar between 70 and 115 mg/dl ; if glucose intolerance or diabetes, HbA1C&amp;lt;             8.5%&lt;/li&gt;&lt;li&gt;Normal ophthalmologic examination in patients with history of blood pressure and/or             diabetes&lt;/li&gt;&lt;li&gt;Effective contraception (IUD, diaphragm and spermicide, condoms and spermicides, oral             contraceptive, progesterone implants (Norplant), medroxyprogesterone acetate             (Depo-provera), tubal ligation, vasectomy) during the treatment period for females.             No breastfeeding during the study period&lt;/li&gt;&lt;li&gt;Signed informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Other liver diseases associated with chronic hepatitis C: co-infection with hepatitis             B (positive HBs antigen); hemochromatosis; alpha-1 anti-trypsin deficiency; wilson             disease; alcoholism-related liver disease; Gilbert disease&lt;/li&gt;&lt;li&gt;Alcohol intake&amp;gt; 50 g/day for males and 40 g/day for females&lt;/li&gt;&lt;li&gt;Ongoing intravenous drug use&lt;/li&gt;&lt;li&gt;Aggravated liver cirrhosis: history or presence of ascitis, oesophageal varicosis,             liver encephalopathy&lt;/li&gt;&lt;li&gt;Hepatocellular carcinoma&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Viral clearance at 72 weeks: assessment of the efficacy, dosing, safety and tolerability of Y- shaped pegylated interferon (YPEG-IFNα-2a) plus ribavirin in Egyptian patients with chronic hepatitis C and with no prior treatment for HCV</Description><Timeframe>72 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Interferon level: assessment of the plasma level of the YPEG-IFN alpha-2a in the first 30 patients in  each group, to ensure therapeutic plasma level of the drug at 2, 6, 10, 24 h, 3, 5, 7, 10, 14 and 28 days</Description><Timeframe>12 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objective is to assess the efficacy, dosing, safety and tolerance of Y- shaped pegylated      interferon (&lt;ulink linkType="Drug" linkID="72168"&gt;YPEG-IFN alpha-2a&lt;/ulink&gt;) plus &lt;ulink linkType="Drug" linkID="5369"&gt;ribavirin&lt;/ulink&gt; in Egyptian patients with chronic hepatitis C and      with no prior treatment for hepatitis C virus (HCV).&lt;br/&gt;Secondary objective: to assess the plasma level of the &lt;ulink linkType="Drug" linkID="72168"&gt;YPEG-IFN alpha-2a&lt;/ulink&gt; in the first 30 patients      in  each group, to ensure therapeutic plasma level of the drug at 2, 6, 10, 24  h and 3, 5, 7, 10,14  and 28 days.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study is divided into three groups in which each group will include 100 patients.&lt;br/&gt;Group A: patients will receive &lt;ulink linkType="Drug" linkID="72168"&gt;YPEG-IFN alpha-2a&lt;/ulink&gt; 180 mcg/week for 48 weeks. &lt;ulink linkType="Drug" linkID="5369"&gt;Ribavirin&lt;/ulink&gt; 15 mg/kg/day for 48 weeks.&lt;br/&gt;Group B: patients will receive &lt;ulink linkType="Drug" linkID="72168"&gt;YPEG-IFN alpha-2a&lt;/ulink&gt; 180 mcg/10 days for 48 weeks. &lt;ulink linkType="Drug" linkID="5369"&gt;Ribavirin&lt;/ulink&gt;  15 mg/kg/day for 48 weeks.&lt;br/&gt;Group C: patients will receive &lt;ulink linkType="Drug" linkID="72168"&gt;YPEG-IFN alpha-2a&lt;/ulink&gt; 180 mcg/ 2 weeks for 48 weeks. &lt;ulink linkType="Drug" linkID="5369"&gt;Ribavirin&lt;/ulink&gt; 15 mg/kg/day for 48 weeks. HCV RNA by      polymerase chain reaction (PCR) will be done at 24 weeks and negative PCR patients will continue treatment for another      24 weeks and PCR positive patients will be considered non responders and will be followed      up. Evaluation of the dose efficacy and side effects will be obtained at 4 weeks and 12 weeks of      treatment, and any serious side effects or significant dose difference in early virological      response in a group will lead to shift of this group to the dose 180 mcg/week.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Egypt"><Sites><Site><Name>Kasr Alaini school of medicne</Name><Address1>Cairo</Address1><Address3>11559</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Mohamed Karim f Ashour, MD</Name></Contact><Contact type="Facility investigator"><Name>AMR H ELdeeb, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hepatitis C virus infection</Disease><PatientSegments><PatientSegment><PatientSegment id="461">Subjects with Chronic Hepatitis C Infection</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="489">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01327729</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hepatitis C virus infection" id="3734"><Endpoint>Assessment of Early Virologic Response (EVR)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Hepatitis C virus infection" id="3808"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Hepatitis C virus infection" id="3809">Assessment of adverse events/serious adverse events</SubEndpoint><SubEndpoint disease="Hepatitis C virus infection" id="3812">Hematological adverse events</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hepatitis C virus infection" id="6863"><Endpoint>Assessment of Viral Load/Viral Kinetics</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Hepatitis C virus infection" id="9434"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hepatitis C virus infection" id="1751"><Criterion>Subjects with Chronic Hepatitis C Infection</Criterion></Inclusion><Inclusion disease="Hepatitis C virus infection" id="1762"><Criterion>Subjects with Positive Serological Markers for Hepatitis C</Criterion><SubCriteria><SubCriterion disease="Hepatitis C virus infection" id="1763">Subjects positive for anti-HCV antibody</SubCriterion><SubCriterion disease="Hepatitis C virus infection" id="1764">Subjects positive for HCV RNA</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatitis C virus infection" id="1786"><Criterion>Subjects with Normal Liver Function Tests/Liver Biopsy</Criterion></Inclusion><Inclusion disease="Hepatitis C virus infection" id="1787"><Criterion>Subjects with Abnormal Liver Function Tests</Criterion><SubCriteria><SubCriterion disease="Hepatitis C virus infection" id="1788">Subjects with abnormal alanine transaminase (ALT) levels</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatitis C virus infection" id="1795"><Criterion>Subjects with Specified Metavir Histological Score</Criterion></Inclusion><Inclusion disease="Hepatitis C virus infection" id="1837"><Criterion>Treatment Naive Subjects</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hepatitis C virus infection" id="2599"><Criterion>Subjects with Liver Cirrhosis</Criterion></Exclusion><Exclusion disease="Hepatitis C virus infection" id="2600"><Criterion>Subjects with Hepatocellular Carcinoma</Criterion></Exclusion><Exclusion disease="Hepatitis C virus infection" id="2602"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Hepatitis C virus infection" id="2603">Subjects with alpha-1 antitrypsin deficiency</SubCriterion><SubCriterion disease="Hepatitis C virus infection" id="2604">Subjects with alcoholic liver disease</SubCriterion><SubCriterion disease="Hepatitis C virus infection" id="2610">Subjects co-morbid with hepatic encephalopathy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hepatitis C virus infection" id="2689"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Hepatitis C virus infection" id="2613">Subjects co-morbid with Wilson's disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hepatitis C virus infection" id="5653"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Hepatitis C virus infection" id="2593">Subjects co-morbid with hepatitis B virus infection</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2011-04-30T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-07-01T07:01:20Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="8102"><TitleDisplay>Insulin Detemir Action in Cerebro</TitleDisplay><TitleOfficial>Effects of INsulin dEtemiR and Neutral protaminE Hagedorn (NPH) Insulin on BRain glucOse Metabolism: a Study in Persons With Type 1 Diabetes</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">DC2007Det001</Identifier><Identifier type="NCT">NCT00626080</Identifier><Identifier type="Secondary Organisational">2007-007255-13</Identifier><Identifier type="Trial Acronym">INcEREBRO</Identifier></Identifiers><Indications><Indication id="836">Insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>insulin aspart</Name><Drug id="10411">insulin aspart</Drug></Intervention><Intervention type="InterventionPrimary"><Name>insulin detemir</Name><Drug id="17426">insulin detemir</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="duo"><Interventions><Intervention type="InterventionControl"><Name>insulin NPH</Name></Intervention><Intervention type="InterventionControl"><Name>insulin aspart</Name><Drug id="10411">insulin aspart</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="10411">insulin aspart</Drug><IndicationsPioneer/><Companies><Company><Company id="30810">VU University Medical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="17426">insulin detemir</Drug><IndicationsPioneer/><Companies><Company><Company id="30810">VU University Medical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="10411" type="Drug"><TargetEntity id="134086" type="siDrug">Insulin aspart</TargetEntity></SourceEntity><SourceEntity id="17426" type="Drug"><TargetEntity id="239855" type="siDrug">Insulin detemir</TargetEntity></SourceEntity><SourceEntity id="30810" type="Company"><TargetEntity id="5035524485" type="organizationId">Vereniging voor christelijk hoger onderwijs wetenschappelijk onderzoek en patientenzorg</TargetEntity></SourceEntity><SourceEntity id="836" type="ciIndication"><TargetEntity id="E10" type="ICD10"/><TargetEntity id="10067584" type="MEDDRA"/><TargetEntity id="D003922" type="MeSH"/><TargetEntity id="-686743471" type="omicsDisease"/><TargetEntity id="507" type="siCondition"/></SourceEntity><SourceEntity id="400" type="Action"><TargetEntity id="609" type="Mechanism">Insulin Secretagogues</TargetEntity><TargetEntity id="1034" type="Mechanism">Insulin Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="30810">VU University Medical Center</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="23014">Insulin ligand</Action><Action id="400">Insulin receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="38211">Human insulin fast acting product</Class><Class id="38212">Human insulin intermediate acting product</Class><Class id="399">Hypoglycemic agent</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="1646">Injectable controlled release formulation</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="80">Peptide</Technology><Technology id="85">Protein recombinant</Technology><Technology id="662">Quick release formulation</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="745">Suspension</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><PatientCountEvaluable>32</PatientCountEvaluable><DateStart>2009-01-31T00:00:00Z</DateStart><DateEnd type="actual">2011-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-03T09:38:38Z</DateChangeLast><DateAdded>2008-03-01T16:53:03Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>VU University Medical Center</Affiliation><Email>m.diamant@vumc.nl</Email><Name>Michaela Diamant</Name><Phone>+31-20-4440533</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Type 1 diabetic patients&lt;/li&gt;&lt;li&gt;Diabetes duration &gt;/= 5 years&lt;/li&gt;&lt;li&gt;HbA1c max 7.5%&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Recent onset of diabetes mellitus (DM)&lt;/li&gt;&lt;li&gt;BMI&amp;lt; 18 or &amp;gt; 35 kg/m2&lt;/li&gt;&lt;li&gt;T2DM&lt;/li&gt;&lt;li&gt;History of major heart/renal disease&lt;/li&gt;&lt;li&gt;Severe untreated proliferative retinopathy&lt;/li&gt;&lt;li&gt;History of recurrent severe hypoglycemia&lt;/li&gt;&lt;li&gt;History of brain disorders&lt;/li&gt;&lt;li&gt;Alcohol abuse&lt;/li&gt;&lt;li&gt;History of drug abuse, benzodiazepines, selective beta-blockers, oral             steroids, oral anticoagulants&lt;/li&gt;&lt;li&gt;Current psychiatric disease/treatment&lt;/li&gt;&lt;li&gt;History of eating disorders&lt;/li&gt;&lt;li&gt;History of severe head trauma accompanied by loss of consciousness&lt;/li&gt;&lt;li&gt;Any endocrine disease not well controlled for at least 3 months&lt;/li&gt;&lt;li&gt;Inability to undergo MRI&lt;/li&gt;&lt;li&gt;Visual acuity&amp;lt; 0.3&lt;/li&gt;&lt;li&gt;Known or suspected allergy to trial product or related products&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Cerebral metabolic rate of glucose, in brain regions associated with appetite control, as determined by FDG-PET</Description><Timeframe>After 12 weeks of treatment</Timeframe></Measure><Measure><Description>Cerebral blood flow, in brain regions associated with appetite control, as determined by H2O-PET</Description><Timeframe>After 12 weeks of treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>CSF insulin concentration</Description><Timeframe>After 12 weeks of treatment</Timeframe></Measure><Measure><Description>Activity in brain regions associated with appetite control (viewing food and non-food pictures), as determined by fMRI</Description><Timeframe>After 12 weeks of treatment</Timeframe></Measure><Measure><Description>Weight change</Description><Timeframe>After 12 weeks of treatment</Timeframe></Measure><Measure><Description>Hunger ratings before and after scanning scored on a Likert scale</Description></Measure><Measure><Description>Eating behaviour scored using the DEBQ</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to test the hypothesis that sc administration of &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt;, as compared to insulin NPH (neutral protamine hagedorn), leads to a more pronounced effect on cerebral glucose      metabolism and/or cerebral blood flow in brain regions associated with appetite regulation,      to account for the reported difference in weight.&lt;/para&gt;&lt;para&gt;This study hypothesized that in type 1 diabetes patients, the weight sparing effect of &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; may be mediated by the enhanced action on the central nervous system (CNS), resulting in blunted activation in bilateral insula, an appetite-regulating brain region, in response to food stimuli [&lt;ulink linkType="Reference" linkID="1624894"&gt;1624894&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In October 2012, results were presented. Following 12 weeks of treatment, daily insulin doses and HbA1c were similar in both treatment groups. Body weight was decreased by 0.8 and 0.5 kg in  &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; and  NPH insulin  (p = 0.02) groups, respectively. During fMRI, mean glucose levels were 8.8 +/- 3.6 and 10.4 +/- 4.0 mmol/l in &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; and NPH insulin groups, respectively  (p= 0.046); no differences were observed between groups for hunger ratings or eating behaviour. There was an increase in brain activity in the bilateral insula in NPH insulin-treated patients when watching food pictures versus non-food pictures compared to &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt;-treated patients  (p &amp;lt; 0.04 FWE); these differences between groups were not affected by adjustment for glucose levels [&lt;ulink linkType="Reference" linkID="1328275"&gt;1328275&lt;/ulink&gt;]. Similar results were published in April 2014, results also added that    brain activation was significantly lower in bilateral insula in response to visual food stimuli in patients treated with &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt;, compared to NPH insulin (p = 0.02 for right and p = 0.05 for left insula). Similarly, higher CSF insulin levels were observed with &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; than with NPH insulin treatment (p = 0.003). However, CSF insulin levels were determined in a subgroup of patients  [&lt;ulink linkType="Reference" linkID="1624894"&gt;1624894&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be given &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; and insulin NPH, 100 IU/ml, qd, dose individually adjusted, to be used for a period of 12 weeks, in combination with &lt;ulink linkType="Drug" linkID="10411"&gt;insulin aspart&lt;/ulink&gt; tid.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients  received a basal bolus regimen for two periods of 12 weeks, starting with either &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; or NPH insulin, in combination with &lt;ulink linkType="Drug" linkID="10411"&gt;insulin aspart&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1328275"&gt;1328275&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1624894"&gt;1624894&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Netherlands"><Sites><Site><Name>VU University Medical Center</Name><Address1>Amsterdam</Address1><Address3>1081 HV</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="7603">Subjects with Specified Duration of Disease</PatientSegment><SubSegments><SubSegment id="7605">Subjects with more than 1 year of diabetes mellitus</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7645">Subjects with Moderate Glycemic Control</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00626080</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2007-007255-13</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Insulin dependent diabetes" id="44211"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18119">Assessment of blood glucose</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Insulin dependent diabetes" id="18158"><Endpoint>Assessment of Insulin Levels</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Insulin dependent diabetes" id="16308"><Criterion>Subjects with Specified Duration with Type 1 Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16310">Subjects with more than 1 year of diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="35051"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16354">Subjects with Poor/Inadequate Glycemic Control</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="35101"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16827">Subjects with Type 1 Diabetes Mellitus</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Insulin dependent diabetes" id="13663"><Criterion>Subjects with Diabetic Complications</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13671">Subjects with diabetic retinopathy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13757"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13758">Subjects with chronic kidney disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13817"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13861"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13883"><Criterion>Subjects with Hypoglycemia/Hypoglycemia Unawareness</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2011-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>29.03 Months</EnrollmentPeriod><EnrollmentRate>1.38 Patients/Month</EnrollmentRate><DateFirstReceived>2008-02-19T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-03-01T16:53:03Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="95532"><TitleDisplay>Relovair PD PK in Chinese Healthy Subjects</TitleDisplay><TitleOfficial>A Randomized, Double-blind, Placebo-controlled, Four-way, Crossover Study to Evaluate and Compare the Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Different Dose Combination (50/25, 100/25 and 200/25 microg) After Single- and Repeat-Dose Administration From a Novel Dry Powder Device in Healthy Chinese Subjects</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">115199</Identifier><Identifier type="NCT">NCT01711463</Identifier></Identifiers><Indications><Indication id="1185">Chronic obstructive pulmonary disease</Indication><Indication id="31">Asthma</Indication></Indications><BiomarkerNames><BiomarkerName id="148" role="Therapeutic effect marker" type="Physiological">QT interval</BiomarkerName><BiomarkerName id="1904" role="Toxic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2098" role="Therapeutic effect marker" type="Biochemical">Potassium</BiomarkerName><BiomarkerName id="2534" role="Therapeutic effect marker" type="Biochemical">Hydrocortisone</BiomarkerName><BiomarkerName id="2586" role="Toxic effect marker" type="Physiological">Blood pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Name><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="59060">fluticasone furoate + vilanterol trifenatate  (oral inhalant, asthma/COPD), GlaxoSmithKline</Drug><IndicationsPioneer/><Companies><Company><Company id="28355">GlaxoSmithKline plc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="59060" type="Drug"><TargetEntity id="686392" type="siDrug">Fluticasone Furoate/Vilanterol</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"/><TargetEntity id="D029424" type="MeSH"/><TargetEntity id="-459670493" type="omicsDisease"/><TargetEntity id="277" type="siCondition"/></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"/><TargetEntity id="493" type="ICD9"/><TargetEntity id="10003553" type="MEDDRA"/><TargetEntity id="D001249" type="MeSH"/><TargetEntity id="-1473716268" type="omicsDisease"/><TargetEntity id="270" type="siCondition"/></SourceEntity><SourceEntity id="3191" type="Action"><TargetEntity id="1738" type="Mechanism">Glucocorticoid Receptor (GR) Agonists</TargetEntity></SourceEntity><SourceEntity id="40" type="Action"><TargetEntity id="60" type="Mechanism">beta2-Adrenoceptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3191">Glucocorticoid receptor agonist</Action><Action id="40">Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class><Class id="646">Bronchodilator</Class></Class><Technologies><Technology id="175">Drug combination</Technology><Technology id="616">Inhalant formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="618">Powder formulation inhalant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="90">Steroid</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>16</PatientCountEnrollment><DateStart>2012-12-31T00:00:00Z</DateStart><DateEnd type="actual">2013-06-01T00:00:00Z</DateEnd><DateChangeLast>2016-12-20T09:48:34Z</DateChangeLast><DateAdded>2012-10-25T07:51:21Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>GlaxoSmithKline</Affiliation><Name>GSK Clinical Trials</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;AST (aspartate aminotransferase), ALT (alanine aminotransferase), alkaline phosphatase and bilirubin&amp;lt;/= 1.5 x ULN (upper limit of normal) (isolated bilirubin &amp;gt; 1.5 x ULN             is acceptable if bilirubin is fractionated and direct bilirubin &amp;lt; 35%)&lt;/li&gt;&lt;li&gt;Healthy male or female between 18 and 45 years of age inclusive&lt;/li&gt;&lt;li&gt;Healthy as determined by a responsible and experienced physician, based on a medical             evaluation including medical history, physical examination, laboratory tests and             cardiac monitoring.  A subject with a clinical abnormality or laboratory parameters             outside the reference range for the population being studied may be included only if             the Investigator and the &lt;ulink linkType="Company" linkID="28355"&gt;GSK&lt;/ulink&gt; medical monitor agree that the finding is unlikely to             introduce additional risk factors and will not interfere with the study procedures.             Subjects with blood pressure values outside the normal range (systolic [90 to139 mmHg)             and diastolic [50 to 89 mmHg]) and subjects with ECG findings suggestive of a previous             MI should always be excluded from enrollment&lt;/li&gt;&lt;li&gt;A female subject is eligible to participate if she is of:&lt;ul&gt;&lt;li&gt;Non-childbearing potential defined as pre-menopausal females with a documented tubal        ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea        (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH]        &amp;gt; 40 mlU/ml and estradiol &amp;lt; 40 picog/ml [&amp;lt; 147 picomol/l] is confirmatory)&lt;/li&gt;&lt;li&gt;Child-bearing potential and agrees to use one of the contraception methods listed in        section 8.1 for an appropriate period of time (as determined by the product label or        investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy        at that point.  Female subjects must agree to use contraception until completion of the        follow-up visit&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Male subjects with female partners of child-bearing potential must agree to use one             of the contraception methods listed in section 8.1.  This criterion must be followed             from the time of the first dose of study medication until completion of the follow-up             visit&lt;/li&gt;&lt;li&gt;Body weight&amp;gt;/= 50 kg and BMI within the range 19 to 24 kg/m2 (inclusive)&lt;/li&gt;&lt;li&gt;Capable of giving written informed consent, which includes compliance with the             requirements and restrictions listed in the consent form&lt;/li&gt;&lt;li&gt;No significant abnormality on 12-lead ECG at screening, including the following             specific requirements:&lt;ul&gt;&lt;li&gt;Ventricular rate&amp;gt;/= 45 beats/min&lt;/li&gt;&lt;li&gt;PR interval&amp;lt;/= 210 ms&lt;/li&gt;&lt;li&gt;No pathological Q waves&lt;/li&gt;&lt;li&gt;QRS interval to be&amp;gt;/= 60 ms and &amp;lt;/= 120 ms&lt;/li&gt;&lt;li&gt;The waveforms        must enable the QT interval to be clearly defined&lt;/li&gt;&lt;li&gt;QTc interval must be&amp;lt; 450 ms (QTcF;        machine or manual reading) based on a single ECG value, or an average from three ECGs        obtained over a brief recording period&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Subjects who are current non-smokers, who have not used any tobacco products in the             12 month period preceding the screening visit, and have a pack history of&amp;lt;/= 5 pack             years&lt;/li&gt;&lt;li&gt;Subjects who are able to use the inhalation device satisfactorily&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;A positive pre-study hepatitis B surface antigen or positive Hepatitis C antibody             result within 3 months of screening&lt;/li&gt;&lt;li&gt;Current or chronic history of liver disease, or known hepatic or biliary             abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)&lt;/li&gt;&lt;li&gt;A positive pre-study drug/alcohol screen or on admission to the unit&lt;/li&gt;&lt;li&gt;A positive urinary cotinine test at screening or on admission to the unit&lt;/li&gt;&lt;li&gt;A positive test for HIV antibody&lt;/li&gt;&lt;li&gt;History of regular alcohol consumption within 6 months of the study defined as: an             average weekly intake of &gt; 21 units or an average daily intake of &gt; 3 units (males) or defined as an average weekly intake of &gt; 14 units             or an average daily intake of &gt; 2 units (females); one unit is equivalent             to a 285 ml glass of full strength beer or 425 ml schooner of light beer or one (30 ml)             measure of spirits or one glass (100 ml) of wine (NHMRC Guidelines [NHMRC, 2001])&lt;/li&gt;&lt;li&gt;The subject has participated in a clinical trial and has received an investigational             product within the following time period prior to the first dosing day in the current             study: 30 days, five half-lives or twice the duration of the biological effect of the             investigational product (whichever is longer)&lt;/li&gt;&lt;li&gt;Exposure to more than four new chemical entities within 12 months prior to the first             dosing day&lt;/li&gt;&lt;li&gt;Use of prescription or non-prescription drugs, including vitamins, herbal and dietary             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a             potential enzyme inducer) or five half-lives (whichever is longer) prior to the first             dose of study medication, unless in the opinion of the Investigator and &lt;ulink linkType="Company" linkID="28355"&gt;GSK&lt;/ulink&gt; medical             monitor the medication will not interfere with the study procedures or compromise             subject safety&lt;/li&gt;&lt;li&gt;History of sensitivity to any of the study medications, or components (magnesium             stearate and lactose etc) or a history of drug or other allergy that, in the opinion             of the investigator or &lt;ulink linkType="Company" linkID="28355"&gt;GSK&lt;/ulink&gt; medical monitor, contraindicates their participation&lt;/li&gt;&lt;li&gt;History of milk protein allergy&lt;/li&gt;&lt;li&gt;History of any adverse reaction including immediate or delayed hypersensitivity to             any ICS (inhaled corticosteroids), beta2-agonist or sympathomimetic drug&lt;/li&gt;&lt;li&gt;Blood donation or sampled as a study subject within three months preceding the first             dose of study drug and blood donation during the entire study&lt;/li&gt;&lt;li&gt;Pregnant females as determined by positive urine pregnancy test at screening or prior             to dosing&lt;/li&gt;&lt;li&gt;Lactating females&lt;/li&gt;&lt;li&gt;Subjects who have suffered an upper or lower respiratory tract infection within 4             weeks of the screening visit&lt;/li&gt;&lt;li&gt;The subject has taken oral corticosteroids&amp;lt; 8 weeks before the screening             visit&lt;/li&gt;&lt;li&gt;The subject has taken inhaled, intranasal or topical steroids&amp;lt; 4 weeks             before the screening visit&lt;/li&gt;&lt;li&gt;Unwillingness or inability to follow the procedures outlined in the protocol&lt;/li&gt;&lt;li&gt;Subject is mentally or legally incapacitated&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Systemic steroid PD effects: serum cortisol</Description><Timeframe>Day 7</Timeframe></Measure><Measure><Description>Systemic beta-adrenergic PD effects:</Description><Timeframe>Days 1 and 7</Timeframe></Measure><Measure><Description>Maximum QTcF 0 to 4 h and whole blood potassium</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Plasma concentrations and derived PK parameters for FF/VI: single dose: Cmax, tmax, t-1/2, AUC (0 to t) (AUC from zero to the last quantifiable timepoint) and AUC (0 to t1) (AUC from zero to the last common quantifiable timepoint in the dose group). Repeat dose: FF: Cmax, t-max, t-1/2, AUC (0 to t) and AUC (0 to t1), Ro and RCmax, Css-min and AUCss , Css-av, DF; VI: Cmax, t-max, t-1/2, AUC (0 to t) and AUC (0 to t1)</Description><Timeframe>Pre-dose, 5, 15 and 30 min, 1, 1.5, 2 and 4 h post-dose on day 1 and pre-dose, 5, 15 and 30 min, 1, 1.5, 2, 4, 6, 8, 12 and 24 h post-dose on day 7 and 8</Timeframe></Measure><Measure><Description>Vital signs: blood pressure and heart rate</Description><Timeframe>Screening visit, day 1 and 7 and follow-up visit</Timeframe></Measure><Measure><Description>A 12-lead ECG</Description><Timeframe>Screening visit, day 1 and 7 and follow-up visit</Timeframe></Measure><Measure><Description>Laboratory tests: clinical chemistry, hematology and urinalysis</Description><Timeframe>Screening visit, day 8 of treatment period four or early withdrawal visit and/or follow-up visit</Timeframe></Measure><Measure><Description>Adverse events: adverse events</Description><Timeframe>From the start of dosing with investigational product and until the follow-up visit</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;In this study, fluticasone furoate/vilanterol (FF/VI) (&lt;ulink linkType="Drug" linkID="59060"&gt;Relovair&lt;/ulink&gt;) in different dose combinations      (50/25, 100/25  and 200/25 microg) would  be administered from a single dry powder device to      evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of the combination in healthy Chinese subjects.      The information gathered would be used as a support of the clinical development program of      the fixed dose combination of &lt;ulink linkType="Drug" linkID="59060"&gt;Relovair&lt;/ulink&gt;  inhalation powder in Chinese population. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This was a single-center, double-blind, placebo-controlled, four-way, crossover, randomized,      single- and repeat-dose study. A total of 16 healthy subjects aged 18 to 45 years would be      randomized with the aim of achieving at least 10 evaluable subjects to each treatment      period. The primary objective was to evaluate the systemic steroid PD effects (serum cortisol      24-h weighted mean on day 7) of fluticasone furoate and systemic beta-adrenergic PD effects (ECG maximum QTcF      0 to 4 h and whole blood potassium 0 to 4  h in day 1 and 7) of vilanterol; the secondary objectives were      aimed to evaluate the PK, safety and tolerability of &lt;ulink linkType="Drug" linkID="59060"&gt;Relovair&lt;/ulink&gt; inhalation powder after a single-      and repeat-dose administration.&lt;/para&gt;&lt;para&gt;Subjects would receive either &lt;ulink linkType="Drug" linkID="59060"&gt;Relovair&lt;/ulink&gt; (50/25 or 100/25 or 200/25 microg) or placebo, inhaled qd for 7 days.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Beijing</Address1><Address3>100032</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01711463</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Asthma" id="6048"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Asthma" id="6048"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Asthma" id="6049"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Asthma" id="6082"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6083">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Asthma" id="6088"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Asthma" id="6093"><Endpoint>Assessment of Physical Examination</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6094">Cardiac evaluation</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><ExclusionCriteria><Exclusion disease="Asthma" id="3839"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Asthma" id="20240"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Asthma" id="20242"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Asthma" id="20245"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Asthma" id="20247"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Asthma" id="20248"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Asthma" id="20249">Subjects with history of/scheduled for asthma drugs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Asthma" id="20252"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Asthma" id="20253">Subjects with contraindication to drugs or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Asthma" id="20255"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-06-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2013-05-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>5.03 Months</EnrollmentPeriod><EnrollmentRate>3.18 Patients/Month</EnrollmentRate><DateFirstReceived>2012-08-30T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-10-25T07:51:21Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="96504"><TitleDisplay>Usefulness of Markers to Predict Recurrence of Atrial Fibrillation After Radiofrequency Catheter Ablation</TitleDisplay><TitleOfficial>The Value of Amino-Terminal Brain Natriuretic Peptide and C-Reactive Protein Serum Levels for Predicting Recurrence of Atrial Fibrillation and/or Atrial Flutter After Radiofrequency Catheter Ablation</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">PRD-03-I-03</Identifier><Identifier type="NCT">NCT00315068</Identifier></Identifiers><Indications><Indication id="1542">Atrial fibrillation</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="106" role="Therapeutic effect marker" type="Proteomic">N-terminal Pro Brain Natriuretic Peptide</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Radiofrequency catheter ablation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1036907" type="Company"><TargetEntity id="5035541484" type="organizationId">Geneva University Hospital</TargetEntity></SourceEntity><SourceEntity id="1542" type="ciIndication"><TargetEntity id="10003658" type="MEDDRA"/><TargetEntity id="D001281" type="MeSH"/><TargetEntity id="-1073626038" type="omicsDisease"/><TargetEntity id="194" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1036907">Hopitaux Universitaires De Geneve</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Longitudinal</Term><Term>Defined Population</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>180</PatientCountEnrollment><DateStart>2004-04-30T00:00:00Z</DateStart><DateChangeLast>2013-09-13T17:48:13Z</DateChangeLast><DateAdded>2012-11-02T08:36:30Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Cardiology Division University Hospital</Affiliation><Name>Pierre-Frederic Keller, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Atrial fibrillation&lt;/li&gt;&lt;li&gt;Indication for catheter ablation of atrial fibrillation&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Significant valvulopathy&lt;/li&gt;&lt;li&gt;Previous catheter ablation for atrial fibrillation or atrial flutter&lt;/li&gt;&lt;li&gt;Left ventricular ejection fraction&amp;lt; 30%&lt;/li&gt;&lt;li&gt;Severe heart failure (NYHA IV)&lt;/li&gt;&lt;li&gt;Severe enlargement of left atrium (&amp;gt; 55 mm)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Confounding factors of increased NT-proBNP will be assessed with echocardiographic imaging</Description></Measure><Measure><Description>C-reactive protein (CRP)</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study is to evaluate blood tests of amino-terminal brain natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) levels to predict recurrence of atrial fibrillation after radiofrequency catheter ablation.&lt;/para&gt;&lt;para&gt;The information      gained from this study will in all probability improve the estimation of the chances of a      successful intervention and may enable investigators to take necessary therapeutic measures in case of      an elevated risk of recurrence.&lt;/para&gt;&lt;para&gt;Multiple studies suggest that the two markers in this study could provide information of this      nature, however, their utility in the radiofrequency catheter ablation treatment of atrial      fibrillation has never been demonstrated.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This is an observation study including 180 patients with the indication of catheter ablation      for atrial fibrillation. Confounding factors of increased NT-proBNP will be assessed with      echocardiographic imaging. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Switzerland"><Sites><Site><Name>Cardiology Division University Hospital</Name><Address1>Geneva</Address1><Address3>1211</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Heart arrhythmia</Disease><PatientSegments><PatientSegment><PatientSegment id="10272">Subjects Scheduled for Arrhythmia Interventions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Atrial fibrillation</Disease><PatientSegments><PatientSegment><PatientSegment id="7286">Atrial fibrillation subjects scheduled for intervention</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00315068</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><OtherEndpoints><OtherEndpoint disease="Atrial fibrillation" id="9571"><Endpoint>Assessment of Cardiac Markers</Endpoint><SubEndpoints><SubEndpoint disease="Atrial fibrillation" id="9573">Assessment of pro-B-type natriuretic peptide(BNP)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Atrial fibrillation" id="9596"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Atrial fibrillation" id="9597">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Atrial fibrillation" id="9630"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></OtherEndpoint><OtherEndpoint disease="Heart arrhythmia" id="14920"><Endpoint>Assessment of Cardiac Markers</Endpoint><SubEndpoints><SubEndpoint disease="Heart arrhythmia" id="14922">Assessment of pro-B-type natriuretic peptide(BNP)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Heart arrhythmia" id="14945"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Heart arrhythmia" id="14946">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Heart arrhythmia" id="14979"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Atrial fibrillation" id="5634"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Atrial fibrillation" id="5640">History of/Scheduled for cardiac ablation</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Heart arrhythmia" id="13984"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Heart arrhythmia" id="13990">History of/Scheduled for cardiac ablation</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Atrial fibrillation" id="7129"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Atrial fibrillation" id="7131">Subjects with valvular heart disease</SubCriterion><SubCriterion disease="Atrial fibrillation" id="7135">Subjects with heart failure as a risk factor</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atrial fibrillation" id="7147"><Criterion>Subjects with Enlarged Left Atrium</Criterion><SubCriteria><SubCriterion disease="Atrial fibrillation" id="7148">Left atrium size of more than or equal to 5 cms</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atrial fibrillation" id="7152"><Criterion>Subjects with Poor Left Ventricular Ejection Fraction(LVEF)</Criterion><SubCriteria><SubCriterion disease="Atrial fibrillation" id="7154">Subjects with LVEF less than 30%</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atrial fibrillation" id="7155"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion><SubCriteria><SubCriterion disease="Atrial fibrillation" id="7157">Subjects with atrial flutter</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atrial fibrillation" id="7256"><Criterion>Subjects with Prior Cardiac Intervention</Criterion><SubCriteria><SubCriterion disease="Atrial fibrillation" id="7258">Subjects with prior cardiac ablation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Heart arrhythmia" id="11311"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Heart arrhythmia" id="11313">Subjects with valvular heart disease</SubCriterion><SubCriterion disease="Heart arrhythmia" id="11317">Subjects with heart failure as a risk factor</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Heart arrhythmia" id="11331"><Criterion>Subjects with Enlarged Left Atrium</Criterion><SubCriteria><SubCriterion disease="Heart arrhythmia" id="11332">Left atrium size of more than or equal to 5 cms</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Heart arrhythmia" id="11336"><Criterion>Subjects with Poor Left Ventricular Ejection Fraction(LVEF)</Criterion><SubCriteria><SubCriterion disease="Heart arrhythmia" id="11338">Subjects with LVEF less than 30%</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Heart arrhythmia" id="11339"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion><SubCriteria><SubCriterion disease="Heart arrhythmia" id="11341">Subjects with atrial flutter</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Heart arrhythmia" id="11443"><Criterion>Subjects with Prior Cardiac Intervention</Criterion><SubCriteria><SubCriterion disease="Heart arrhythmia" id="11445">Subjects with prior cardiac ablation</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-11-02T08:36:30Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>